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Estrogenic compounds exert their effects on cells through the binding and activation 
of estrogen receptors (ERs) [1]. Major biological events influenced by estrogenic 
compounds upon activation of the ERs are related to the cell cycle and (tumor) cell 
growth, like cell proliferation and apoptosis [2-4]. In the present thesis it is investigated 
to what extent different factors involved in the mode of action of the ER-mediated 
cellular responses influence the cell proliferation and/or apoptosis induced upon binding 
of estrogenic compounds to ERs. In the following sections these factors are explained in 
some more detail.
Estrogenic compounds: agonists and antagonists
Estrogens are naturally occurring steroid hormones present in both men and women [5]. 
Levels of circulating estrogens vary markedly between individuals. 17β-Estradiol (E2) levels 
of 10-20 pg/ml have been reported in postmenopausal women, while in vitro fertilisation 
(IVF) hyperstimulated women showed E2 levels of >2000 pg/ml. Premenopausal women 
with a normal cycle usually show values in the range of 50-500 pg/ml [6]. E2 levels 
reported in men are around 20 pg/ml [7]. Three different estrogenic compounds are 
present in the body in significant quantity; estrone (E1) is the precursor for E2, which 
in turn can be converted to estriol (E3) [8] (Figure 1). E2 is the most potent estrogenic 
compound naturally occurring in the human body [9]. It is about 10-fold more potent 
than estrone [10]. 
Figure 1: Schematic representation of the conversion of estrogenic compounds naturally present in 












Estrogenic compounds can also be found in plants. These plant-derived estrogens 
are called phytoestrogens. One of the best characterized phytoestrogens is genistein, 
commonly found in soy beans and soy products including food supplements [12, 13]. 
Xenoestrogens are chemically synthesized estrogenic compounds [14]. These non-
steroidal compounds can be present in for example plasticizers, food preservatives, 
pesticides, dyes, and chemical pollutions [15]. 
From this wide variety and diverse presence of compound classes it can be 
concluded that several types of estrogenic compounds exist, which may have different 
modes of action inducing different cellular responses varying from stimulation of cell 
proliferation [2], cancer cell migration [16], and estrogen receptor turnover [17] to 
stimulation of apoptosis and reduction of cell proliferation [3, 4, 18-20]. There are 
compounds that provoke estrogenic (E2-like) responses (agonists) and compounds that 
counteract estrogenic responses (antagonists), with the latter binding to the ER without 
inducing a physiological response [21]. Antagonistic responses can be partial or full [22] 
and this can even be dependent on the tissue. These tissue-specific anti-estrogens are 
called Selective Estrogen Receptor Modulators (SERMs) [23]. All types of estrogenic 
compounds exert their effect through binding to estrogen receptors [1].
Estrogen receptors
The estrogen receptor (ER) was first discovered by Jensen et al. in 1958 [24, 25]. In 1996 
Kuipers et al. discovered that there are actually 2 types of ERs. The one discovered by 
Jensen et al. was renamed ERα and the one discovered by Kuipers et al. was named ERβ 
[26, 27]. Even though these two ERs are encoded by different genes localized on different 
chromosomes, they share a high homology in their functional regions (Figure 2). ERα and 
ERβ share 28% amino acid homology in the A/B domain, which contains the activation 
function 1 (AF-1) domain involved in ligand-independent transactivation. The C domain, 
also referred to as the DNA binding domain (DBD), is 96% homologous between the two 
ER subtypes. This region of the ER binds to the estrogen response element (ERE) in the 
DNA to initiate transcription [28]. Little is known about the function of the D domain 
other than that it contains the nuclear localization site of the ERs and post-translational 
modification sites [29] and that homology between ERα and ERβ for this region is only 
17%. The E and F domains respectively share 58% and 18% homology between ERα and 
ERβ. The activation function 2 (AF-2) domain is present within the E/F region. This region 










ERs belong to the group of nuclear hormone receptors (NR) [30]. The ERs are 
present in the cell cytoplasm and are stabilized by heat shock protein (HSP)70 and HSP90 
which specifically bind the LBD [31]. Upon binding of the ligand, a conformational change 
is induced and dimerization of the ERs occurs [32]. The type of dimerization (ERα-ERα or 
ERβ-ERβ homodimerization or ERα-ERβ heterodimerization) is dependent on the ERα/
ERβ ratio [33]. It has been suggested that by ERα-ERβ heterodimerization ERβ is able to 
modulate ERα-mediated responses [34, 35].
Both ERs are widely distributed throughout the body. As depicted in Table 1, 
literature reports differential results in detected ERα and ERβ expression in various 
tissues. Even when ERα and ERβ are expressed in the same tissue, their expression might 
still vary per cell type [1]. 
Figure 2: Schematic representation of the domain classification of the human ERα and ERβ proteins. 
The domains are represented in ERα, the homology percentages in ERβ. Adapted from [28].
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The G protein-coupled receptor 30 (GPR30) has proposed to be a membrane bound 
estrogen receptor [39, 40]. However, GPR30 agonist G1 does not stimulate estrogen-
like effects in the uterus or mammary gland of mice [41], and GPR30 is incapable of 
mediating any actions of estrogen in cells in which ERα and ERβ are absent [42, 43]. 
Therefore, this receptor will not be included in the current thesis.
Coregulators
Upon binding of an estrogenic compound to the estrogen receptor and dimerization of 
the ERs, specific coregulators are attracted to or rejected from the dimerized ligand-ER 
complex [44]. Coregulators do not bind to the DNA directly, but they interact through 
association with the ERs [31]. There are two types of coregulators; coactivators and 
corepressors, which will respectively enhance or inhibit gene transcription. Some 
coregulators have a receptor-dependent coactivator or corepressor function. PELP1 
(proline, glutamate and leucine rich protein 1) for example is a coactivator of estrogen 
receptor-mediated transcription and a corepressor of other nuclear hormone receptors 
[50]. Coactivator binding has been attributed to the AF-1 and AF-2 domain as well as the 
D domain of the ERs. For corepressor binding it seems that mostly AF-2 is responsible 
[28]. Coregulators (coactivators and corepressors) mostly interact with ERs through 
their LXXLL motifs (leucine - any amino acid - any amino acid - leucine - leucine) that 
can bind to the LBD [31]. However, interactions with the A/B domain have also been 
reported [51-53].
The ligand binding domain of ERs consists of 12 α-helices. Helix 12 folds differently 
upon agonist binding than upon antagonist binding [54]. In the presence of an agonist, 
coactivators are able to bind to a hydrophobic groove on the surface of the ligand 
binding domain. When an antagonist binds to the receptor, the folding of helix 12 blocks 
the coactivator binding surface and thereby influences coregulator recruitment [54]. 
Upon recruitment, coregulators form complexes and do not act as monomers 
[31, 55]. Although the role of several coregulators involved in ER signaling has been 
investigated (Table 2), the complexity of how modulation of the interaction of ERs with 
coregulators affect ER activation remains to be studied in more detail. In addition, in 
studies investigating modulation of the interaction of ERs with coregulators often no 
differentiation is made between coregulators involved in ERα signaling and coregulators 










Table 2: Overview of ER-mediated coregulators, adapted from [44]. Coactivators presented in 
white, corepressors in grey background. (continued)







Binds ERs AF-2 through 
LXXLL motifs (highly 
conserved motifs that 


















HAT Binds ERs AF-2 through 
LXXLL motifs




(CREB) [46])-binding protein 





Binds ERs AF-2 through 
LXXLL motifs
ASC-1 Activating signal 
cointegrator-1








Binds HATs and NRs Binds ERs AF-2 through 
LXXLL motifs
SRA Steroid receptor activator Splicing Binds ERα AF-1






Binds ERs AF-2 
indirectly through 
association with p160s
PRMT1 Protein methyltransferase 1 Arginine histone 
methyltransferase














Table 2: Overview of ER-mediated coregulators, adapted from [44]. Coactivators presented in 
white, corepressors in grey background. (continued)
Coregulator Full name Function/activity Interaction with ER
CoCoA Coiled-coil coactivator Arginine histone 
methyltransferase
Binds ERs AF-2 
indirectly through 
association with p160s
E6-AP E6-associated protein Ubiquitin ligase Binds ERs AF-2
RPF-1 Receptor potentiating 
factor-1
Ubiquitin ligase Binds ERs AF-2
PGC-1α
PGC-1β
PPARγ coactivator 1 Tethering surface 
for other co-factors; 
splicing





Coactivator of (AP-1) and 
estrogen receptors
Coactivator activator
Potentiate ER activity; 
splicing









Binds ERs AF-2 through 
CoRNR box motifs 
(motifs similar to LXXLL 
motifs [49])
SMRT Silencing mediator for 
retinoid and thyroid 
receptors
HDAC Binds ERs AF-2 through 
CoRNR box motifs
RIP140 (NRIP) Receptor interacting protein 
of 140 kiloDalton (kDa)
Competes for AF-2 
coactivator binding; 
associates with HDACs
Binds ERs AF-2 through 
LXXLL motifs
REA Repressor of estrogen 
receptor activity
Interferes with SRC-1 
access to the ERs
Indirect
RTA Repressor of tamoxifen 
transcriptional activity
Interferes with SRC-1 





mSiah2 Mammalian homolog 
of Drosophila Seven in 
absentia (sina)
Mediates cell-specific 
repression of NRs 
by targeting NCoR 
for proteasomal 
degradation












Towards gene and protein expression
When coactivators are recruited, they enhance transcriptional activity through a 
combination of mechanisms, including the recruitment of transcription factors. 
Through interaction with amongst others acetyltransferases there is a disruption of the 
local nucleosomal structure of the DNA [31]. According to the classical pathway of ER 
signaling, the ligand-ER complex with the recruited coregulators will bind to the DNA 
at the site of the ERE sequences in the promotor sites of target genes. In the case of an 
agonistic ligand, this initiates transcription and mRNA production and ultimately protein 
synthesis [31]. Within the DBD of the ERs, an amino acid sequence called the P-box is 
present. This motif is critical for receptor-DNA recognition and specificity. The P-box 
motif is identical between ERα and ERβ. This leads to similar affinity and specificity of 
ERα and ERβ in ERE binding [1].
Figure 3: Schematic representation of the mechanism of action of estrogens; the classical ER signalling 
pathway. Figure by Wang [58], with permission. 
ER agonists and ER antagonists have a different mechanism of action. As depicted 
in Figure 4, ER binding of agonists like E2 results in dimerization of the ligand-receptor 
complex and activation of both AF-1 and AF-2. Upon binding of the dimerized ligand-
receptor complex to the ERE, both AF-1 and AF-2 recruit coregulators and this leads 












upon ligand-receptor binding and dimerization. This leads to AF-1 and no AF-2-mediated 
coregulator recruitment, upon which transcription is partially activated. The full ER 
antagonist fulvestrant blocks the estrogen receptors and thereby keeps both AF-1 and 
AF-2 in an inactive state. As a result no coregulators are recruited and transcription is 
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response element; ER = estrogen receptor 
There are other pathways described in the literature by which ERs can induce 
gene expression. Growth factors like epidermal growth factor (EGF), insulin-like growth 
factor 1 (IGF-1), and cAMP are able to activate the ER and induce expression of ER target 
genes in the absence of ligand [60]. Ligand-ER complex induction of gene expression 
without an ERE-like sequence present in the promotor site of the target gene has also 
been reported [61]. Finally, ERs can be activated by phosphorylation instead of by a 
ligand-mediated mode of action [62].
In the current thesis the mechanisms of action behind the ER signaling pathways 
as described in Figure 3 and 4 were studied in more detail. More particularly, the ER 
signaling pathways were studied to assess differential effects of estrogenic compounds 
and their interaction with differentially expressed ERα and ERβ.
Figure 4: Mechanism of action of estradiol (ER agonist), tamoxifen (partial ER antagonist), and 











Upon gene transcription induced by estrogenic compounds, protein expression is altered 
which eventually leads to biological effects. Estrogenic compounds have been reported 
to show a variety of cellular effects. Estradiol is for example reported to stimulate 
cancer cell migration [16]. Anti-estrogenic compound ICI 164,384 reduces ER expression 
by increasing its turnover [17]. Stimulation of ERα by estrogenic compounds leads to 
different effects than stimulation of ERβ. ERα activation induces cell proliferation [2], 
while ERβ activation counteracts this and is suggested to induce apoptosis [3, 4, 18-20]. 
As a result the cellular ERα/ERβ ratio is essential for the ultimate effect of estrogenic 
compounds [63, 64]. 
Estrogens take part in distinct biological processes. In reproduction for example 
they are involved in growth and sexual differentiation [65]. Estrogens are also connected 
to various diseases [66] such as osteoporosis [67], cardiovascular disease [67, 68], and 
obesity [31]. 
Estrogens regulate skeletal homeostasis. They inhibit bone turnover by reducing 
bone resorption and enhancing bone formation. E2 deficiency is therefore linked to 
bone loss and osteoporosis [31, 67]. This inhibition of bone resporption and increase 
in bone formation is mainly regulated through ERα, while the role for ERβ in skeletal 
homeostasis is less clear [69].
The risk for cardiovascular disease rises in postmenopausal woman, just when 
circulating estrogen levels decrease. This implies that estrogens protect the female 
cardiovascular system [31]. This might be linked to similar types of mechanisms by which 
estrogens are involved in obesity. Estrogens regulate both the metabolism and the 
localization of white adipose tissue and are involved in adipogenesis, adipose deposition, 
lipogenesis, lipolysis, and adipocyte proliferation. An excess of white adipose tissue 
results in obesity. The lowering of circulating E2 in postmenopausal women is associated 
with an increase in body fat. This might be due to a decrease in E2-induced suppression 
of lipoprotein lipase, a lipogenic enzyme, which gene is a direct transcriptional target of 
estrogens. Lipoprotein lipase regulates the metabolism of plasma triglycerides to free 
fatty acids and increases lipid storage by adipocytes [69]. 
Estrogens have been associated with cancer occurring in estrogen-sensitive tissue 
like the breast, uterus, ovary, prostate, and testicles [70-73]. This thesis focuses mainly 
on the implications of a differential ERα/ERβ ratio for cell proliferation, and ultimately 
breast cancer. There are two hypotheses to explain the association between estrogens 
and breast cancer. The first hypothesis proposes binding of the estrogens to the ERs, 












number. Due to the increased cell division and DNA synthesis the risk for replication 
errors is elevated, which may result in detrimental mutations which could interfere 
with cellular processes like apoptosis, cell proliferation, and DNA repair. In the second 
hypothesis the metabolism of estrogens leads to genotoxic by-products that could 
directly cause DNA damage, resulting in point mutations [69].
In breast tumors, ERβ expression is generally lost while ERα expression persists, 
resulting in a higher ERα/ERβ ratio [74]. The persistent expression of ERα in ER(α)-
positive breast cancers is an interesting target for breast cancer therapy. Endocrine 
therapy for ER(α)-positive breast cancer with ER antagonistic compounds like tamoxifen 
or fulvestrant is common practice [75]. They are amongst the least toxic and most 
effective treatments for hormone-responsive breast cancer patients. The response to 
endocrine therapy for ER(α)-positive breast cancer patients (regardless of progesterone 
receptor and human epidermal growth factor receptor 2 (HER2) status, which also 
influence therapy choice and outcome) is 53%, while only 13% of the patients with an 
ER(α)-negative status responds to endocrine therapy [65]. Until now it is unknown what 
role the ERβ plays in these responses as usually its presence is not measured.
Objective, approach, and outline of this thesis
The aim of the work presented in the current thesis is to elucidate the role of differential 
expression of cellular ERα and ERβ levels and ERα/ERβ ratios and the impact on cell 
proliferation and apoptosis induced by estrogenic compounds. To this end, different 
types of ER agonists (with a preference for either ERα or ERβ) and ER antagonists (partial 
or full) were assessed in vitro for their intrinsic potency towards ERα and ERβ, the 
modulation of the interaction of ERs with coregulators upon binding of the estrogenic 
compounds to the different ER subtypes, and their ultimate biological effect on cell 
proliferation depending on the cellular ERα/ERβ ratio. 
Chapter 1 presents an introduction to estrogenic compounds, estrogen receptors, 
and their mechanism of action. 
Given the importance of the cellular ERα/ERβ ratio, in chapter 2 it is investigated 
whether the T47D-ERβ cell model, using differentially expressed ERβ levels, can be used 
to mimic ERα/ERβ ratios in estrogen-responsive tissues. Also the physiological relevance 
of the ERα/ERβ ratios in the native T47D and MCF-7 cell models commonly used in 
estrogen research is characterized.
Chapter 3 and 4 present the results obtained with the ERα-LBD as well as the 
newly developed ERβ-LBD-based Microarray Assay for Real-time Coregulator – Nuclear 










coregulators is studied in more detail. Although the role of several coregulators involved 
in ER signaling has been investigated to some extent, the complexity of how modulation 
of the interaction of the ERs with coregulators can affect ERα and ERβ activation is not 
completely elucidated. 
In chapter 3 first different types of ER agonists are characterized for ER subtype 
preference and their effect on cell proliferation. Next, using the MARCoNI assay 
containing 154 unique coregulator motifs derived from 66 different coregulators, 
coregulator modulation induced by the ER agonists upon binding to the ERα- or 
ERβ-LBD is assessed. This chapter should provide insight in the possible contribution of 
coregulators to the differences in ERα- or ERβ-induced cellular responses by ER agonists.
In chapter 4 the modulation of the interaction of ERα and ERβ with coregulators 
in ligand-dependent responses by the ER antagonistic compounds 4-hydroxytamoxifen 
(4OHT) and fulvestrant is investigated. By comparing these results to ligand-dependent 
modulation of the interaction of ERα and ERβ with coregulators induced by the ER agonist 
E2, it is investigated if and how differences in the (ant)agonist-dependent modulation 
profiles of the interaction of ERα and ERβ with coregulators contribute to the differences 
in (ant)agonist responses. 
In both chapter 3 and 4 it is also investigated whether the MARCoNI assay is able 
to discriminate ER agonists and antagonists by means of differential profiling based on 
the modulation of the interaction of ERα and ERβ with coregulators. For this purpose 
various modulation profiles are established for every estrogenic compound tested and 
these profiles are compared upon clustering of the modulation profiles.
In chapter 5 a quantitative proteomics study into ER subtype-mediated effects of 
4OHT, the active metabolite of tamoxifen, on cell proliferation and apoptosis of T47D-ERβ 
breast cancer cells is described. In this chapter it is investigated how the cellular ERα/
ERβ ratio influences important biological effects like cell proliferation and apoptosis at 
the protein level in cells which are exposed to 4OHT. 
Chapter 6 presents a general discussion on the newly obtained insights into the 
mode of action of ER agonists and antagonists, including the importance of ERα and ERβ 
levels and ratios for the ultimate biological effects of estrogen agonists or antagonists on 
cell cycle processes like cell proliferation and apoptosis, and the coregulators involved 
in ligand-dependent gene transcription. Chapter 6 also presents implications for the 
clinical practice and perspectives for mechanistic and clinical future research. 
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T47D-ERβ breast cancer cells with tetracycline-dependent ERβ expression and 
constant ERα expression can be used to investigate effects of varying ERα/ERβ 
ratios on estrogen-induced cellular responses. This study defines the conditions 
at which ERα/ERβ ratios in T47D-ERβ cells best mimic ERα/ERβ ratios in breast 
and other estrogen-sensitive tissues in vivo in rat as well as in human. Protein 
and mRNA levels of ERα and ERβ were analyzed in T47D-ERβ cells exposed to a 
range of tetracycline concentrations and compared to ERα and ERβ levels found 
in breast, prostate, and uterus or endometrium from rat and human origin. The 
ERα/ERβ ratio in T47D-ERβ cells exposed to >150 ng/ml tetracycline is comparable 
to the ratio found in rat mammary gland and in human breast tissue. The ERα/ERβ 
ratio of other estrogen-sensitive rat and human tissue can also be mimicked in 
T47D-ERβ cells. The ERα/ERβ ratio found in MCF-7 and native T47D breast cancer 
cell lines did not reflect ratios in analyzed rat and human tissues, which further 
supports the use of T47D-ERβ cells as model for estrogen-responsive tissues. 
Using 17β-estradiol (E2) and the T47D-ERβ cells under the conditions defined to 
mimic various tissues it could be demonstrated how these different tissues vary 






























Estrogen receptors (ERs) modulate the effects of estrogens on cells and tissues [1] with 
ERα and ERβ being the two major ERs [2]. ERα and ERβ are encoded by distinct genes 
[3] and have different roles in gene regulation [4]. As a consequence ERα and ERβ have 
differential effects on the cell cycle in various estrogen-sensitive tissues. It has been 
shown that ERα activation in breast and uterus enhances cell proliferation, which is 
necessary for growth and maintenance of tissues [5]. ERβ has been shown to counteract 
the ERα-mediated stimulation of cell proliferation [6-10]. Hence ERα and ERβ have 
different roles in gene regulation and their relative level and varying ratio within tissues 
may influence the response towards different estrogens. When the response to estrogens 
by the endocrine system is deregulated, ERα activation might eventually result in tumor 
formation [1, 11-14], whilst ERβ activation has been shown to stimulate apoptosis [15-17]. 
In certain types of cancer, the ERα/ERβ ratio is increased compared to healthy tissue. 
This has been shown for both ER-positive breast tumors and ovarian carcinomas [18, 19]. 
It was shown that the increase in ERα/ERβ ratio was due to a decreased level of ERβ [20, 
21]. This observation might be related to the antagonistic effect of ERβ-mediated gene 
expression on cell proliferation induced by ERα activation [10].
Given the different biological effects on the cell cycle resulting from differential 
ERα or ERβ activation, it is of interest to note that ERα and ERβ also differ in their relative 
and absolute tissue distribution and tissue levels [3]. Levels of ERα and ERβ have been 
shown to vary in such a way that one of them is dominantly present in a specific tissue. 
For example, ERα is predominant in the uterus [22], while ERβ is predominant in the 
prostate [22, 23]. The different levels of ERα and ERβ within specific tissues are expected 
to determine the responses of these tissues to estrogens and to estrogenic compounds, 
which may have different affinities for ERα and ERβ [24] .
To investigate the potential impact of the ERα/ERβ ratio on estrogen-induced cellular 
effects, Ström et al. [7] developed the T47D-ERβ cell line. This model consists of T47D 
human ductal breast epithelial cancer cells with tetracycline-dependent ERβ expression 
(short, 485 amino acids isoform) and a constant ERα expression. When exposed to 
an increasing concentration of tetracycline, ERβ expression in these T47D-ERβ cells 
decreases and thus the ERα/ERβ ratio increases [7]. In previous studies the cell model 
was applied to investigate the influence of various ERβ levels on cellular proliferation in 
response to E2 and other estrogenic and anti-estrogenic compounds [7, 9]. In order to 
be able to better translate the findings reported in in vitro studies with T47D-ERβ cells 
with tetracycline-dependent ERβ expression towards the in vivo situation, the ERα/ERβ 














































to be compared to levels actually occurring in breast and other estrogen-responsive 
tissues in both experimental animals and humans to assess the physiological relevance 
compared to the levels in vivo. Therefore, the aim of the present study was to define 
the conditions at which the ERα/ERβ ratio in the T47D-ERβ breast cancer cells with 
tetracycline-dependent ERβ expression would best mimic the actual ERα/ERβ ratio in 
rat and human breast and other estrogen-sensitive tissues (uterus or endometrium and 
prostate) in vivo to further support their use as models for estrogen-responsive tissues. 
For comparison also the MCF-7 and native T47D cell lines were investigated for their 
ERα/ERβ ratios to see to what extent these cell lines provide an adequate model for 
mimicking physiologically relevant ERα/ERβ ratios.
Materials and Methods
Cell culture
The T47D human ductal breast epithelial cancer cell line was purchased from the 
American Type Tissue Culture Collection (Manassas, VA, USA). The T47D-ERβ cell line was 
made and provided by Ström [7]. Native T47D and T47D-ERβ cells were cultured in a 1:1 
mixture of Ham’s nutrient mixture F12 and Dulbecco’s modified Eagle’s medium (DMEM) 
(Gibco, Paisley, Scotland, #31331-038) supplemented with 5% fetal calf serum (FCS) 
(Invitrogen, Paisley, Scotland, #10099). For the T47D-ERβ cells, 1000 ng/ml tetracycline 
(Sigma, Zwijndrecht, the Netherlands, #T7660) to fully inhibit ERβ expression [9] was 
added to the medium. Sotoca et al. [9] reached maximal induction of an enhanced 
green fluorescent protein (EGFP) gene which is co-expressed with ERβ after 24 hours 
of depleting the T47D-ERβ cells from tetracycline, thus suggesting that at 24 hours also 
ERβ expression is maximal. ERα levels in T47D-ERβ cells are constant and quantification 
of the ERβ levels in the cells upon 48 hours of cultivation in the absence of tetracycline 
revealed similar ERβ levels as detected at 24 hours (data not shown). This supports 
that at the time of quantification of the ERα/ERβ ratios (24 hours) the ERβ expression 
reached a steady state and ERα/ERβ ratios are stable. Therefore, exposure to specific 
tetracycline concentrations was for 24 hours.
MCF-7 human breast adenocarcinoma cells were purchased from the American 
Type Tissue Culture Collection (Manassas, VA, USA). They were cultured in a 1:1 mixture 
of Ham’s nutrient mixture F12 and DMEM (Gibco, Paisley, Scotland, #31331-038) 
supplemented with 5% FCS. All cells were incubated at 37°C and 5% CO2 in a humidified 
atmosphere. 
Because phenol red exerts estrogenic activity [25], at least 24 hours before 





























Paisley, Scotland, #10010-015) and transferred to phenol red free medium (Gibco, Paisley, 
Scotland, #21041-025) supplemented with 5% hormone-free dextran-coated charcoal-
treated fetal calf serum (DCC-FCS) (Perbio Science, Waltham, MA, USA, #SH30068.05).
Tissue collection
Estrogen-responsive tissues from adult (13-16 weeks old) male and female Sprague 
Dawley rats were collected at the animal facility of Merck Sharp & Dohme (MSD) in 
Schaijk, the Netherlands. Before autopsy, animals were anesthesized and tissues were 
removed, placed in foil, and immediately emerged in liquid nitrogen. This experiment 
was approved by the animal welfare committee of MSD. Estrus cycle data as determined 
by histological examination of vaginal smears after haematoxylin and eosin (HE) staining 
of the female rats, as described by Allen and Doisy [26], are shown in Table A.








Collection of human material was approved by the medical ethical committees 
of the respective hospitals. Human breast tissue was collected from female donors 
at hospital De Gelderse Vallei in Ede, the Netherlands. Human endometrium samples 
were obtained at Maastricht University Medical Centre in Maastricht, the Netherlands 
from premenopausal women undergoing hysterectomy for benign indications. Prostate 
tissue from male patients with benign prostatic hyperplasia (BPH) was collected at the 
Radboud University Nijmegen Medical Centre in Nijmegen, the Netherlands. Known 
relevant characteristics from the tissue donors are displayed in Table B.
Protein and mRNA isolation
For protein and messenger ribonucleic acid (mRNA) isolation, 80% confluent cells in 
75 cm² cell culture flasks (Corning, #430641) were scraped in 1 ml TRIzol (Invitrogen, 
Paisley, Scotland, #15596-018) and stored at -80°C. Tissue samples were snap-frozen in 
liquid nitrogen and stored at -80°C. Frozen tissue (50-100 mg) was homogenized in 1 ml 
TRIzol using a mini-beadbeater (MBB-8 Cell Disrupter, Biospec products, Bartlesville, 














































GLH 220, Omni International, Kennesaw, GA, USA) for bone and uterus or endometrium. 
Protein and mRNA were isolated from TRIzol containing homogenized samples according 
to the manufacturer’s instructions. Only protein samples with a concentration of more 
than 125 µg/ml as determined with the Pierce bicinchoninic acid (BCA) protein assay 
kit (Thermo Scientific, Waltham, MA, USA, #23225) were included in the analysis. The 
mRNA concentration was measured using a NanoDrop Spectrophotometer (ND-1000, 
NanoDrop Technologies, Wilmington, DE, USA). Only mRNA samples with a 260/280 
absorbance ratio between 1.8 and 2.1 were included in the analysis. 
Table B: Background data for human breast and endometrium samples.
Sample 
no. Age Characteristics
Breast 1 76 No use of oral contraceptives, tissue irradiated, no tumor in 
sampled breast, post-menstrual
2 52 No use of oral contraceptives, tissue not irradiated, tumor in 
sampled breast, menstrual cycle day 14
3 75 No use of oral contraceptives, tissue not irradiated, tumor in 
sampled breast, post-menstrual
4 37 No use of oral contraceptives, tissue not irradiated, tumor in 
sampled breast, menstrual cycle day 14
5 48 No use of oral contraceptives, tissue not irradiated, no tumor 
in sampled breast, post-menstrual
Endometrium 1 45 No use of contraceptives, menstrual cycle day 5-6
2 46 No use of contraceptives, menstrual cycle day 7-8
3 46 No use of contraceptives, menstrual cycle day 8-10
4 45 No use of contraceptives, menstrual cycle day 10
5 49 No use of contraceptives, menstrual cycle day 13-15
Western blot
For Western blot analysis, 10 µg of the cell or tissue protein sample was mixed 
with 5x Laemmli sample buffer (60 mM Tris-HCl pH 6.8 (Tris: Roche, Mannheim, 
Germany, # 732010) (HCl: Merck, Darmstadt, Germany, #1.00317.1000), 2% sodium 
dodecyl sulfate (SDS) (Sigma, Zwijndrecht, the Netherlands, #L4390), 10% glycerol 
(Acros Organics, Pittsburg, PA, USA, #327255000), 0.01% bromophenol blue (Sigma, 
Zwijndrecht, the Netherlands, #B0126)) supplemented with 5% β-mercaptoethanol 
(Fluka, Buchs, Switzerland, # R02701). After denaturation at 95°C for 3 minutes, 30 µl 





























the Netherlands, #456-1033). Electrophoresis was carried out at 50V for 30 minutes 
followed by 100V for 30 minutes using anode buffer (0.2 M Tris-HCl, pH 8.9) and cathode 
buffer (Biorad, Veenendaal, the Netherlands, # 161-0744, 1x buffer containing 0.1 M Tris, 
0.1 M Tricine, 0.1% SDS, pH 8.3). Protein was transferred to Immobilon-FL, 0.45 µm pore 
size PVDF membrane (Millipore BV, Billerica, MA, USA, # IPFL00010) at 100V for 1 hour 
in Tris-glycine buffer (1.92 M glycine, 0.25 M Tris) (glycine: Calbiochem, Nottingham, 
UK, #3570) containing 20% methanol (Biosolve, Valkenswaard, the Netherlands, 
#13683502). Subsequently, the membranes were blocked with Odyssey blocking buffer 
(LI-COR, Lincoln, NE, USA, #927-40000) for 1 hour after which the membranes were 
probed overnight with an ERα primary antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA, 2Q418 # sc-71064) or an ERβ primary antibody (Cell Signaling, Danvers, MA, 
USA, #5513), both diluted 1:500, and with glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) primary antibodies (Cell Signaling, Danvers, MA, USA, #2118) diluted 1:1000 in 
Tris-buffered saline (NaCl: Merck, Darmstadt, Germany, #1.06404.1000) containing 1% 
Tween 20 (Merck, Darmstadt, Germany, #8.221840500) (TBS-T) and 5% bovine serum 
albumin (BSA) (Sigma, Zwijndrecht, the Netherlands, #A6003). The following day the 
membranes were washed with TBS-T and incubated for 1 hour with infrared dye-labeled 
IRDye 800CW Donkey anti-mouse IgG (LI-COR, Lincoln, NE, USA, # 926-32212) and IRDye 
680 Donkey Anti-Rabbit IgG (LI-COR, Lincoln, NE, USA, #926-32223). The final protein 
level was detected and quantified using an Odyssey infrared imaging system (Westburg, 
Leusden, the Netherlands).
cDNA synthesis
Prior to cDNA (complementary DNA) synthesis, 1 µg of mRNA sample was made 
DNA free by DNase treatment (Invitrogen, Paisley, Scotland, #18068-015) performed 
according to the manufacturer’s instructions. DNase was inactivated by addition of 
ethylenediaminetetraacetic acid (EDTA) (J.T. Baker, Phillipsburg, NJ, USA, # 1073) and 
heating the sample to 65°C for 10 minutes. Additionally, 0.5 µg of oligo dT (Invitrogen, 
Paisley, Scotland, DNA oligo dT 15 primer) and pd(N)6 random hexamer (Amersham, 
Buckinghemshire, UK, # 27-2166-01) were added to the sample prior to heating. The mix 
was placed directly on ice and 200 units of Moloney Murine Leukemia Virus (M-MLV) 
reverse transcriptase, RNaseH Minus, Point Mutant (Promega, Madison, WI, USA, 
#M3683), 10 nmol of each deoxynucleotide triphosphate (dNTP, Invitrogen, Paisley, 
Scotland, #18427-088), and reverse transcriptase (RT) buffer (Promega, Madison, WI, 
USA, #M531A, 1x buffer containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, and 
10 mM DTT) were added to a final volume of 20 µl. The mix was incubated for 10 minutes 














































cDNA samples were stored at -20°C. cDNA was diluted 20 times and 5 µl was added to a 
mixture of 12.5 µl of SYBR green supermix (BioRad, Veenendaal, the Netherlands, #170-
8885), 1 µl of each 10 μM primer, and 5.5 µl of milliQ. The quantitative polymerase chain 
reaction (qPCR) was performed on an iCycler iQ (BioRad, Veenendaal, the Netherlands) 
and data were analyzed with iCycler 3.1 software. Primer sequences for cell and human 
tissue samples were: ERα: forward 5’-CCTAACTTGCTCTTGGACAGGA-3’ and reverse 
5’-GCCAGCAGCATGTCGAAGAT-3’ (Biolegio, Nijmegen, the Netherlands), ERβ: forward 
5’-CGACAAGGAGTTGGTACACATGA-3’ and reverse 5’-CCAAGAGCCGCACTTGGT-3’ 
(Biolegio, Nijmegen, the Netherlands), heterochromatin protein 1 (HP-1): forward 5’-CC 
CACGTCCCAAGATGGAT-3’ and reverse 5’-CTGATGCACCACTCTTCTGGAA-3’ (Biolegio). 
Primer sequences for rat tissue samples were: ERα: forward 5’- TAAGAACCGGAGG 
AAGAGTTG-3’ and reverse 5’- TCATGCGGAATCGACTTG-3’ (Biolegio, Nijmegen, the 
Netherlands), ERβ: forward 5’- GAGCTCAGCCTGTTGGACC-3’ and reverse 5’- GGCCTTCAC 
ACAGAGATACTCC-3’ (Biolegio, Nijmegen, the Netherlands), rat ribosomal protein S18 
(S18): forward 5’- GTCCCCCAACTTCTTCTTAGAG-3’ and reverse 5’- CACCTACGGAAAC 
CTTGTTAC-3’ (Biolegio, Nijmegen, the Netherlands).
BrdU proliferation assay
T47D-ERβ cells were seeded in 96-well view plates at a density of 1.8*105 cells/ml, 100 μl/
well in phenol red free medium. Twenty-four hours after seeding, cells were washed with 
PBS and exposed to different tetracycline concentrations (0 to 1000 ng/ml as indicated, 
in phenol red free medium). Forty-eight hours after seeding, keeping the tetracycline 
concentrations constant, cells were exposed to the test compound. After 48 hours of 
exposure to the test compound, cell proliferation was determined by measuring 5-bromo-
2’-deoxyuridine (BrdU) incorporated into the DNA following Roche’s colorimetric BrdU 
protocol [9, 27]. BrdU, a pyrimidine analogue, was added to the cells during the last 
4 hours of exposure to the test compounds and was incorporated into the DNA of 
proliferating cells. This was detected by an antibody raised against BrdU, conjugated 
with the enzyme peroxidase, which was in turn detected by a substrate reaction. The 
subsequently produced blue color was quantified by measuring absorbance at 370 and 
492 nm (background) using a spectrophotometer (Spectramax microplate reader M2, 
MSD analytical technologies) [27].
Data analysis
The intensity of the ERα and ERβ bands on the Western blot reflecting the level of ERα 
and ERβ respectively, was quantified using the Odyssey infrared imaging system. The 
band intensities were expressed relative to the level of the endogenous GAPDH control 





























to the intensity of the corresponding ERα and ERβ protein bands of the T47D-ERβ cells 
without tetracycline (T47D-ERβ calibration standard, T47D-ERβ-CS), which was set to 1. 
Western blot T47D-ERβ-CS ERα intensity normalized to the reference protein was 11.6 
and ERβ intensity was 1.2. Although the GAPDH antibody used for the human and rat 
samples was the same, it cannot be excluded that it is more prone to bind either one, 
hampering direct comparison of absolute values for the ERα and ERβ levels found in rat 
and human samples or the human cell lines. For the calculation of the ERα/ERβ ratios, 
the preference of the GAPDH antibody to bind either to rat or human samples does not 
make a difference in the outcome, and therefore the protein ERα/ERβ ratios of rat and 
human samples and of human cell lines can be compared directly. Rat and human tissue 
ERα and ERβ levels represent the average result of 5 individual donor tissues ± standard 
deviation (SD).
QPCR data for the expression of ERα and ERβ in all cell and human samples were 
expressed relative to the expression of the reference gene HP-1 [29]. For more accurate 
normalization of ER levels and ratios it would be best to use multiple reference genes 
[30], but due to limited sample availability, this was not possible. QPCR data for the 
expression of ERα and ERβ in all rat samples were expressed relative to the expression of 
the reference gene S18 [31]. Although both are highly constitutive reference genes, one 
should keep in mind that absolute ERα and ERβ levels found in rat tissue samples cannot 
be directly compared to the ERα and ERβ gene expression levels found in human samples 
or the human cell lines. For the calculation of the ERα/ERβ ratios, the normalization to 
different reference genes does not make a difference in the outcome, and therefore the 
ERα/ERβ ratios of rat and human samples can be compared directly. Cell and tissue ERα 
and ERβ levels thus obtained were expressed relative to the T47D-ERβ-CS, determined 
as calibration sample on all plates to correct for plate-to-plate variations. The ERα and 
ERβ levels of the T47D-ERβ-CS were set to 1. QPCR T47D-ERβ-CS ERα level normalized 
to the reference gene was 0.6 and ERβ level was 2.2. Rat and human tissue ERα and ERβ 
levels represent the average result of 5 individual donor tissues ± SD. Levels higher than 
1 represent that the level is higher than that in the T47D-ERβ-CS, while levels lower 
than 1 represent a lower level than that in the T47D-ERβ-CS. 
Based on the results obtained, it appeared that the difference between individual 
rats was in the same order of magnitude as the difference between cycle points. Power 
analysis on the data revealed that 70 rats per cycle point would have to be used to be 
able to discriminate estrogen receptor levels per cycle point. Therefore it was decided 
to combine the data of the rats from different estrus cycles to determine the average 
ER levels (see results section). Also the results for the human tissues indicated that the 














































as the difference between cycle points. Assuming that a similar amount of human tissue 
donors would be needed to be able to discriminate estrogen receptor levels per cycle 
point as for the rat tissue, a very large number of human tissues would have to be used 
per cycle point. Therefore, it was decided to combine the data of the different menstrual 
cycle phases as was done for the rats (see results section).
For the BrdU cell proliferation assay, an EC
50
 concentration of E2 has been tested 
(n=6) for calibration of the results (30 pM E2). Obtained data points were expressed 
relative to the response of the cells treated with the EC
50
 concentration of E2, 
determined as calibration sample on all plates to correct for plate-to-plate variations. 
Cell proliferation levels have been measured in multiple 3 biological replicates, data 
presented here show results of one representative experiment ± SD of 6 technical 
replicates. EC
50
 values were calculated using PRISM V (GraphPad, San Diego, CA, USA). 
Results
ER levels and ratios in breast cancer cell models
In T47D-ERβ cells exposed to increasing tetracycline concentrations for 24 hours, both 
Western blot (Figure 1) and qPCR (Supplementary Figure S1) data reveal a tetracycline 
concentration-dependent decline in ERβ expression. As the ERα expression remained 
relatively constant (both Western blot and qPCR), a dose-dependent increase of the 
ERα/ERβ ratio was apparent. 
In addition to the T47-ERβ cells, also other breast cancer cell models were analyzed 
for their ERα/ERβ levels (Table C). The level of ERα in native T47D and MCF-7 cell lines is 
higher than the ERα level in the T47D-ERβ-CS, although the difference is less than one 
order of magnitude. Neither the native T47D, nor the MCF-7 cell model seem to express 
a detectable amount of ERβ (Table C). 
Table C: Level of ERα and ERβ in different breast cancer cell lines. 
Celltype
Western blot QPCR
ERα level ERβ level ERα level ERβ level
T47D-ERβ 1 1 1 1
T47D-wt 1.03 <DL 7.6 <DL
MCF-7 1.27 <DL 5.6 <DL
Levels expressed relative to the T47D-ERβ-CS set to 1, as determined by Western blot and qPCR. <DL: 
below detection limit. Cellular ERα and ERβ levels have been measured in multiple biological replicates, 





























Figure 1: Western blot results T47D-ERβ cells. (A) Western blot image of T47D-ERβ cells exposed to 
an increasing concentration of tetracycline for 24 hours. Upper (red) bands show ERα expression 
(image compiled from 2 gels) with right below (green) the corresponding GAPDH expression used for 
normalization. Lower (green) bands show ERβ expression (image compiled from 2 gels) with right below 
(also green) the corresponding GAPDH expression used for normalization. Corresponding tetracycline 
concentration is stated on top. (B) ERα and (C) ERβ protein level of T47D-ERβ cells exposed to increasing 
concentrations of tetracycline for 24 hours, normalized for GAPDH intensity and expressed relative to 
the levels in T47D-ERβ-CS set to 1 (n=1). (D) Corresponding ERα/ERβ ratio, expressed relative to the 
ERα/ERβ ratio in T47D-ERβ-CS set to 1. Cellular ERα and ERβ levels have been measured in 3 biological 
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ER levels and ratios in rat mammary gland tissue
The relative ERα and ERβ gene expression and protein levels and resulting ERα/ERβ 
ratios were also determined in rat mammary gland tissue. The results obtained are 
presented in Figure 2 (Western blot) and Supplementary Figure S2 (qPCR). Western blot 
results indicate that all tissue samples have ERα protein levels that are similar to the 
ERα protein levels detected in the T47D-ERβ-CS. At protein level, the ERβ level of the 
rat mammary gland tissue samples is up to 2 times lower than the ERβ protein levels 
detected in the T47D-ERβ-CS. At protein level, the relative ERα/ERβ ratio is up to 1.9-fold 
higher than that of the T47D-ERβ-CS. QPCR results confirm that to mimic rat mammary 
gland tissue ERα/ERβ ratios both at protein and mRNA level, the T47D-ERβ cells have to 
be exposed to tetracycline concentrations of >150 ng/ml. 
ER levels and ratios in human breast tissue
The relative ERα and ERβ levels and resulting ERα/ERβ ratios were also determined in 
human breast tissue. The results obtained are presented in Figure 2 (Western blot) and 
Supplementary Figure S2 (qPCR). Human breast tissues show ERα protein levels similar 




















Figure 2: Western blot results rat mammary gland and human breast tissue. ERα and ERβ protein 
levels in rat mammary gland and human breast tissue samples, normalized for GAPDH intensity 
and expressed relative to the levels in T47D-ERβ-CS set to 1, and the corresponding ERα/ERβ ratio, 
expressed relative to the ERα/ERβ ratio in T47D-ERβ-CS set to 1. Rat and human tissue ERα and ERβ 
levels represent the average result of 5 individual donor tissues ± SD. Black bars: ERα level. White bars: 





























are 0.7 times those in the T47D-ERβ-CS. At protein level, the relative ERα/ERβ ratio is 
1.5 times the ERα/ERβ ratio of the T47D-ERβ-CS. Combining these results with those of 
the qPCR shows that to mimic human breast tissue ERα/ERβ ratios at mRNA or protein 
level, the T47D-ERβ cells have to be exposed to tetracycline concentrations of >150 ng/ml.
ER levels and ratios in other estrogen-sensitive rat tissues
Relative ERα and ERβ levels and the resulting ERα/ERβ ratios determined in uterus from 
female, and prostate from male Sprague Dawley rats are presented in Figure 3 (Western 
blot) and Supplementary Figure S3 (qPCR). By applying similar reasoning as given 
above for the rat mammary gland and human breast tissue, the Western blot and qPCR 
data reveal that to best mimic uterus from female rats or prostate from male rats the 
T47D-ERβ cells should be exposed to respectively 500 and 0 ng/ml tetracycline (Table D). 
ER levels and ratios in other estrogen-sensitive human tissues
ERα and ERβ levels and the resulting ERα/ERβ ratios were also determined in human 
endometrium from premenopausal women undergoing hysterectomy for benign 
indications and prostate from BPH patients (Figure 3 (Western blot) and Supplementary 
Figure 3: Western blot results rat and human uterus or endometrium and prostate tissue. ERα and ERβ 
protein levels in rat and human uterus or endometrium and prostate tissue, normalized for GAPDH 
intensity and expressed relative to the levels in T47D-ERβ-CS set to 1, and the corresponding ERα/ERβ 
ratio, expressed relative to the ERα/ERβ ratio in T47D-ERβ-CS set to 1. Rat and human tissue ERα and 
ERβ levels represent the average result of 5 individual donor tissues ± SD. Black bars: ERα level. White 














































Figure S3 (qPCR)). By applying similar reasoning as given above for the rat mammary 
gland and human breast tissue, the Western blot and qPCR data reveal that to best 
mimic human endometrium or human prostate from BPH patients the T47D-ERβ cells 
should be exposed to respectively >500 and >150 ng/ml tetracycline (Table D).
Table D: Amount of tetracycline the T47D-ERβ cell line should be exposed to to best mimic ERα/ERβ 






Rat breast >150 >150
Human breast >150 >150
Rat uterus >150 ±500
Rat prostate 0 0
Human endometrium >500 ±500
Human prostate >150 >150
Figure 4: Cell proliferation measured as absorbance in the BrdU colorimetric method of T47D-ERβ cells 
exposed to 30 pM E2 at different tetracycline concentrations ranging from 0 (high ERβ expression) to 
1000 (no ERβ expression) ng/ml tetracycline. Cell proliferation levels have been measured in multiple 
biological replicates, data presented here show results of one representative experiment ± SD of 
6 technical replicates. Tetracycline exposure conditions to mimick ERα/ERβ ratios of several tissues 
are represented. Black: rat prostate. Light grey: rat mammary gland and human breast. Dark grey: 
human endometrium. At the higher tetracycline concentrations human breast (>150), rat mammary 





























The effect of E2 on cell proliferation at physiologically relevant ERα/ERβ ratios
In a final set of experiments the tetracycline-calibrated T47D-ERβ cell model was applied 
to characterize possible differences in tissue-specific responses to E2. To stimulate cell 
proliferation, cells were exposed to 30 pM E2. Figure 4 shows the tetracycline-dependent 
(and thus ERα/ERβ ratio-dependent) increase in cell proliferation. At 0 ng/ml tetracycline 
an absorbance (measure for cell proliferation) of 1 is measured, increasing up to 1.6 
times at 1000 ng/ml tetracycline. In this cell proliferation curve, the ERα/ERβ ratios of 
relevant tissues are represented. This reflects the different cell proliferation rates at the 
different ERα/ERβ ratios that are found in the different tissues. At the higher tetracycline 
concentrations human breast, rat mammary gland, and human endometrium partially 
overlap, showing a relatively high cell proliferation, while rat prostate ERα/ERβ ratios are 
best reflected by 0 ng/ml tetracycline, at which there is relatively low cell proliferation. 
Discussion
The aim of the present study was to define the conditions at which the ERα/ERβ levels 
in the T47D-ERβ breast cancer cells with tetracycline-dependent ERβ expression would 
best mimic the ERα/ERβ levels in rat and human breast and other estrogen-sensitive 
tissues in vivo, in order to further support their use as models for investigating the 
relationship of ERα and ERβ levels in estrogen-responsive tissues. To this end, the 
ERα/ERβ protein and mRNA levels and ratios in rat and human breast tissue and other 
estrogen-sensitive tissues (uterus or endometrium, prostate) were compared to the 
ERα/ERβ protein and mRNA levels and ratios found in the T47D-ERβ cell line exposed to 
increasing tetracycline concentrations.
The ERα/ERβ ratio has been shown to affect both physiology and pathology of 
hormone-sensitive organs [32] and a shift in the ERα/ERβ ratio could lead to adverse 
effects including proliferation and stimulation of tumor formation. This has been 
observed in breast and uterus when the ERβ level is relatively low compared to the ERα 
level [33, 34]. In contrast, a shift in the ERα/ERβ ratio could also lead to growth reduction 
(and progression of apoptosis) as observed in prostate when the ERβ level is relatively 
high compared to the ERα level and ERβ is stimulated with an ERβ-selective agonist 
[35]. It has been shown already for distinctive physiological processes that the ERα/ERβ 
ratios are at least as important as the levels of the two receptors [36]. However, the final 
cellular response to estrogenic compounds is dependent on ERα/ERβ ratios, but also on 
absolute ER subtype levels [37].
The T47D-ERβ cell line offers the potential to study different ERα/ERβ ratios at 














































Results from Western blot and qPCR analysis confirm that in the T47D-ERβ cell line 
the ERα/ERβ ratio increases with higher tetracycline concentration due to decreasing 
ERβ expression (Figure 1 and Supplementary Figure 1). This result is in line with data 
reported before by Ström et al. based on Western blot and qPCR analysis [7] and Sotoca 
et al. based on Western blot analysis [9]. ER levels have been measured with Western 
blot and qPCR. Western blot is a semi-quantitative technique, while qPCR is quantitative 
but does not measure absolute ERα and ERβ levels. It is important to note that the ERα/
ERβ ratios are expressed on a relative scale because Western blot and qPCR analysis do 
not quantify absolute values but quantify the ERα and ERβ levels on a relative scale. This 
is due to the use of different primers and antibodies with possible differences in affinity 
and effectiveness. The ERα/ERβ expression levels relative to the expression levels in 
the T47D-ERβ-CS reveal that for protein expression levels the data can be displayed on 
a log 2 scale while for mRNA expression levels a log 10 scale can be used. This reflects 
that at mRNA level ER expression is induced more distinctive than the subsequent ER 
expression at protein level. Such differences between levels of expression of a gene 
at protein or mRNA level are observed more often [38, 39]. These differences were 
systematic and observed for all samples, and thus do not affect the conclusions on the 
tetracycline concentration needed to mimic a specific tissue.
In addition to the T47D-ERβ cell line, also other cell lines which are frequently used to 
characterize estrogen-mediated activity, native T47D and MCF-7 cells, were tested for their 
ERα/ERβ levels and ratios and were compared to those from rat and human tissues. This 
revealed that the ERα levels in native T47D and MCF-7 cells were comparable to the ERα 
level in the T47D-ERβ-CS. The ERα/ERβ ratios found in the MCF-7 and native T47D cell lines, 
however, do not reflect the ratios in the analyzed tissues, mainly because these cell lines 
do not seem to possess ERβ. This raises the question to what extent the responses of these 
MCF-7 and native T47D cell lines to estrogen (ant(agonists)) reflect physiological relevance. 
The absence of ERβ and the resulting deviating ERα/ERβ ratios in these cell lines may be due 
to the fact that these are cancer cell lines, not representing the situation of normal tissue. 
Since the rat is one of the most used animal models, also in estrogen research, it was 
decided to compare the ERα/ERβ ratios in mammary gland collected from female rats to 
ERα/ERβ ratios which can be obtained in the T47D-ERβ cell model system measured at 
both protein and mRNA level. Although the results for Western blot (protein) and qPCR 
(mRNA) are not always directly comparable since mechanisms like post-translational 
regulation and (partial) degradation can play a role [37, 40], it was found that both 
protein and mRNA analysis in most cases show a similar trend, indicating that to mimic 
rat mammary gland tissue ERα/ERβ ratios the T47D-ERβ cells have to be exposed to 





























In a next step the ERα/ERβ ratios found in human breast tissue were compared 
to the ERα/ERβ ratios that can be obtained in the T47D-ERβ cell model system. Human 
breast tissue could be obtained from patients undergoing breast reducing surgery 
due to tumor formation. In normal breast tissue, the ERα/ERβ ratio is low and this 
ratio increases when a breast tumor progresses [20]. In this study the ERα/ERβ ratio 
relative to the T47D-ERβ-CS in the analyzed human breast tissues revealed limited inter-
individual variation in spite of differences between subject characteristics such as age, 
whether the analyzed tissue was irradiated, whether a tumor was present in the sampled 
breast, or the phase in the menstrual cycle at the moment of sampling (Table B). Our 
results indicate that to mimic human breast tissue levels of ERβ and ERα/ERβ ratios 
at both mRNA and protein level the T47D-ERβ cells have to be exposed to 150 ng/ml 
tetracycline or more. Rat and human samples from breast tissue showed similar results. 
This indicates that, at least based on ERα/ERβ levels, the rat is a valid model for human 
tissue in estrogen receptor research.
The ERα/ERβ ratio of other estrogen-sensitive rat and human tissues can also be 
mimicked in the T47D-ERβ cells, although differences in the role of coactivators and 
corepressors cannot be excluded. There could also be possible differential levels of ERα 
and ERβ expression between different cell types in these tissues [41-43]. The data of 
the present study further validate the T47D-ERβ cell line as an in vitro model to study 
the role of ERα/ERβ ratios. It is noted that this model is restricted to the T47D breast 
cancer cell line and if models in other cell types would be essential the use of siRNA as 
an efficient alternative approach to modulate ERα/ERβ ratios can be considered.
For rat uterus the ERα/ERβ ratios at both protein and mRNA level are in a similar 
range as the ratios in T47D-ERβ cells exposed to 500 ng/ml tetracycline or more. The 
phase of the estrus cycle of the sampled rats are presented in Table A. This cycle might 
influence the estrogen receptor levels present in the uterus. Wang et al. [44] described 
that during the proestrus phase the ERα level was most elevated, while the ERα level 
was a little less elevated during diestrus and even less during metestrus. ERβ levels did 
not differ too much between the phases of the estrus cycle of the rats, levels were only 
slightly elevated during metestrus and diestrus. 
Rat prostate ERα/ERβ ratios are relatively low compared to the ratios in other 
tissue samples, due to a high ERβ level. This relatively high level of ERβ in rat prostate 
tissue is in line with previously reported data [45, 46]. For the rat prostate samples, 
the resulting ERα/ERβ ratio is comparable to the ERα/ERβ ratio seen in the T47D-ERβ-
CS or even lower. This indicates that the best way to mimic the ERα/ERβ ratio in rat 
prostate with the T47D-ERβ cell model at both protein and mRNA level is to deprive the 














































an even slightly lower ERα/ERβ ratio. This cannot be accomplished with the T47D-ERβ 
cell line.
Human endometrium tissue predominantly expresses the ERα receptor [22]. The 
relatively high level of ERα in the human endometrium samples compared to other 
tissues was also confirmed in this research by both Western blot and qPCR analysis. 
For human endometrium tissue, ERα/ERβ ratios can be mimicked by the T47D-ERβ 
cell model at both protein and mRNA level after exposure of the cells to 500 ng/ml 
tetracycline or more.
Human prostate tissue was obtained from men with benign prostate hyperplasia. 
It is known that, in contrast to breast and endometrium tissue, in prostate tissue 
predominantly ERβ is present [22]. BPH patients have an increased level of both the ERα 
and the ERβ receptor in their prostate compared to healthy individuals [47]. The results 
for the human prostate samples indicate that to mimic human prostate tissue levels of 
ERβ and ERα/ERβ ratios at both protein and mRNA level the T47D-ERβ cells have to be 
exposed to 150 ng/ml tetracycline or more. The prostate tissue ERα/ERβ ratios varied 
between rat and human; rat ERα/ERβ ratios turned out to be much lower. This is in line 
with the finding that rat prostate has been shown to contain high levels of ERβ [46]. The 
deviating results for the observed ERα/ERβ ratio in rat and human prostate in our study 
could possibly be explained by the fact that the human subjects were diagnosed with 
BPH. For the human tissues it should be taken into account that, although the analyzed 
samples were not tumorous tissue, the presence of tumorous tissue in the patient could 
have altered the ERα/ERβ ratio compared to healthy tissue.
Comparing all ERα and ERβ levels of the analyzed tissues, it is striking that 
especially in rat and human breast tissue and human endometrium and prostate ERα 
levels are quite stable, while the variation in ERβ levels determines the variation in ERα/
ERβ ratio. This makes the T47D-ERβ cell line particularly suitable to investigate various 
estrogen-responsive tissues, since in this T47D-ERβ cell line the level of ERα is stable and 
comparable to the level of ERα in the various tissues, while the ERβ level can be varied 
by the addition of tetracycline.
In a final set of experiments the tetracycline-calibrated T47D-ERβ cell model was 
used to reveal possible differences in tissue-specific responses to estrogens using E2 as the 
model compound. Rat prostate tissue (mimicked by 0 ng/ml tetracycline) is less sensitive 
to induction of cell proliferation by E2 than human breast tissue or rat breast (mimicked 
by >150 ng/ml tetracycline), which in turn is less sensitive than human endometrium 
(mimicked by >500 ng/ml tetracycline). It is of interest to note that proliferation of the 
T47D-ERβ cells but also of estrogen-sensitive cells in vivo may be influenced by other 





























ligand-induced cell proliferation via estrogen-mediated pathways, the influence of other 
nuclear and growth factor receptors should also be considered, such as for example the 
activation of the progesterone receptor, which in certain cell lines has been shown to 
block estrogen-induced growth [48-50].
In summary, the results of the present study demonstrate how the T47D-ERβ cell 
line with tetracycline-dependent ERβ expression can mimic the ERα/ERβ ratio of rat 
and human breast and other estrogen-sensitive tissues, which further supports the use 
of this T47D-ERβ cell line as a valuable in vitro model to investigate the effect of this 
differential ERα and ERβ expression of tissues observed in vivo.
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Supplementary Figure S1: QPCR results T47D-ERβ cells. (A) ERα and (B) ERβ mRNA level of T47D-ERβ 
cells exposed to increasing concentrations of tetracycline for 24 hours, normalized for housekeeping 
gene and expressed relative to the levels in T47D-ERβ-CS set to 1, and (C) the corresponding ERα/
ERβ ratio, expressed relative to the ERα/ERβ ratio in T47D-ERβ-CS set to 1. Data presented here show 
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Supplementary Figure S2: QPCR results rat mammary gland and human breast tissue. ERα and ERβ 
mRNA levels in rat mammary gland and human breast tissue samples, normalized for housekeeping 
gene and expressed relative to the levels in T47D-ERβ-CS set to 1, and the corresponding ERα/ERβ 
ratio, expressed relative to the ERα/ERβ ratio in T47D-ERβ-CS set to 1. Rat and human tissue ERα and 
ERβ levels represent the average result of 5 individual donor tissues ± SD. For the human breast tissue, 
in this case there are 4 individual donor tissues, due to breakdown of the mRNA of the 5th sample. For 
one of those 4 samples, the ERα levels were below detection limits (<DL), and therefore also no ERα/
ERβ ratio was determined for this sample, so the results of 3 samples are presented. Black bars: ERα 
level. White bars: ERβ level. Grey bars: ERα/ERβ ratio.
Supplementary Figure S3: QPCR results rat and human uterus or endometrium and prostate tissue. 
ERα and ERβ mRNA levels in rat and human uterus or endometrium and prostate tissue, normalized 
for housekeeping gene and expressed relative to the levels in T47D-ERβ-CS set to 1. Levels ± SD (n=3), 
and the corresponding ERα/ERβ ratio, expressed relative to the ERα/ERβ ratio in T47D-ERβ-CS set to 1. 
Rat and human tissue ERα and ERβ levels represent the average result of 5 individual donor tissues 
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The aim of the present study was to investigate modulation of the interaction of 
ERα and ERβ with coregulators in responses induced by estrogenic compounds. 
To this end, selective ERα and ERβ agonists were characterized for intrinsic 
relative potency reflected by EC
50
 and maximal efficacy towards ERα and ERβ 
in ER-selective reporter gene assays, subsequently tested for induction of cell 
proliferation in T47D-ERβ cells with variable ERα/ERβ ratio, and finally for ligand-
dependent modulation of the interaction of ERα and ERβ with coregulators using 
the MARCoNI assay with 154 unique nuclear receptor coregulator peptides derived 
from 66 different coregulators. Results obtained reveal an important influence of 
the ERα/ERβ ratio and receptor selectivity of the compounds tested on induction of 
cell proliferation. ERα agonists activate cell proliferation, whereas ERβ suppresses 
ERα-mediated cell proliferation. The responses in the MARCoNI assay reveal that 
upon ERα or ERβ activation by a specific agonist, the modulation of the interaction 
of the ERs with coregulators are very similar, indicating only a limited number of 
differences upon ERα or ERβ activation by a specific ligand. Differences in the 
modulation of the interaction of the ERs with coregulators between the different 
agonists were more pronounced. Based on ligand-dependent differences in the 
modulation of the interaction of the ERs with coregulators, the MARCoNI assay 
showed to be able to classify the ER agonists discriminating between different 
agonists for the same receptor, a characteristic not defined by the ER-selective 
reporter gene or proliferation assays. It is concluded that the ultimate effect of 
the model compounds on proliferation of estrogen-responsive cells depends on 
the intrinsic relative potency of the agonist towards ERα and ERβ and the cellular 
ERα/ERβ ratio, whereas differences in the modulation of the interaction of the 
ERα and ERβ with coregulators contribute to the ligand-dependent responses 














































Estrogens present in the human body exert different physiological effects, for example 
in the development of secondary sexual characteristics and regulating the menstrual 
cycle in women [1, 2], as well as in the reproductive system in men [2, 3]. Estrogens 
also influence cell growth in several tissues [3-5]. They exert their effects by binding 
to estrogen receptor (ER)α and/or ERβ, thereby regulating gene transcription through 
ligand binding and modulation of the interaction of the ERs with coregulators [1, 6, 7]. 
The estrogenic effects of compounds depend on their relative binding affinities for both 
estrogen receptors [8, 9], but also on the ERα/ERβ ratio in the cells or tissue of interest 
and the type of coactivators binding to the ligand-ER complex [6, 7]. ERα and ERβ have 
been shown to differ in relative and absolute distribution and tissue levels, with ERα 
being dominantly present in for example breast and uterus [3, 5, 10, 11] and ERβ for 
example in the prostate [10, 12]. ERα and ERβ have been reported to exert counteracting 
effects on cell proliferation. Whereas ERα activation enhances cell proliferation [13], 
ERβ activation counteracts ERα-mediated cell proliferation [9, 14-17] and has been 
suggested to stimulate apoptosis [18-21].
Besides the ERα/ERβ ratio [22] and the ER selectivity of the estrogenic compound, 
also coregulator binding is of importance to induce estrogenic responses [11]. Coregulators 
influence the ER-mediated activation and transcription of target genes. Coactivators and 
corepressors regulate the response to estrogenic compounds, chromatin condensation, 
and mediate transcription [6, 23]. Dependent on the type of coregulators present in the 
cell that can bind to the ligand-ER complex, gene expression is induced and biological 
effects become prominent. This aspect of coregulator interaction with the ligand-ER 
complex in the cell has not been studied yet in great detail.
The aim of the present study was to investigate the modulation of the interaction 
of ERs with coregulators in the ERα- and ERβ-mediated cellular responses induced 
by estrogenic compounds. To this end, selective ERα and ERβ agonists were tested 
for intrinsic relative potency reflected by EC
50
 and efficacy towards ERα and ERβ to 
characterize their ER selectivity. The T47D-ERβ cell model, T47D human ductal breast 
epithelial cancer cells with variable ERα/ERβ ratio, was used to investigate the role of the 
ERα/ERβ ratio on the induction of cell proliferation by the selected model compounds. 
The ligand-dependent modulation of the interaction of ERα or ERβ with coregulators 
by the model compounds was investigated using a newly established Microarray Assay 
for Real-time Coregulator – Nuclear receptor Interaction (MARCoNI) based on ERβ-





























































The model compounds selected for the study were 17β-estradiol (E2), ERA-45, ERB-041, 
and genistein. E2 is known to be both an ERα and ERβ agonist with an approximate 10-fold 
higher potency towards ERα over ERβ as shown in ligand binding experiments with 
solubilized Spodoptera frugiperda 9 (Sf9) insect cell extracts and human osteosarcoma 
U2OS reporter cell lines [9, 26, 27]. ERA-45 has been reported to be a selective ERα 
agonist with a more than 35 times higher potency towards ERα over ERβ as shown in ERα 
and ERβ transactivation assays with Chinese hamster ovary (CHO) cells [28]. ERB-041 
has been reported to be a selective ERβ agonist with a more than 900-fold higher 
binding affinity for ERβ over ERα as shown in a competitive radio ligand binding assay 
[29]. Genistein is an ERβ-selective phytoestrogen [29] with a more than 14 times higher 
potency for ERβ over ERα when tested in U2OS reporter gene assays [17]. Progesterone 
is included in the studies as a negative control for ER activation [30, 31].
Cell culture
The human osteosarcoma (U2OS) cell lines, stably expressing ERα or ERβ in addition to a 
3x estrogen response element and TATA box binding protein combined with a luciferase 
gene (3x ERE-TATA-luciferase gene), were kindly provided by the Hubrecht Institute, 
Utrecht [9]. U2OS-ERα cells were grown in DMEM:F12, a 1:1 mixture of Dulbecco’s 
modified Eagle’s medium (DMEM) and Ham’s nutrient mixture F12 (Gibco, Paisley, 
Scotland, 31331-028), supplemented with 10% fetal calf serum (FCS) (Invitrogen, Paisley, 
Scotland, #10099), 0.5% non-essential amino acids (NEAA) (Gibco, Paisley, Scotland, 
11140-035), 0.2 mg/ml geneticin G418 (PAA Laboratories GmbH, Pasching, Austria, #P02-
012), and 0.05 mg/ml hygromycin (Duchefa, Haarlem, the Netherlands, # H0192.0001). 
U2OS-ERβ cells were grown in 1:1 DMEM:F12 culture medium supplemented with 10% 
FCS, 0.5% NEAA, and 0.2 mg/ml geneticin G418 [9]. 
T47D-ERβ cells were grown in a 1:1 DMEM:F12 culture medium (Gibco, Paisley, 
Scotland, #31331-038) supplemented with 5% FCS. To fully inhibit ERβ expression, 
1000 ng/ml tetracycline (Sigma, Zwijndrecht, the Netherlands, #T7660) was added to 
the medium. Every 10 passages, the cells were reselected with 0.5 μg/ml puromycin 













































to either 0 (high ERβ expression) or 1000 (no ERβ expression) ng/ml tetracycline for 
24  hours [9, 11]. All cells were incubated at 37°C and 5% CO2 in a humidified atmosphere. 
Because phenol red exerts estrogenic activity [32], at least 24 hours before 
exposure to the selected model compounds the cells were washed three times with 
phosphate buffered saline (PBS) (Gibco, Paisley, Scotland, #10010-015) and transferred 
to phenol red free medium (Gibco, Paisley, Scotland, #21041-025) supplemented with 
5% hormone-free dextran-coated charcoal-treated fetal calf serum (DCC-FCS) (Perbio 
Science, Waltham, MA, USA, #SH30068.05). For the U2OS cell lines, the phenol red free 
medium was also supplemented with 0.5% NEAA.
U2OS reporter gene assay
Cells were seeded in 96-well view plates (PerkinElmer, Groningen, the Netherlands, 
#655180) at a density of 105 cells/ml for U2OS-ERα and 7.5*104 cells/ml for U2OS-ERβ, 
100 μl/well. Twenty-four hours after seeding, medium was changed to phenol red free 
medium. Forty-eight hours after seeding, cells were exposed to the test compounds in 
triplicate in phenol red free medium. After 24 hours of exposure, cells were washed with 
0.5*PBS and lysed with 30 μl of hypotonic low-salt buffer containing (final concentrations) 
10 mM Tris (Sigma-Aldrich, St. Louis, MO, USA, #T1503), 2 mM dithiothreitol (DTT) (Sigma-
Aldrich, St. Louis, MO, USA, #D-0632), and 2 mM 1,2-diaminocyclohexanetetraacetic 
acid (CDTA) (Sigma-Aldrich, St. Louis, MO, USA, #32869); pH 7.8. Plates were kept on ice 
for at least 10 minutes and were subsequently stored at -80°C until analysis. One hour 
before measurement, plates were thawed on a plate shaker until they reached room 
temperature. Luciferase activity was determined using a luminometer (Labsystems, 
Luminoskan RS). In short, background light emission was measured for 2 seconds, 
after which 100 μl of flashmix (20 mM tricine (Sigma-Aldrich, St. Louis, MO, USA, 
#T5816), 1.07 mM (MgCO
3
)4Mg(OH)2*5H2O (Aldrich, Milwaukee, WI, USA, #22,766-8), 
2.6 mM magnesium sulfate (MgSO4, Sigma-Aldrich, St. Louis, MO, USA, #24.697-2), 
0.1 mM ethylenedinitrilotetraacetic acid (EDTA.2H2O, Merck, Darmstadt, Germany, 
#1.08418.1000), 2 mM DTT, 0.47 mM D-luciferin (Duchefa Biochemie, Haarlem, the 
Netherlands, # L1349.0250), and 5 mM adenosine triphosphate (ATP, Duchefa Biochemie, 
Haarlem, the Netherlands, # A1335.0010); pH 7.8) was automatically injected, followed 
by measurement of light emission for another 2 seconds, after which the light emission 
was extinguished with 50 μl 0.2 M sodium hydroxide (NaOH, Merck, Darmstadt, 


























































T47D-ERβ cells were seeded in 96-well view plates at a density of 1.8*105 cells/ml, 100 μl/
well in phenol red free medium. Twenty-four hours after seeding, cells were washed with 
PBS and exposed to different tetracycline concentrations (0 or 1000 ng/ml as indicated, 
in phenol red free medium). Forty-eight hours after seeding, cells were exposed to the 
test compounds which were added from 250 times concentrated stock solutions in 
dimethyl sulfoxide (DMSO) to result in the final concentrations indicated in the figures, 
keeping the tetracycline concentrations the same. After 48 hours of exposure to the test 
compounds, cell proliferation was determined by measuring 5-bromo-2’-deoxyuridine 
(BrdU) incorporated into the DNA following Roche’s colorimetric BrdU protocol [9, 34]. 
BrdU, a pyrimidine analogue, was added to the cells during the last 4 hours of exposure 
to the test compounds and was incorporated into the DNA of proliferating cells. This was 
detected by an antibody raised against BrdU, conjugated with a peroxidase, which was 
in turn detected by conversion of tetramethyl-benzidine. The subsequently produced 
blue color was quantified by measuring absorbance at 370 and 492 nm (background) 
using a spectrophotometer (Spectramax microplate reader M2, MSD analytical 
technologies) [34].
MARCoNI assay
Ligand-modulated interaction of coregulators with ERα or ERβ was assessed using 
a PamChip peptide microarray with 154 unique coregulator motifs derived from 66 
different coregulators (#88102 and #90012, PamGene International BV, Den Bosch, the 
Netherlands) as described previously [35]. In short, all incubations were performed 
on a PamStation®-12 or -96 (handling 12 or 96 arrays in parallel per run respectively) 
(PamGene) at 20°C using two cycles per minute. Polyhistidine (His) tagged ERα ligand 
binding domain (amino acids 302-552, partly purified from Escherichia coli (E. coli), 
final concentration between 1 and 10 nM) and His antibody penta-His Alexa Fluor 488 
conjugate (Qiagen, Germantown, MD, USA,#35310, final concentration 25 nM) were 
diluted in time-resolved fluorescence resonance energy transfer (TR-FRET) reaction 
buffer containing 20 mM Tris-HCl; pH 7.5 (Tris: Sigma-Aldrich, St. Louis, MO, USA, 
#T1503) (HCl: Merck, Darmstadt, Germany, #1.00317.1000), 500 mM NaCl (Merck, 
Darmstadt, Germany, #1.06404.1000), 0.2% bovine serum albumin (BSA, Calbiochem, 
Merck, Darmstadt, Germany, #126609), and 0.05% Tween 20 (Bio-Rad, Veenendaal, 
the Netherlands, #170-6531). Glutathione S-transferase (GST) tagged ERβ subtype-
specific ligand binding domain (amino acids 243-530 final concentration 10 nM) 
and anti-GST Alexa Fluor 488 conjugate (Molecular probes, Life Technologies Ltd, 













































coregulator buffer E (Invitrogen, Paisley, Scotland, #PV4540) supplemented with 5 mM 
DTT (Sigma, Zwijndrecht, the Netherlands, #43819). All mixtures were kept on ice until 
they were transferred to the PamChip microarrays. Ligand was predissolved in DMSO 
(concentrations as indicated, final DMSO concentration 2%). A reaction mixture with 
only DMSO (2% final concentration) served as negative control. 
Each array was blocked for 20 cycles using 25 μl of blocking buffer (Tris-buffered 
saline) (TBS, Bio-Rad, Veenendaal, the Netherlands, #170-6435) supplemented with 
0.01% Tween 20 (Bio-Rad, Veenendaal, the Netherlands, #170-6531) and 1% BSA 
(Calbiochem, Merck, Darmstadt, Germany, #126609). Next, the blocking buffer was 
removed by aspiration and the reaction mixture was added to the PamChip microarray 
together with the ligand in a final volume of 25 μl. This reaction-ligand mixture was 
incubated (pumped up and down the porous microarray membrane containing the 
154 unique coregulator peptides) for 80 cycles. Subsequently, unbound receptor was 
removed by washing of the arrays with 25 µL TBS and finally a tiff image of each array 
was acquired by the charge coupled device (CCD) camera of the PamStation.
Data analysis
For calibration of the results of all U2OS and BrdU assays, several concentrations of 
E2 were tested (each of the concentrations tested at least in triplicate) on each plate 
to correct for plate-to-plate variations. Data from the U2OS reporter gene assay were 
expressed in relative light units (RLU) corrected for the corresponding background 
signal measured before luciferase induction. EC
50
 values were calculated using PRISM 
V (GraphPad, San Diego, CA, USA). Potency of the compounds was determined based 
on the EC
50
 value and efficacy based on maximal height of induction of luciferase 
activity in the U2OS reporter gene assays and the maximal height of induction of cell 
proliferation as determined in the BrdU assay. Data from the BrdU assay were expressed 
as absorbance measured at 370 nm, corrected for the corresponding background signal 
at 492 nm. 
The concentrations of the model compounds tested in the MARCoNI assay were 
chosen based on their relative estrogenic potencies in the U2OS reporter gene assays. 
To accomplish a substantial binding signal in the MARCoNI assay, a concentration of 
approximately 105 times the EC
50 
concentration in the U2OS assays was tested. The 
highest concentration tested in MARCoNI assay was 10-4 M. MARCoNI assay image 
analysis was performed using BioNavigator (Version 5.1, PamGene International B.V.). 
Per array, the fluorescent signal of each spot, representative of ER binding to that 
particular coregulator motif, was quantified. Each tiff image (single array) was overlaid 

























































of each circle around its respective spot (actual peptide position) on the tiff image. The 
median fluorescence within each circle, as well as that in a defined area surrounding 
the circle, was quantified. For each spot, the binding signal as median fluorescent 
signal minus background for each peptide was calculated. The modulation index (MI) 
was subsequently calculated as the compound-induced log 10-fold change of binding 
(fluorescence) in the presence of ligand over that in the presence of solvent only. In 
addition, a Student’s t-test on ER binding was conducted to assess the significance 
of the compound effect (DMSO vs. compound-stimulated). Each array contains 154 
unique coregulator motifs and hence each compound is characterized by a 154-point 
MI signature.  Compound signatures were subjected to hierarchical clustering by 
Euclidean distance and average linkage. Hierarchical clustering was performed using 
stats packages in R (version 2.15.3, copyright© 2013 The R Foundation for Statistical 
Computing). Per receptor, compound (dis)similarities were visualized as a dendrogram 
of a clustered MI heatmap in which significance of the modulation of each interaction 
is indicated.
For E2, concentration-response curve fitting was performed using the dose 
response curve (DRC) package in R, by means of a sigmoidal, 4-parameter Hill (logistic) 
model (response=((A-D)/(1+((concentration/C)B)))+D, with parameters A=response 
minimum, B=Hill slope, C=EC
50
, and D=response maximum). 
Results
Characterization of the relative potency and efficacy of the model estrogens for ERα or ERβ
The U2OS-ERα and U2OS-ERβ reporter gene assays stably expressing ERα or ERβ were 
used to establish the intrinsic ability of the selected model compounds E2, ERA-45, 
ERB-041, genistein, and progesterone to induce ERα- or ERβ-mediated gene expression 
(Figure 1). Previously, E2 and genistein were characterized in these U2OS cell models, 
leaving the specificity of the other selective agonist in these models to be established 
to allow comparison. From the observed concentration-response curves, EC
50
 values 
were determined and these are presented in Table A. E2 showed a 9-fold lower EC
50
 
value in the U2OS-ERα than in the U2OS-ERβ cell line (Figure 1A, 1C, Table A). The EC
50
 
value for the selective ERα agonist ERA-45 was 200-fold lower in the U2OS-ERα than in 
the U2OS-ERβ cell line and its Estradiol Equivalence Factor (EEF) ERα/EEF ERβ ratio was 
22 (Figure 1B, 1D, Table A), corroborating its development as a selective ERα agonist. 
ERB-041 showed selective ERβ properties, with an EC
50
 value of 0.5 μM in U2OS-ERβ cells, 
while for the U2OS-ERα cell line the EC
50
 value appeared to be higher than the highest 













































ERβ ratio of <0.0017 (Figure 1B, 1D, Table A), indicating ER selectivity of >588 (EEF ERβ/
EEF ERα ratio), corroborating its development as a selective ERβ agonist. EC
50
 values for 
genistein were 47-fold lower for ERβ compared to ERα and the EEF ERα/EEF ERβ ratio 
was 0.0023 (Figure 1A, 1C, Table A), which was in line with the previous identification 
of this phytoestrogen as a selective ERβ agonist (EEF ERβ/EEF ERα ratio of 435). The 
negative control progesterone showed no ER-mediated luciferase induction in either the 
U2OS-ERα or the U2OS-ERβ cell line. For the U2OS-ERα reporter gene assay, the order 
for maximal efficacy of the ligands is genistein = E2 ≈ ERA-45, while for the U2OS-ERβ 
reporter gene assay, the order for efficacy is genistein > E2 > ERA-45 > ERB-041.
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Figure 1: ERE-mediated luciferase activity in U2OS-ERα (A and B) and U2OS-ERβ (C and D) cells 
exposed to E2 (●), genistein (▼), ERA-45 (▲), ERB-041 (♦), and progesterone (■). Data points ± standard 
















































































































































































































































































































































































































































































































































































































































































The effect of the different model estrogens on cell proliferation at varying ERα/ERβ ratios
The T47D-ERβ cell line, T47D human ductal breast epithelial cancer cells with 
tetracycline-dependent ERβ expression and a constant ERα expression, was used as a 
model to investigate estrogen-mediated cellular effects on cell proliferation induced 
by the selected model estrogens as a function of cellular ERα/ERβ ratios [16]. The 
T47D-ERβ cells depleted of tetracycline, with ERβ being highly expressed, showed no 
cell proliferation upon incubation with the estrogenic model compounds (Figure 2).
When suppressing ERβ by exposing the cells to 1000 ng/ml tetracycline, cell 
proliferation was induced by an increasing concentration of E2, ERA-45, and at relatively 
high concentrations also by genistein (Figure 2A-C). EC
50
 values for cell proliferation 
of the T47D-ERβ cells with only ERα expressed are in the same order as EC
50
 and EEF 







genistein (Table A). As for maximal efficacy, the order ERA-45 ≈ E2 > genistein differs 
from the U2OS-ERα reporter gene assay (genistein = E2 ≈ ERA-45), which points towards 
a more prominent role for the potency rather than the efficacy of a compound in the 
correlation between the induction of gene expression and the induction of biological 
effects. The ERβ agonist ERB-041 as well as the negative control progesterone did not 
induce cell proliferation (Figure 2D, 2E).
Estrogen receptor-specific modulation of the interaction of ERs with coregulators by 
selective estrogenic model compounds 
To investigate differential compound-induced modulation of the interaction of ERs with 
coregulators upon ligand binding to either ERα or ERβ, both ERs were tested for ligand-
induced coregulator binding in the MARCoNI assay [25]. As an example, Figure 3 shows 
the E2 concentration-dependent induction of ERα-LBD binding (Figure 3A) and ERβ-LBD 
binding (Figure 3B) to the coactivator-derived peptide NCOA1_677_700. 
Supplementary Figure S shows the E2 concentration-response curves of ERα-LBD 
binding (Supplementary Figure S1) and ERβ-LBD binding (Supplementary Figure S2) to 
all 154 unique coregulator-derived peptides from 66 different coregulators. Of the 154 
unique coregulator motifs, ERα showed concentration-dependent responses for 75 and 
ERβ for 52 coregulator motifs when induced with E2 (taking into account the goodness-
of-fit to the sigmoidal model with a coefficient of determination (R2) >0.9). Forty-six 
coregulator motifs showed a concentration-dependent effect with E2 for both ERα and 
ERβ. This implies that of the 52 modulated interactions of the ERβ-LBD with coregulator 

























































Figure 2: Effect of (A) E2, (B) genistein, (C) ERA-45, (D) ERB-041, and (E) progesterone on the 
proliferation of T47D-ERβ cells exposed to 0 (●) or 1000 (■) ng/ml tetracycline (respectively high and 










































































































































 values for the coregulator motifs with R2 >0.9 were generally in the same order of 
magnitude (Supplementary Table S). The median EC
50
 value for the coregulator motifs 
with an R2 >0.9 activated upon E2 binding to the ERα-LBD was lower than that for E2 
binding to the ERβ-LBD, i.e. 13 and 34 nM respectively (Supplementary Table S). This lower 
EC
50
 value for ERα compared to ERβ is in line with the lower EC
50
 for E2 in the U2OS-ERα 
than the U2OS-ERβ reporter gene assay, although the fold difference is somewhat less 
in the MARCoNI assay (i.e. 2.6-fold) as compared to the 9-fold difference in the reporter 
gene assays. Among the E2 activated coregulators showing a concentration-response 
with R2 >0.9 for both ERα and ERβ were for example nuclear coactivator (NCOA) motifs 
NCOA1_677_700, NCOA2_628_651, and NCOA3_673_695, derived from the Sarcoma 
(SRC)-family of coregulators known to stimulate gene expression [36, 37]. It is also of 
interest to note that of the modulation of the interaction of ERs with all 154 coactivator 
motifs, 74 (48%) were not modulated in a well-fitting concentration-dependent 
manner (R2 <0.9) upon ligand binding. For example coactivator centromere protein R 
(CENPR_1_18) and zinc transporter 9 (ZNT9_449_471) did not show E2-induced binding 
for both ERα and ERβ, even though other studies have shown them to be likely a 
coactivator for ERα [24, 38, 39]. In addition also some well-known nuclear corepressor 
(NCOR) motifs, like NCOR1_1925_1946 and NCOR2_2330_2352 [40], did not show a 




















Figure 3: Concentration-response curves for (A) ERα-LBD and (B) ERβ-LBD binding to the coactivator-
derived binding motif NCOA1_677_700 in the MARCoNI assay induced by E2. Binding in arbitrary units 




































































































Figure 4 shows a comparison of the modulation of the interaction of ERα with 
coregulators and modulation of the interaction of ERβ with coregulators for E2. From 
this figure it can be concluded that the MI patterns for E2 for ERα- and ERβ-mediated 
coregulator binding are remarkably similar with only a few subtle differences for possible 
ER-specific coregulator motifs. One of those possible ER-specific coregulator motifs is 
DEAD box (DDX)5_133_155 (indicated with an arrow in Figure 4). Figure 5 shows that this 
possible ER type specificity of coregulator motif DDX5_133_155 also holds for ERA-45, 
ERB-041, and genistein.
The model compounds were classified based on hierarchical clustering of the ER-
coregulator MI profiles using Euclidian distance (Figure 6). The results reveal that ERA-45, 
ERB-041, and genistein resulted in MI patterns similar to the reference compound E2, 
but each of these compounds showed its own specific potency (the potentcy of the 
compounds in the U2OS reporter gene assay correlates with color intensity in the 
hierarchical clustering). As expected, the negative control progesterone hardly induced 
any modulation of the interaction of ERs with coregulators. For ERα (Figure 6A), E2 was 
found to cluster together with the ERα agonist ERA-45, whereas ERB-041 and genistein, 
which both have a preference for ERβ (based on EEF in the reporter gene assay), also 
cluster together. The negative control progesterone only clusters with the DMSO control. 
For ERβ (Figure 6B), ERα agonist ERA-45, ERB-041, and genistein cluster together, while 
E2 is also associated with these model compounds, and here again progesterone did not 
cluster with the other model compounds except for the DMSO control. As for maximal 
efficacy, the order ERA-45 ≈ E2 > genistein in the cell proliferation assay is different from 
the U2OS-ERα reporter gene assay (genistein = E2 ≈ ERA-45). For the U2OS-ERβ reporter 
gene assay, the order for maximal efficacy is genistein > E2 > ERA-45 > ERB-041. The 
hierarchical clustering of the MARCoNI assay does not explain these orders in efficacy. 
It seems that other factors than modulation of the interaction of ERs with coregulators 
are responsible for these differences.
Differences in the MI patterns for the four ER agonists tested mainly appeared in 
the extent of the modulation being generally higher for ERα (Figure 6A) with E2 and 
ERA-45 (compounds with higher potency) than with genistein and ERB-041 (compounds 
with lower potency). For ERβ (Figure 6B), the extent of the modulation was generally 
higher with E2 than with the other three agonists.  
When multiple binding motifs of one coregulator are present in the MARCoNI 
assay, the modulation of the interaction of ERs with different motifs belonging to one 
coregulator are not all modulated in the same manner (for example all melanoma 
antigen preferentially expressed In tumors (MAPE) motifs, Figure 6). This might indicate 




























































































































































































































































































































































































































































































































































































































































Figure 6: MI heatmap of (A) ERα and (B) ERβ interaction with coregulators across compounds and 
coregulators. Red represents positive MI, blue represents negative MI. In the heatmap the significance 
















































An important factor that may influence the ultimate gene expression and biological 
effect induced by estrogenic compounds is the type of coregulators present in the 
cell that can interact with the ligand-ER complex. The aim of the present study was 
to investigate the modulation of the interaction of ERα and ERβ with coregulators in 
the ligand-dependent responses induced by estrogenic compounds. This study was 
conducted to better understand the differential effects and possible mechanisms of the 
model compounds that could explain their mode of ER subtype interactions.
E2 and the selective ERα agonist ERA-45 were able to induce ERE-mediated gene 
transcription in U2OS-ERα and -ERβ reporter gene assay with a higher potency towards 
ERα than towards ERβ. For E2, the 9-fold difference between the EC
50
 for ERα and the 
EC
50
 for ERβ in the U2OS reporter gene assays is in line with previous results [9]. For 
ERA-45, the U2OS reporter cell model shows a clear preference for ERα with EC
50
 values 
which are 200 times higher for ERβ than for ERα and an EEF ERα/EEF ERβ ratio of 22. 
Genistein was also able to activate both ERs, but with a 47-fold higher potency towards 
ERβ and the EEF ERα/EEF ERβ ratio of 0.0023 (Figure 1A, 1C, Table A), which is in line 
with the previous identification of this phytoestrogen as a selective ERβ agonist. This 
higher potency of genistein towards ERβ than towards ERα has been related to the 
inhibiting effects of genistein on tumor cell growth since ERβ activation has been shown 
to suppress ERα-mediated induction of cell proliferation [41-43], a phenomenon also 
observed in the present study. E2, the ERα agonist ERA-45, and genistein, which were 
able to induce ERE-mediated luciferase activity in the U2OS-ERα reporter cell model, 
were also able to induce cell proliferation in the T47D-ERβ cells when ERβ expression 
was inhibited. When ERβ was highly expressed in the T47D-ERβ cell model, these model 
compounds could no longer induce cell proliferation. This confirms that ERα induction 
leads to cell proliferation, whereas expression of ERβ counteracts cell proliferation. 
Together, these data in the T47D-ERβ cells corroborate the importance of the cellular 
ERα/ERβ ratio for the ultimate effect of an estrogenic compound on cell proliferation and 
indicate that the effect on a tissue of interest will vary with the cellular ERα/ERβ ratio. 
This is especially of importance given that ERβ levels are generally low in tumor tissue 
[14] facilitating estrogen-mediated cell proliferation of these cells, but also explaining 
the effectiveness of ER antagonists like for example tamoxifen [44] and fulvestrant [45] 
in cancer treatment. 
The results of the present study also indicate that the selectively developed ERβ 
agonist ERB-041 could induce ERE-mediated luciferase activity in the U2OS-ERβ cell 

























































agonist has also been described as not highly potent [6, 7, 24, 46]. Given the potential 
for highly potent ERβ agonists to counteract ERα-mediated effects on cell proliferation, 
development of more selective and potent ERβ agonists seem an important challenge for 
future research. Genistein tested in the present study is a good example of a compound 
that activates ERα only at concentrations at which it also activates ERβ, possibly 
underlying its more favourable estrogenic activity profile compared to the estrogenic 
activity profile of E2 which, at lower concentrations, may activate ERα without activating 
ERβ, as indicated in Figure 1. 
Given the fact that the reporter gene assays and the T47D-ERβ cell proliferation 
assays do not provide detailed mode of action on ERα- and ERβ-mediated estrogenic 
effects, a high-throughput in vitro assay enabling quantification of the modulation 
of the interaction of ERs with coregulators upon ligand binding would have the 
potential to add relevant information on the mode of action of the compounds under 
investigation. Previously it was shown that the ERα-based MARCoNI assay enables 
not only discrimination of ER agonists from antagonists, but could also discriminate 
between different agonists, a potential not provided by the U2OS or T47D cell models 
[25]. In the present study, a newly established MARCoNI assay based on ERβ-LBD was 
used together with the ERα-LBD-based MARCoNI [24, 25] to investigate modulation of 
the interaction of ERα and ERβ with coregulators in the ligand-dependent responses 
induced by estrogenic compounds.
The results of the present study revealed that the interaction of ERs with coregulators 
induced by either ERα- or ERβ-specific agonists are very similar. All model compounds 
show induction of known transcription coactivator motifs possessing intrinsic histone 
acetyltransferase activity NCOA1_677_700, NCOA2_628_651, and NCOA3_673_695 
[47]. Only a few ERα and ERβ subtype-specific modulations of the interaction of ERs 
with coregulators were detected. For example, the interaction of ERs with coregulator 
motif DDX5_133_155 showed positive modulation with ERβ, but not with ERα, for all 
agonists. DDX5 is a transcriptional coactivator for the tumor suppressor protein p53 
and is involved in the p53 transcriptional response to DNA damage and p53-dependent 
apoptosis [48]. The modulation of the interaction of ERβ with this DDX5 coactivator, but 
not of ERα, is in line with ERβ counteracting ERα-mediated cell proliferation by means 
of apoptosis. 
It is of interest to note that the differences in the modulations of the interaction of 
ERs with coregulators between the different ERα or ERβ agonists incubated with their 
respective receptors are limited, although subtle differences do allow discrimination 













































in the magnitude of the coregulator response resulting in variable MI values in the 
MARCoNI assay for different ER agonists. In this way modulation of the interaction of 
ERs with coregulators may affect the differences in the ultimate physiological response 
generated upon ER activation. However, the limited differences observed could also 
point towards possible competition for the ERE and for available coregulators as a mode 
of action explaining ERβ-mediated effects on ERα-induced responses.
The results of the present study also revealed that the ERβ agonist ERB-041 
did not induce ERE-mediated luciferase activity in the U2OS-ERα reporter cell model 
or cell proliferation in the T47D-ER cell model at the tested concentrations, but, in 
contrast to this, ERB-041 was able to induce modulation of the interaction of ERα with 
coregulators in the MARCoNI assay. It could be that at the high concentration (10-4 M) 
of ERB-041 tested in the MARCoNI assay ERB-041 binds to the ERα as well, an effect 
not detected in the U2OS assay and the BrdU cell proliferation assay since in these 
assays only concentrations up to 30 μM could be tested due to cytotoxicity occurring 
at higher concentrations. The ERβ-based MARCoNI assay was performed for the first 
time, and therefore agonist concentrations at expected maximum efficiacy were chosen 
and compared to efficacy of the agonists in the U2OS reporter gene assays and cell 
proliferation assay. To be able to investigate the potency of the antagonistic compounds 
in the MARCoNI assay, full dose response curves should be conducted. It is expected 
that the compounds that have a higher potency towards one of the ER subtypes will 
show modulation of the interaction of ERs with coregulators at a lower concentration 
upon interaction with the high potency ER subtype compared to the low potency ER 
subtype. This can be a valuable hypothesis for follow-up studies.
Quantitative hierarchical clustering of the estrogenic model compounds and the 
negative control progesterone tested in the present study based on modulation of the 
interaction of ERs with coregulators (Figure 6) showed that for ERα E2 was found to 
cluster together with the ERα agonist ERA-45, whereas the preferential ERβ agonists 
ERB-041 and genistein, although able to activate ERα, could be discriminated from E2 
and ERA-45. This illustrates the potential of the MARCoNI assay to discriminate between 
ERα and ERβ agonists. Progesterone, the negative control, stands alone and only clusters 
with the DMSO control. The hierarchical clustering of the model compounds in this study 
can be linked to their effect on cell proliferation as E2 and ERA-45, that are both able to 
induce cell proliferation in cells expressing ERα, and ERB-041 and genistein, ERβ agonists 
able to inhibit this ERα-mediated cell proliferation, cluster together in the hierarchic 

























































This compound comparison by using hierarchical clustering, discriminating E2 and 
ERA-45 from ERB-041 and genistein, could not be performed based on the U2OS or cell 
proliferation data. For ERβ, the ERα agonist ERA-45 turned out to be more similar to 
ERB-041 and genistein than to E2 as ERA-45, ERB-041, and genistein all cluster together. 
This clustering of the model compounds in the ERα- and ERβ-based MARCoNI assay is 
partially in line with what is expected based on the EC
50
 and EEF values of the model 
compounds in the U2OS cell models. In the U2OS-ERα cell line EC
50
 and EEF values of E2 
and ERA-45 are quite close, while for the U2OS-ERβ cell line the EC
50
 and EEF value of 
ERA-45 is closer to that of genistein than to that of E2 (Table A). Also for the ERβ-based 
data progesterone did not cluster with the other model compounds. 
As for maximal efficacy, the order ERA-45 ≈ E2 > genistein in the cell proliferation 
assay is different from the U2OS-ERα reporter gene assay (genistein = E2 ≈ ERA-45). 
For the U2OS-ERβ reporter gene assay, the order for maximal efficacy is genistein > 
E2 > ERA-45 > ERB-041. The hierarchical clustering of the MARCoNI assay does not 
explain these orders in efficacy. It seems that other factors than the modulation of the 
interaction of ERs with coregulators are responsible for the observed differences.
In the present study, although the profiles of the modulation of the interaction of 
ERs with coregulators between the different ERα or ERβ agonists incubated with their 
respective receptors are generally similar, the MARCoNI assay was shown to be able to 
classify the different ERα and ERβ agonists discriminating between different agonists 
for the same receptor, a characteristic not defined by the ER-selective reporter gene or 
proliferation assays. Most importantly, several coregulators showed distinct modulation 
upon exposure of the same ligand to ERα- and ERβ-LBDs. These coregulators have a 
potential to be used as markers to distinguish selective ERα agonists from ERβ agonists. 
The importance of the subtle differences for the ultimate biological effect remains to 
be established and is an important topic for future research, in which the presence of 
different coregulators in cells or tumors should be taken into account. It is concluded 
that in addition to the U2OS reporter gene assays and the T47D-ERβ cell proliferation 
assay, the MARCoNI-based coregulator binding assay provides valuable information in 
the ERα- and ERβ-dependent responses induced by estrogenic compounds.  
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Supplementary Figure S: Concentration-response curves for (1) ERα-LBD and (2) ERβ-LBD binding to 
the 154 coregulator-derived binding motifs in the MARCoNI assay induced by E2. Binding displayed in 
arbitrary units (AU).






























































 (underlined) values for ERα-LBD and ERβ-LBD binding 
to coregulator-derived binding motifs in the MARCoNI assay induced by E2, only displayed for 
concentration-response curves with R2 > 0.9. (continued)
Coregulator R2 ERα EC
50 
ERα (M) R2 ERβ EC
50 
ERβ (M)
BL1S1_1_11 0.99 1.38*10-08 0.93 2.94*10-08





EP300_69_91 0.99 2.55*10-08 0.95 3.14*10-08
GNAQ_21_43 0.99 9.09*10-09
HAIR_745_767_C755S/C759S 0.10 1.65*10-08 0.94 3.75*10-08
IKBB_277_299 0.98 4.18*10-08 0.96 5.02*10-08
ILK_131_153 0.90 8.96*10-09
JHD2C_2054_2076 0.99 2.12*10-08 0.95 3.01*10-08
LCOR_40_62 0.10 3.91*10-08 0.96 1.78*10-07
MAPE_382_404_C388S 0.10 3.47*10-12
MED1_591_614 0.10 1.08*10-08 0.95 2.50*10-08
MED1_632_655 0.98 3.16*10-08 0.92 3.41*10-08
MEN1_255_277 0.95 1.68*10-10
MLL2_4175_4197 0.10 1.26*10-08 0.92 6.13*10-07
MLL2_4702_4724 0.90 2.34*10-08
MTA1S_388_410_C393S/C396S 0.97 1.54*10-10 0.99 1.13*10-05
NCOA1_1421_1441 0.10 4.70*10-09 0.93 2.61*10-08
NCOA1_620_643 0.10 1.19*10-08 0.95 2.67*10-08
NCOA1_677_700 0.10 8.23*10-09 0.97 1.59*10-08
NCOA1_737_759 0.10 1.22*10-08 0.96 3.60*10-08
NCOA2_628_651 0.10 8.95*10-09 0.96 3.06*10-08
NCOA2_677_700 0.10 8.61*10-09 0.93 3.03*10-08
NCOA2_733_755 0.10 9.67*10-09 0.95 3.22*10-08
NCOA3_104_123_N-KKK 0.91 8.76*10-08 0.93 3.78*10-08
NCOA3_609_631 0.99 8.17*10-09
NCOA3_609_631_C627S 0.96 3.37*10-08 0.96 2.07*10-08
NCOA3_673_695 0.97 1.51*10-07 0.97 8.08*10-08

















































 (underlined) values for ERα-LBD and ERβ-LBD binding 
to coregulator-derived binding motifs in the MARCoNI assay induced by E2, only displayed for 
concentration-response curves with R2 > 0.9. (continued)
Coregulator R2 ERα EC
50 








NR0B1_1_23 0.10 1.19*10-08 0.96 2.89*10-08
NR0B1_136_159 0.99 7.91*10-09
NR0B1_68_90_C69S 0.10 8.97*10-09 0.97 2.78*10-08
NR0B2_106_128 0.96 3.05*10-08 0.93 3.45*10-08
NR0B2_201_223_C207S 0.10 1.31*10-08
NR0B2_9_31_C9S/C11S 0.98 4.97*10-08 0.97 3.03*10-08
NRBF2_128_150 0.99 3.28*10-07 0.93 2.76*10-08
NRIP1_1055_1077 0.10 6.71*10-09
NRIP1_120_142 0.10 1.33*10-08 0.96 4.42*10-08
NRIP1_121_143_P124R 0.10 1.17*10-08 0.94 3.45*10-08
NRIP1_173_195 0.99 1.43*10-08
NRIP1_173_195_C177S 0.10 9.78*10-09
NRIP1_253_275_C263S 0.10 1.13*10-08 0.96 4.71*10-08
NRIP1_368_390 0.96 3.58*10-08 0.99 3.75*10-08
NRIP1_488_510 0.10 1.09*10-08 0.98 2.78*10-08
NRIP1_700_722 0.10 1.09*10-08 0.97 4.19*10-08
NRIP1_701_723 0.10 1.49*10-08 0.98 6.44*10-08
NRIP1_805_831 0.98 1.64*10-08 0.96 4.21*10-08
NRIP1_924_946 0.10 1.25*10-08
NRIP1_924_946_C945S 0.10 1.09*10-08 0.98 2.33*10-08
NSD1_894_916 0.10 1.50*10-08 0.96 4.23*10-08
PELP1_168_190 0.94 3.70*10-08
PELP1_20_42 0.10 1.18*10-08 0.91 2.61*10-08


































































 (underlined) values for ERα-LBD and ERβ-LBD binding 
to coregulator-derived binding motifs in the MARCoNI assay induced by E2, only displayed for 
concentration-response curves with R2 > 0.9. (continued)
Coregulator R2 ERα EC
50 
ERα (M) R2 ERβ EC
50 
ERβ (M)
PRGC1_130_155 0.98 1.74*10-09 0.96 2.77*10-08
PRGC1_134_154 0.96 1.04*10-09
PRGC2_146_166 0.10 9.13*10-09 0.96 4.34*10-08
PRGC2_338_358 0.93 1.96*10-08 0.95 3.43*10-07
PROX1_57_79 0.95 1.21*10-06
TIF1A_373_395_C394S 0.97 9.48*10-09
TIF1A_747_769 0.10 4.51*10-09 0.92 1.70*10-08
TIP60_476_498 0.99 4.31*10-08 0.94 6.54*10-08
TREF1_168_190 0.10 1.09*10-08
TRXR1_132_154 0.96 7.84*10-08 0.92 3.41*10-08
UBE3A_649_671 0.93 4.76*10-08
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The aim of the present study was to investigate modulation of the interaction 
of ERα and ERβ with coregulators in the ligand-dependent responses induced 
by the ER antagonistic compounds 4OHT and fulvestrant. Comparison of these 
results to ligand-dependent interaction of ERα and ERβ with coregulators 
expressed in MI profiles for the ER agonist E2 will elucidate whether differences 
in the (ant)agonist-dependent interaction of ERα and ERβ with coregulators 
expressed in MI profiles contribute to the differences in (ant)agonist responses. 
To this end, the selected ER antagonistic compounds were first characterized for 
intrinsic relative potency reflected by IC
50
 and efficacy towards ERα and ERβ using 
ER-selective U2OS reporter gene assays, and subsequently tested for ligand-
dependent modulation of the interaction of ERα and ERβ with coregulators using 
the MARCoNI assay with 154 different nuclear receptor coregulator peptides 
derived from 66 different coregulators. Results obtained with the U2OS reporter 
gene assays indicate a preference of 4OHT to antagonize ERβ and find fulvestrant 
to be less ER-specific. The responses in the MARCoNI assay reveal that ERα- and 
ERβ-mediated interaction with coregulators expressed in MI profiles are similar 
for 4OHT and fulvestrant and generally opposite to the MI profile of the ER agonist 
E2. Hierarchical clustering with Euclidian distance as the cluster distance metric 
based on the MI profiles appeared able to clearly discriminate the two compounds 
with ER antagonistic properties from the ER agonist E2. Taken together, the data 
reveal that modulation of the interaction of ERs with coregulators discriminates 
ER agonists from antagonists but does not discriminate between the preferential 
ERβ antagonistic compound 4OHT and the less specific ER antagonist fulvestrant. 
It is concluded that differences in modulation of the interaction of ERα and ERβ 
with coregulators contribute to the differences in ligand-dependent responses 
induced by ER agonists and ER antagonists, but the importance of the subtle 
differences in modulation of the interaction of ERs with coregulators between 
the ER antagonistic compounds 4OHT and fulvestrant for the ultimate biological 














































Estrogens affect cell growth in several tissues [1-3]. These effects are modulated 
by binding of the estrogens to estrogen receptor (ER)α and ERβ, thereby regulating 
gene transcription [4-6]. Estrogenic compounds that bind to ERα and ERβ may be 
agonists inducing a physiological response similar to that induced by the natural ligand 
17β-estradiol (E2), or antagonists, of which the binding results in inhibition of the E2-
mediated activation and cellular responses [7, 8]. In addition to the nature of the ligand, 
being an agonist or antagonist, also the intrinsic potency and efficacy (partial or full) 
of the ligand for the two receptors [7, 9], and the ERα/ERβ ratio in the cells or tissue of 
interest is important for the ultimate biological effect [5-7, 10]. 
ERα and ERβ have been reported to exert counteracting effects on cell proliferation. 
ERα activation enhances cell proliferation [11], whereas ERβ activation counteracts ERα-
mediated cell proliferation [7, 12-15]. Therefore, ERα antagonism leads to repression of 
cell growth [16], whereas ERβ antagonism leads to enhanced cell proliferation [17]. It has 
been suggested that estrogen-mediated effects on cell proliferation through the action 
of ERα and ERβ are involved in the development and progression of cancer of especially 
estrogen-responsive tissues [12, 18]. For ER-positive breast tumors as well as for other 
estrogen-dependent tumors, it has been shown that in tumorous tissue compared to 
normal tissue the ERα/ERβ ratios increase due to a decreased ERβ expression [12]. This 
role for ER-mediated effects on cell proliferation and cancer is also reflected in the 
use of ER antagonists in hormonal cancer therapy for the treatment of ERα-positive 
breast cancer [8]. With appropriate endocrine therapy based on ER antagonists, patients 
with ERα-positive breast tumors have a better prognosis than those with ERα-negative 
tumors [19].
ER antagonistic compounds for the treatment of breast cancer include tamoxifen 
[20, 21] and fulvestrant [22]. Tamoxifen is a first line breast cancer drug widely used for 
treatment of ERα-positive breast cancers [23]. It acts by blocking the ER (both ERα and 
ERβ) [24, 25]. Tamoxifen would only properly work in breast cancer cells with relatively 
high ERα and low ERβ expression, since then tamoxifen will block ERα and thereby reduce 
ERα-induced cell proliferation [17]. 4-Hydroxytamoxifen (4OHT) is the active metabolite 
of tamoxifen, tested in the current study in the trans isoform, which possesses stronger 
anti-estrogenic activity than the cis isoform [26]. It has a 100 times higher potency 
towards both ER isoforms than tamoxifen itself [27]. In competition binding assays with 
E2, the compound 4OHT has a 1.6 times higher binding affinity for ERβ over ERα [28]. 
However, tamoxifen and 4OHT are not full ER antagonists, but are Selective Estrogen 





























































depending on the physiological context [21]. In contrast, fulvestrant is a full ERα and 
ERβ antagonist and is used as a second line breast cancer drug [29]. Fulvestrant acts by 
blocking both ERs and reducing cellular levels of ERα [8, 30-33]. In tests for its antagonist 
activity towards E2, it has a 9 times higher antagonistic preference for ERα over ERβ [34]. 
An important factor that may influence the ultimate gene expression and biological 
effect induced by estrogenic compounds is the type of coactivators that can bind to the 
ligand-ER complex. This aspect of interaction of ERs with coregulators has not been 
studied in great detail. It has been shown that these coregulators influence the ER-
mediated activation or repression and transcription of target genes. Coactivators and 
corepressors have a role in the response to estrogenic and anti-estrogenic compounds, 
chromatin condensation, and mediating transcription [5, 10, 35, 36]. 
Recently the modulation of the interaction of ERα and ERβ with coregulators in 
the ligand-dependent responses induced by ER agonists was investigated [37]. The data 
obtained revealed that differences in modulation of the interaction of ERα and ERβ 
with coregulators contribute to the different ligand-dependent responses induced by 
different ER agonists, but do not contribute significantly to the differences between ERα- 
and ERβ-mediated responses by a given ER agonist. The aim of the present study was 
to investigate modulation of the interaction of ERs with coregulators upon exposure to 
the ER antagonistic compounds 4OHT and fulvestrant. To this end, 4OHT and fulvestrant 
were tested for intrinsic relative potency reflected by IC
50
 and efficacy towards ERα and 
ERβ using human osteosarcoma U2OS reporter gene assays, and the ligand-dependent 
modulation of the interaction of ERα and ERβ with coregulators induced by the model 
compounds was investigated using a Microarray Assay for Real-time Coregulator – 
Nuclear receptor Interaction (MARCoNI) with 154 unique nuclear receptor coregulator 
peptides derived from 66 different coregulators. 
Materials and Methods
Cell culture
The U2OS cell lines, stably expressing ERα or ERβ in addition to a 3x estrogen response 
element and TATA box binding protein combined with a luciferase gene (3x ERE-
TATA-luciferase gene) were kindly provided by the Hubrecht Institute, Utrecht [7]. 
U2OS-ERα cells were grown in DMEM:F12, a 1:1 mixture of Dulbecco’s modified Eagle’s 
medium (DMEM) and Ham’s nutrient mixture F12 (Gibco, Paisley, Scotland, 31331-028) 
supplemented with 10% fetal calf serum (FCS, Invitrogen, Paisley, Scotland, #10099), 
0.5% non-essential amino acids (NEAA, Gibco, Paisley, Scotland, 11140-035), 0.2 mg/ml 













































hygromycin (Duchefa, Haarlem, the Netherlands, # H0192.0001). U2OS-ERβ cells were 
grown in 1:1 DMEM:F12 culture medium supplemented with 10% FCS, 0.5% NEAA, and 
0.2 mg/ml geneticin G418 [7]. All cells were incubated at 37°C and 5% CO2 in a humidified 
atmosphere. 
Because phenol red exerts estrogenic activity [38], at least 24 hours before exposure 
to the selected model compounds, cells were washed 3 times with phosphate buffered 
saline (PBS, Gibco, Paisley, Scotland, #10010-015) and transferred to phenol red free 
medium (Gibco, Paisley, Scotland, #21041-025) supplemented with 5% hormone-free 
dextran-coated charcoal-treated fetal calf serum (DCC-FCS, Perbio Science, Waltham, 
MA, USA, #SH30068.05) and 0.5% NEAA.
U2OS reporter gene assay
Cells were seeded in 96-well view plates (PerkinElmer, Groningen, the Netherlands, 
#655180) at a density of 105 cells/ml for U2OS-ERα and 7.5*104 cells/ml for U2OS-ERβ, 
100 μl/well. Twenty-four hours after seeding, medium was changed to phenol red free 
medium. Forty-eight hours after seeding, cells were exposed to the test compounds 
in triplicate, in phenol red free medium. 17β-Estradiol (E2) was chosen as the positive 
standard estrogenic agonist and used to characterize the antagonist properties of 
fulvestrant and 4OHT. E2 is known to be both an ERα and ERβ agonist with an approximate 
10-fold higher preference for ERα over ERβ as shown in ligand binding experiments with 
solubilized Spodoptera frugiperda 9 (Sf9) insect cell extracts and U2OS reporter cell lines 
[5, 39, 40]. Progesterone was included as a negative control for ER binding [41, 42]. 
After 24 hours of exposure, cells were washed with 0.5*PBS and lysed with 
30 μl of hypotonic low-salt buffer containing (final concentrations) 10 mM Tris, 
2 mM dithiothreitol (DTT, Sigma-Aldrich, St. Louis, MO, USA, # D-0632), and 2 mM 
1,2-diaminocyclohexanetetraacetic acid monohydrate (CDTA, Sigma-Aldrich, St. Louis, 
MO, USA, #32869); pH 7.8. Plates were kept on ice for at least 10 minutes and 
subsequently stored at -80°C until analysis. One hour before measurement, plates were 
thawed on a plate shaker until they reached room temperature. Luciferase activity was 
determined using a luminometer (Labsystems, Luminoskan RS). In short, background 
light emission was measured for 2 seconds, after which 100 μl of flashmix (20 mM tricine 
(Sigma-Aldrich, St. Louis, MO, USA, #T5816), 1.07 mM (MgCO
3
)4Mg(OH)2*5H2O (Aldrich, 
Milwaukee, WI, USA, #22,766-8), 2.6 mM magnesium sulfate (MgSO4, Sigma-Aldrich, 
St. Louis, MO, USA, #24.697-2), 0.1 mM ethylenedinitrilotetraacetic acid (EDTA*2H2O, 
Merck, Darmstadt, Germany, #1.08418.1000), 2 mM DTT, 0.47 mM D-luciferin (Duchefa 
Biochemie, Haarlem, the Netherlands, # L1349.0250), and 5 mM adenosine triphosphate 





























































automatically injected, followed by measurement of light emission for another 
2 seconds, after which the light emission was extinguished with 50 μl 0.2 M sodium 
hydroxide (NaOH, Merck, Darmstadt, Germany, # 1.06498.1000) [43].
For calibration of the results of all U2OS assays, 3 concentrations of E2 were tested 
(each of the concentrations tested at least in triplicate) on each plate to correct for plate-
to-plate variations. Data from the U2OS reporter gene assay were expressed in relative 





 values were calculated using PRISM V (GraphPad, San 
Diego, CA, USA). Potency of the compounds was determined based on the IC
50
 value 
and efficacy based on maximal height of the induction of luciferase activity in the U2OS 
reporter gene assays.
MARCoNI assay
Ligand-modulated interaction of coregulators with ERα or ERβ was assessed using 
a PamChip peptide microarray with 154 unique coregulator motifs derived from 66 
different coregulators (#88102 and #90012, PamGene International BV, Den Bosch, the 
Netherlands) as described previously [44]. In short, all incubations were performed 
on a PamStation®-12 or -96 (handling 12 or 96 arrays in parallel per run respectively) 
(PamGene) at 20°C using two cycles per minute. Polyhistidine (His) tagged ERα ligand 
binding domain (amino acids 302-552, partly purified from Escherichia coli (E. coli), 
crude lysate, final concentration between 1 and 10 nM) and His antibody penta-His 
Alexa Fluor 488 conjugate (Qiagen, Germantown, MD, USA,#35310, final concentration 
25 nM) were diluted in time-resolved fluorescence resonance energy transfer (TR-FRET) 
reaction buffer containing 20 mM Tris-HCl; pH 7.5 (Tris: Sigma-Aldrich, St. Louis, MO, 
USA, #T1503) (HCl: Merck, Darmstadt, Germany, #1.00317.1000), 500 mM NaCl (Merck, 
Darmstadt, Germany, #1.06404.1000), 0.2% bovine serum albumin (BSA, Calbiochem, 
Merck, Darmstadt, Germany, #126609), and 0.05% Tween 20 (Bio-Rad, Veenendaal, the 
Netherlands, #170-6531). Glutathione S-transferase (GST) tagged ERβ subtype-specific 
ligand binding domain (amino acids 243-530 final concentration 10 nM) and anti-GST 
Alexa Fluor 488 conjugate (Molecular probes, Life Technologies Ltd, UK, #A11131, 
final concentration 50 nM) were diluted in reaction buffer containing coregulator 
buffer E (Invitrogen, Paisley, Scotland, #PV4540) supplemented with 5 mM DTT (Sigma, 
Zwijndrecht, the Netherlands, #43819). All mixtures were kept on ice until they were 
transferred to the PamChip microarrays. The concentrations of the model compounds 





in the U2OS assays with 10
-4 M being the highest concentration tested in the MARCoNI 













































indicated, final DMSO concentration 2%). Reaction mixture with 2% DMSO served as 
negative control. Each array was blocked for 20 cycles using 25 μl of blocking buffer (Tris-
buffered saline) (TBS, Bio-Rad, Veenendaal, the Netherlands, #170-6435) supplemented 
with 0.01% Tween 20 (Bio-Rad, Veenendaal, the Netherlands, #170-6531) and 1% BSA 
(Calbiochem, Merck, Darmstadt, Germany, #126609). Next, the blocking buffer was 
removed by aspiration and the reaction mixture was added to the PamChip microarray 
together with the ligand in a final volume of 25 μl. This reaction-ligand mixture was 
incubated (pumped up and down the porous microarray membrane containing the 
154 different coregulator peptides) for 80 cycles. Subsequently, unbound receptor was 
removed by washing of the arrays with 25 µL TBS and finally a tiff image of each array 
was acquired by the charge coupled device (CCD) camera of the PamStation.
Data analysis
MARCoNI assay image analysis was performed using BioNavigator (Version 5.1, PamGene 
International B.V.). Per array, the fluorescent signal of each spot, representative of 
ER binding to that particular coregulator motif, was quantified. Each tiff image (single 
array) was overlaid with a synthetic grid of spot-sized circles. An algorithm was used to 
optimise placement of each circle around its respective spot (actual peptide position) 
on the tiff image. The median fluorescence within each circle as well as that in a defined 
area surrounding the circle (background) was quantified. For each spot the binding 
signal as median fluorescent signal minus background for each peptide was calculated. 
The modulation index (MI) was subsequently calculated as the compound-induced 
log 10-fold change of binding (fluorescence) in the presence of ligand over that in the 
presence of solvent only. In addition, a Student’s t-test on ER binding was conducted to 
assess the significance of the compound effect (DMSO vs. compound-stimulated). As 
each array contains 154 unique coregulator motifs, each compound was characterized 
by a 154-point MI profile. Obtained MI profiles were subjected to hierarchical clustering 
by Euclidean distance and average linkage. Hierarchical clustering was performed using 
stats packages in R (version 2.15.3, copyright© 2013 The R Foundation for Statistical 
Computing). Per receptor, compound (dis)similarities were visualized as a dendrogram 
of a clustered MI heatmap in which statistical significance of the modulation of each 
interaction was indicated.
For E2, ligand dose-response curve fitting was performed using the drc package 
in R, by means of a sigmoidal, 4-parameter Hill (logistic) model (response=((A-D)/
(1+((concentration/C)B)))+D, with parameters A=response minimum, B=Hill slope, C=EC
50
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Characterization of the intrinsic relative ERα or ERβ potency and efficacy of the selected 
antagonistic compounds
Intrinsic relative ERα or ERβ potency and efficacy of the ER antagonistic compounds was 
characterized using the U2OS cell lines stably expressing ERα or ERβ. The U2OS-ERα and 
U2OS-ERβ reporter gene assays were used to establish the intrinsic ability of the selected 
antagonistic compounds 4OHT and fulvestrant to counteract E2-mediated activation of 
ERα- (Figure 1) or ERβ- (Figure 2) dependent gene expression. Antagonistic effects were 
investigated by testing the compounds in the presence of E2 at its EC
50
; 6 pM for ERα 
(Figure 1) and 60 pM for ERβ (Figure 2). From the results obtained, the IC
50
 values for 
the antagonistic compounds were determined (Table A). 4OHT and fulvestrant show 
antagonistic effects towards both ERα and ERβ (Figure 1B and 2B). IC
50
 values for 4OHT 
are 18-fold lower for ERβ compared to ERα and the Estradiol Equivalence Factor (EEF) 
ERβ/EEF ERα ratio is 169, indicating a preference for ERβ (Figure 1B and 2B, Table A). IC
50
 
values for fulvestrant are about 4- to 5-fold lower for ERα than for ERβ, although the EEF 
ERβ/EEF ERα ratio is 2.1, indicating a much lower specific preference for one of the ER 
subtypes (Figure 1B and 2B, Table A). 
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Figure 1: ERE-mediated luciferase activity in U2OS-ERα cells exposed to (A) E2 (●), 4OHT (Ð), 
fulvestrant (ä), and progesterone (■) alone, or (B) 4OHT (Ð), fulvestrant (ä), and progesterone (■) 













































The negative control progesterone shows no changes in ER-mediated luciferase 
activity in the U2OS-ERα or U2OS-ERβ cell line, either in the presence or absence of 
E2. In both the U2OS-ERα or U2OS-ERβ reporter gene assay, efficacy for 4OHT and 
fulvestrant appear to be similar reflected by a similar maximum reduction of luciferase 





































E2 6.5 - NA 59.8 - NA NA 9.2 (agonist)
4OHT - 413 0.016 - 22.6 2.65 169 0.05 
(antagonist)
Fulvestrant - 308 0.021 - 1370 0.044 2.1 4.5 
(antagonist)
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Figure 2: ERE-mediated luciferase activity in U2OS-ERβ cells exposed to (A) E2 (●), 4OHT (Ð), 
fulvestrant (ä), and progesterone (■) alone, or (B) 4OHT (Ð), fulvestrant (ä), and progesterone (■) 





























































Estrogen receptor-specific modulation of interaction with coregulators by 4OHT and 
fulvestrant
To investigate differential compound-induced modulation of the interaction of ERα or 
ERβ with coregulators during ligand binding, both antagonistic compounds were tested 
with the so called MARCoNI assay in the presence of the ligand binding domain (LBD) of 
either ERα or ERβ [45]. 
In Figure 3 the ligand-dependent interaction of ERα and ERβ with different 
coregulator peptides for the two model compounds is displayed, expressed as the 
MI profile which is the ligand-induced log fold modulation of binding, for comparison 
presented together with the MI profile for the agonist E2. For both ERα (Figure 3A) and 
ERβ (Figure 3B), the interaction with coregulators expressed as modulation patterns 
induced by 4OHT and fulvestrant seem to be very similar and are clearly different 
from the modulation patterns for E2. In fact, the MI profiles of 4OHT and fulvestrant 
are for most coregulator motifs opposite to that of E2. For example, for both ERα and 
ERβ upon incubation with 4OHT and fulvestrant, nuclear coactivator (NCOA) motifs 
NCOA1_677_700, NCOA2_628_651, and NCOA3_673_695 show negative modulation, 
whereas upon incubation of the ERs with the agonist E2, positive modulation of 
interaction of ERs with these coactivator motifs is shown. 
For both 4OHT and fulvestrant, when multiple binding motifs of one coregulator 
are present in the MARCoNI assay, the binding to different motifs belonging to one 
coregulator are all negatively modulated, though not all equally strong (for example all 
nuclear receptor interacting protein 1 (NRIP1) motifs, Figure 3). 
Although the MI profiles induced by 4OHT and fulvestrant appeared similar, for ERβ 
one distinct difference is observed between the two antagonistic model compounds. 
Fulvestrant shows negative and 4OHT positive modulation of interaction of ERs with 
coregulator motif DEAD box (DDX)5_133_155 (indicated with an arrow in Figure 3B). The 
negative control progesterone showed only limited modulation of interaction of ERα 
and ERβ with coregulators (Supplementary Figure S).
To investigate to what extent the MARCoNI assay is able to discriminate ER agonist 
E2 from ER antagonistic compounds based on their MI profile, the model compounds 
were classified based on hierarchical clustering of the MI profile using Euclidian distance 
(Figure 4). For clustering based on ERα (Figure 4A) or ERβ (Figure 4B), the antagonistic 
compounds 4OHT and fulvestrant cluster together, discriminating clearly from agonist 
E2, whereas the negative control progesterone did not cluster with the other model 








































































































































































































































































































Figure 4: MI heatmap of (A) ERα and (B) ERβ, interaction with coregulators across compounds and 
coregulators. Red represents positive MI, blue represents negative MI. In the heatmap significance 
















































An important factor that may influence the ultimate gene expression and biological 
effect induced by ER antagonists is the type of coregulators that can bind to the ligand-ER 
complex. The aim of the present study was to investigate coregulator interaction with 
ERα and ERβ upon exposure to the ER antagonistic compounds 4OHT and fulvestrant. 
First the antagonist activity of these two model compounds towards ERα and ERβ was 
characterized using the U2OS-ERα and U2OS-ERβ reporter gene assays performed in the 
presence of E2. E2 was able to induce ERE-mediated gene transcription in the U2OS-ERα 
and U2OS-ERβ reporter gene assay with a higher potency for ERα than for ERβ. The 
9-fold difference between the EC
50
 for ERα and the EC
50
 for ERβ in the U2OS reporter 
gene assays is in line with previous results [7]. When combined with 6 or 60 pM E2 
in respectively the U2OS-ERα and U2OS-ERβ reporter gene assay (Figure 1B and 2B), 
both 4OHT and fulvestrant show clear antagonistic effects. 4OHT is not able to bring 
the E2-induced response completely back to baseline in the U2OS-ERα reporter gene 
assay, which can be interpreted as partial agonism [46]. The IC
50
 value for the antagonist 
activity of 4OHT appeared to be 18-fold lower for ERβ than for ERα with an EEF ERβ/EEF 
ERα ratio of 169, indicating a higher antagonistic potency towards ERβ. For fulvestrant, 
the IC
50
 value is 4.5-fold lower for ERα than for ERβ and the EEF ERβ/EEF ERα ratio is 2.1, 
indicating a much lower specific preference for one of the ER subtypes (Table A). The 
negative control progesterone was not able to induce or inhibit E2-induced responses 
in the U2OS-ERα and U2OS-ERβ reporter gene assay. These data indicate a difference 
in ERα or ERβ preference for the two model compounds. Efficacy towards the ERs were 
similar for 4OHT and fulvestrant.
To investigate whether differences in modulation of the interaction of ERs with 
coregulators play a role in the ERα- and ERβ-dependent responses to the antagonistic 
compounds, ligand-dependent modulation of the interaction of ERα and ERβ with 
coregulators by the different model compounds was determined in the MARCoNI assay. 
The ERβ-based MARCoNI assay was performed for the first time with antagonistic 
compounds and therefore antagonist concentrations at expected maximum efficacy 
were chosen. 
The results of the present study revealed that the MI profiles induced by 4OHT and 
fulvestrant appeared similar, but are clearly different from the MI profile for E2 (Figure 3). 
The MI profiles of 4OHT and fulvestrant are opposite to that of E2. The NCOA1, NCOA2, 
NCOA3, and NCOA6 coactivator motifs are negatively modulated by both ER antagonistic 
compounds in combination with both ER receptors, while for E2 these NCOA motifs are 





























































NCOR2 motifs are significantly negatively modulated in combination with both ERs, 
while both ER antagonistic compounds do not show significant modulation of these 
motifs (Figure 3). It is worth noting that in the MARCoNI assay the MI profiles induced by 
the antagonistic compounds 4OHT and fulvestrant can be detected directly, i.e. without 
the requirement for addition of E2, which is an unique property of the MARCoNI assay 
over the U2OS reporter gene assays.
The MI profiles induced by 4OHT and fulvestrant appeared similar, which indicates 
that these two compounds do share, to some extent, the same mode of action, 
especially by blocking the interaction of the ER with coactivator peptides. However, 
for ERβ, one distinct difference is observed between the two antagonistic compounds. 
Fulvestrant shows negative and 4OHT positive modulation of the interaction of ERβ 
with coregulator motif DDX5_133_155 (indicated with an arrow in Figure 3B). DDX5 is 
a transcriptional coactivator for the tumor suppressor protein p53 and is involved in 
the p53 transcriptional response to DNA damage and p53-dependent apoptosis [47]. 
The recruitment of this DDX5 coactivator motif by ERβ as induced by tamoxifen could 
be beneficial for ERβ reducing ERα-mediated cell proliferation since it could stimulate 
p53-dependent apoptosis. It is of interest to note that previously tested agonistic 
compounds showed positive modulation of the interaction of ERβ with coregulator 
motif DDX5_133_155 as well [37]. This could possibly be linked to the partial agonistic 
actions tamoxifen and 4OHT have in specific tissue [21].
The differences in the type of modulation of the interaction of ERs with coregulators 
between the different ER antagonistic compounds incubated with ERα or ERβ are limited. 
The MI profiles as well as the efficacy of 4OHT and fulvestrant in the U2OS reporter gene 
assays are very similar. 
Quantitative hierarchical clustering of the two ER antagonistic compounds 4OHT 
and fulvestrant, the ER agonist E2, and the negative control progesterone tested in the 
present study based on the interaction of ERs with coactivators (Figure 4) showed that 
for both ERα and ERβ, 4OHT was found to cluster together with fulvestrant and could 
clearly be discriminated from the negative control progesterone clustering together with 
DMSO, as well as from the ER agonist E2. This illustrates the potential of the MARCoNI 
assay to clearly discriminate between ER agonists and antagonists. A similar type of 
approach was previously shown for ERα coregulator modulation [45, 48]. 
In the present study, only subtle differences in the modulation of the interaction 
of ERα and ERβ with coregulators by a specific ligand were detected. The importance of 
the subtle differences for the ultimate biological effect remains to be established and 
they are an important topic for future research, in which also should be established 













































ligand-dependent differences in modulation of the interaction of ERs with coregulators 
the MARCoNI assay was shown to be able to discriminate the ER agonist E2 from ER 
antagonistic compounds. The similarity of the MI profiles induced by 4OHT and 
fulvestrant indicate that these two compounds share a similar mode of action. The 
differences in antagonistic activity of 4OHT and fulvestrant towards ERα and ERβ 
might be due to the subtle differences observed on the level of interaction of ERs with 
coregulators, however, further research is necessary to better understand the function 
of the identified coregulators in a cellular context.
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 (underlined) values for ERα-LBD and ERβ-LBD binding to 
coregulator-derived binding motifs in the MARCoNI assay induced by E2, only displayed for dose 
response curves with coefficient of determination R2 >0.9. (continued)
Coregulator R2 ERα EC
50 
ERα R2 ERβ EC
50 
ERβ
BL1S1_1_11 0.99 1.38*10-08 0.92 2.94*10-08





EP300_69_91 0.99 2.55*10-08 0.95 3.14*10-08
GNAQ_21_43 0.99 9.09*10-09
HAIR_745_767_C755S/C759S 1.00 1.65*10-08 0.94 3.75*10-08
IKBB_277_299 0.98 4.18*10-08 0.96 5.02*10-08
ILK_131_153 0.90 8.96*10-09
JHD2C_2054_2076 0.99 2.12*10-08 0.95 3.01*10-08
LCOR_40_62 1.00 3.91*10-08 0.96 1.78*10-07
MAPE_382_404_C388S 1.00 3.47*10-12
MED1_591_614 1.00 1.08*10-08 0.95 2.50*10-08
MED1_632_655 0.98 3.16*10-08 0.92 3.41*10-08
MEN1_255_277 0.95 1.68*10-10
MLL2_4175_4197 1.00 1.26*10-08 0.92 6.13*10-07
MLL2_4702_4724 0.90 2.34*10-08
MTA1S_388_410_C393S/C396S 0.97 1.54*10-10 0.99 1.13*10-05
NCOA1_1421_1441 1.00 4.70*10-09 0.93 2.61*10-08
NCOA1_620_643 1.00 1.19*10-08 0.95 2.67*10-08
NCOA1_677_700 1.00 8.23*10-09 0.97 1.59*10-08
NCOA1_737_759 1.00 1.22*10-08 0.96 3.60*10-08
NCOA2_628_651 1.00 8.95*10-09 0.96 3.06*10-08
NCOA2_677_700 1.00 8.61*10-09 0.93 3.03*10-08
NCOA2_733_755 1.00 9.67*10-09 0.95 3.22*10-08
NCOA3_104_123_N-KKK 0.91 8.76*10-08 0.93 3.78*10-08
NCOA3_609_631 0.99 8.17*10-09
NCOA3_609_631_C627S 0.96 3.37*10-08 0.96 2.07*10-08
NCOA3_673_695 0.97 1.51*10-07 0.97 8.08*10-08

































































 (underlined) values for ERα-LBD and ERβ-LBD binding to 
coregulator-derived binding motifs in the MARCoNI assay induced by E2, only displayed for dose 
response curves with coefficient of determination R2 >0.9. (continued)
Coregulator R2 ERα EC
50 








NR0B1_1_23 1.00 1.19*10-08 0.96 2.89*10-08
NR0B1_136_159 0.99 7.91*10-09
NR0B1_68_90_C69S 1.00 8.97*10-09 0.97 2.78*10-08
NR0B2_106_128 0.96 3.05*10-08 0.93 3.45*10-08
NR0B2_201_223_C207S 1.00 1.31*10-08
NR0B2_9_31_C9S/C11S 0.98 4.97*10-08 0.97 3.03*10-08
NRBF2_128_150 0.99 3.28*10-07 0.93 2.76*10-08
NRIP1_1055_1077 1.00 6.71*10-09
NRIP1_120_142 1.00 1.33*10-08 0.96 4.42*10-08
NRIP1_121_143_P124R 1.00 1.17*10-08 0.94 3.45*10-08
NRIP1_173_195 0.99 1.43*10-08
NRIP1_173_195_C177S 1.00 9.78*10-09
NRIP1_253_275_C263S 1.00 1.13*10-08 0.96 4.71*10-08
NRIP1_368_390 0.96 3.58*10-08 0.99 3.75*10-08
NRIP1_488_510 1.00 1.09*10-08 0.98 2.78*10-08
NRIP1_700_722 1.00 1.09*10-08 0.97 4.19*10-08
NRIP1_701_723 1.00 1.49*10-08 0.98 6.44*10-08
NRIP1_805_831 0.98 1.64*10-08 0.96 4.21*10-08
NRIP1_924_946 1.00 1.25*10-08
NRIP1_924_946_C945S 1.00 1.09*10-08 0.98 2.33*10-08
NSD1_894_916 1.00 1.50*10-08 0.96 4.23*10-08
PELP1_168_190 0.94 3.70*10-08
PELP1_20_42 1.00 1.18*10-08 0.91 2.61*10-08






















































 (underlined) values for ERα-LBD and ERβ-LBD binding to 
coregulator-derived binding motifs in the MARCoNI assay induced by E2, only displayed for dose 
response curves with coefficient of determination R2 >0.9. (continued)
Coregulator R2 ERα EC
50 
ERα R2 ERβ EC
50 
ERβ
PRGC1_130_155 0.98 1.74*10-09 0.96 2.77*10-08
PRGC1_134_154 0.96 1.04*10-09
PRGC2_146_166 1.00 9.13*10-09 0.96 4.34*10-08
PRGC2_338_358 0.93 1.96*10-08 0.95 3.43*10-07
PROX1_57_79 0.95 1.21*10-06
TIF1A_373_395_C394S 0.97 9.48*10-09
TIF1A_747_769 1.00 4.51*10-09 0.92 1.70*10-08
TIP60_476_498 0.99 4.31*10-08 0.94 6.54*10-08
TREF1_168_190 1.00 1.09*10-08
TRXR1_132_154 0.96 7.84*10-08 0.92 3.41*10-08
UBE3A_649_671 0.93 4.76*10-08
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The aim of the present study was to investigate by quantitative proteomics whether 
4OHT, active metabolite of the breast cancer drug tamoxifen, exerts ERα/ERβ 
ratio-dependent effects on cell proliferation and apoptosis. This is of importance 
given that the ERα/ERβ ratio usually increases in tumorous tissue compared to 
normal tissue due to decreased ERβ expression. ERα/ERβ ratio-dependent effects 
of 4OHT on protein expression were characterized in the T47D-ERβ human breast 
cancer cell line with tetracycline-dependent ERβ expression. Results reveal 
ERα/ERβ ratio-dependent effects of 4OHT on cell proliferation and apoptosis. 
Proteomics data are in line with decreased cell proliferation and increased 
apoptosis induced by 4OHT in the cells expressing only ERα. In cells expressing 
ERα and ERβ, proteomics data point at increased cell proliferation and decreased 
apoptosis upon 4OHT exposure. 4OHT also induced ERα/ERβ ratio-dependent post-
translational modifications, i.e. acetylation, methylation, and phosphorylation 
of several ribosomal and mitochondrial protein groups. Most post-translational 
modifications were observed upon 4OHT exposure in T47D-ERβ cells with both ERα 
and ERβ expressed. It is concluded that 4OHT affects major biological functions 
in T47D-ERβ cells including cell proliferation and apoptosis, with ultimate effects 
being dependent on the cellular ERα/ERβ ratio. There may be opposite effects 
regarding cell proliferation and apoptosis of 4OHT in tissue depending on the level 
of ERβ expression, with 4OHT being more effective in reducing cell proliferation 
and increasing apoptosis if ERα dominates and ERβ expression levels are low 
since 4OHT then antagonizes ERα. Based on the proteomics data of the present 
study it is concluded that ERα and ERβ levels and the ERα/ERβ ratio could be used 
as predictors of tamoxifen therapy responsiveness, with presence of ERα and 
absence of ERβ expression being optimal for inducing a 4OHT-mediated decrease 


























The two major estrogen receptors (ER), ERα and ERβ, influence cell proliferation and 
are suggested to be involved in the development and progression of certain forms of 
cancer of especially estrogen-responsive tissues, like breast and uterus [1-3]. Whereas 
ERα activation enhances cell proliferation [4], ERβ activation counteracts this effect [2, 
5-8]. Several studies associate ERβ activation with apoptosis [9-11]. It has been shown 
for ER-positive breast tumors (tumors that express ERs) as well as for other estrogen-
dependent tissue tumors at both messenger RNA (mRNA) and protein level that in 
tumorous tissue compared to normal tissue ERα/ERβ ratios increase due to a decreased 
ERβ expression [2]. 
Tamoxifen is used as a breast cancer drug in ER-positive breast cancer [12, 13]. 
4-Hydroxytamoxifen (4OHT) is the active metabolite of tamoxifen displaying a 100 times 
higher binding affinity than tamoxifen for both ERα and ERβ [14]. In this study, 4OHT 
is tested in its trans isoform, which is a stronger anti-estrogenic molecule than the 
cis isoform [15]. 4OHT is considered a partial ERα agonist and an antagonist for both 
ERα and ERβ [16]. The partial ERα agonist classification is due to the anti-estrogenic 
properties attributed to 4OHT in breast tissue, but pro-estrogenic behavior of 4OHT 
in the endometrium [17]. Given the counteracting influence of ERβ on ERα-mediated 
effects [7], it is of importance to take the ER specificity of 4OHT into account. Relative 
binding assays with recombinant ERα and ERβ in the presence of 17β-estradiol (E2) 
to show antagonism activity confirm this preference of 4OHT for ERβ, resulting in a 
2.3 times higher binding affinity for ERβ over ERα [18], while competition binding assays 
with E2 show a 1.6 times higher binding affinity for ERβ over ERα [19]. 
Furthermore, when studying the effects of 4OHT it is of importance to take into 
account the ERα/ERβ ratio of the cells or tissues under investigation. ERα and ERβ 
levels and the resulting ERα/ERβ ratios are known to be different in different estrogen-
responsive tissues [20-22]. For example human endometrium expresses mainly ERα, 
while in human prostate tissue ERβ is more prominently expressed. Human breast tissue 
normally expresses both receptors [20, 22].
Another mechanism which might be involved in the ERα/ERβ ratio-dependent 
effects of 4OHT could be the induction of post-translational modifications like 
methylation and acetylation, which can repress or activate gene transcription [23-25], 
and ubiquitination, which may affect protein degradation [26].
The aim of the present study was to investigate by quantitiative proteomics the 
4OHT-induced ERα/ERβ ratio-dependent proteins that affect cell proliferation and 









































the T47D-ERβ human breast cancer cell line with tetracycline-dependent ERβ expression 
by a mass spectrometry (MS)-based proteomics approach. 
Materials and methods
Cell culture
The T47D-ERβ cell line, consisting of T47D human ductal breast epithelial cancer cells 
with tetracycline-dependent ERβ expression, was made and provided by Ström et al. 
[6]. T47D-ERβ cells were cultured in a 1:1 mixture of Ham’s nutrient mixture F12 and 
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Paisley, Scotland, #31331-038) 
supplemented with 5% fetal calf serum (FCS) (Invitrogen, Paisley, Scotland, #10099). 
To fully inhibit ERβ expression, 1000 ng/ml tetracycline (Sigma, Zwijndrecht, the 
Netherlands, #T7660) was added to the medium [7]. To vary the cellular ERα/ERβ ratio, 
24 hours before exposure to 4OHT, the cells were exposed to specific tetracycline 
concentrations (either maintained at 1000 ng/ml (for full suppression of ERβ expression, 
only ERα expression) or brought to 0 ng/ml (ERα and ERβ expression)) [20]. The cells 
were incubated at 37°C and 5% CO2 in a humidified atmosphere. 
Because phenol red exerts estrogenic activity [27], at least 24 hours before 
exposure, cells were washed three times with phosphate buffered saline (PBS) (Gibco, 
Paisley, Scotland, #10010-015) and transferred to phenol red free medium (Gibco, 
Paisley, Scotland, #21041-025) supplemented with 0.5% hormone-free dextran-coated 
charcoal-treated fetal calf serum (DCC-FCS) (Perbio Science, Waltham, MA, USA, 
#SH30068.05).
BrdU proliferation assay
T47D-ERβ cells were seeded in 96-well view plates at a density of 1.8*105 cells/ml, 100 μl/
well in phenol red free medium. Twenty-four hours after seeding, cells were washed 
with PBS and exposed to 0 or 1000 ng/ml tetracycline (as indicated, in phenol red free 
medium). Forty-eight hours after seeding, keeping the tetracycline concentrations the 
same, cells were exposed to a concentration range of 4OHT, as well as to 30 pM E2 to 
induce cell proliferation. 30 pM E2 was determined to be the EC
50
 concentration for E2 
induction of cell proliferation in T47D-ERβ cells expressing only ERα [20]. After 48 hours of 
co-exposure to E2 and 4OHT, cell proliferation was determined by measuring 5-bromo-
2’-deoxyuridine (BrdU) incorporated into the DNA following Roche’s colorimetric BrdU 
protocol [7, 28]. BrdU, a pyrimidine analogue, was added to the cells during the last 
4 hours of exposure to the test compounds and was incorporated into the DNA of 

























with a peroxidase, which was in turn detected by conversion of tetramethyl-benzidine. 
The subsequently produced blue color was quantified by measuring absorbance at 370 
and 492 nm (background) using a spectrophotometer (Spectramax microplate reader 
M2, MSD analytical technologies) [28].
Protein sample preparation for proteomics analysis
T47D-ERβ cells were exposed to 0 or 300 nM 4OHT for 24 hours. Cells were washed 
twice in PBS and lysed in 1 ml of modified radio immunoprecipitation assay (RIPA) buffer 
consisting of 50 mM Tris-HCl; pH 7.4 (Tris (tris(hydroxymethyl)aminomethane): Roche, 
Mannheim, Germany, #732010) (HCl (hydrochloric acid): Merck, Darmstadt, Germany, 
#1.00317.1000), 1% Triton X-100 (BioRad, Veenendaal, the Netherlands, #161-0407), 0.25% 
sodium deoxycholate (Merck, Darmstadt, Germany, #6504), 150 mM sodium chloride 
(NaCl, Merck, Darmstadt, Germany, #1.06404.1000), 1 mM ethylenediaminetetraacetic 
acid (EDTA, Merck, Darmstadt, Germany, #1.08418.1000), and protease inhibitor 
cocktail (Complete, Mini) (Roche, Basel, Switzerland, #11836153001) at 4°C for 
20 minutes. Samples were sonicated for 30 minutes and centrifuged at 8000 rounds per 
minute (RPM), at 4°C for 15 minutes. The protein concentration of the supernatant was 
determined using a bicinchoninic acid (BCA) Protein Assay Kit (Pierce, Thermo Scientific, 
Waltham, MA, USA, #23225). 
Then 20 μg of the protein sample was mixed with 5x concentrated Laemmli sample 
buffer (250 mM Tris-HCl; pH 6.8, 10% sodium dodecyl sulfate (SDS, Sigma, Zwijndrecht, 
the Netherlands, #L4390), 50% glycerol (Acros Organics, Pittsburg, PA, USA, #327255000), 
0.1% bromophenol blue (Sigma, Zwijndrecht, the Netherlands, #B0126)). Subsequently, 
48 μl sample was loaded on a 12% Mini-PROTEAN_ TGX™ (Tris-glycine extended) precast 
gel (BioRad, Veenendaal, the Netherlands, #456-1044). Electrophoresis was carried 
out at 50 V for 30 minutes followed by 100 V for 30 minutes using 0.2 M Tris-HCl, pH 
8.9 as anode buffer and 0.1 M Tris, 0.1 M Tricine, 0.1% SDS, pH 8.3 as cathode buffer. 
The gel was stained using colloidal Coomassie blue (NOVEX® Colloidal blue staining kit, 
Invitrogen, Paisley, Scotland, #LC6025). Excess colloidal Coomassie blue was washed 
off with water (performed twice). Each lane was cut into 5 equal sections. Then 100 μl 
50 mM dithiotreitol (DTT, Sigma, Zwijndrecht, the Netherlands, #D9163) in 50 mM 
ammonium bicarbonate (NH4HCO3, Fluka, Sigma Aldrich, Zwijndrecht, the Netherlands, 
#09830) was added to each sample for cysteine reduction. The samples were sonicated 
for 1 minute and then incubated for 1 hour at 60°C. DTT was removed and 100 μl 50 mM 
iodoacetamide (Sigma, Zwijndrecht, the Netherlands, #I1149) in 50 mM NH4HCO3 was 
added for alkylation. The samples were sonicated for 1 minute and then incubated 









































100 μl 50 mM NH4HCO3 at pH 8. Subsequently, 100 μl 10 ng/μl trypsin (sequencing 
grade, Roche, Basel, Switzerland, #11047841001) in 50 mM NH4HCO3 was added to the 
gel pieces to perform proteolytic digestion at room temperature overnight. Samples 
were centrifuged and 25 μl of the supernatant containing the digested peptides was 
recovered and transferred to a new eppendorf tube. The pH was brought to 2-4 with 
10% trifluoracetic acid (TFA, Merck, Whitehouse Station, NJ, USA, #1.08262.0100). All 
samples were measured one time by nano liquid chromatography (LC)-LTQ (Linear Trap 
Quadropole)-OrbitrapXL-MS as described by Lu et al. [29].
Data analysis
For calibration of the results of the BrdU assays, on all plates, several concentrations of E2 
were tested (each concentration at least in n=3) to correct for plate-to-plate variations. 
Data from the BrdU assay were expressed as absorbance measured at 370 nm, corrected 
for the corresponding background signal at 492 nm.
LCMS runs with all MSMS spectra obtained were analyzed with MaxQuant 1.3.0.5 
[30] using default settings for the Andromeda search engine [31], except that extra 
variable modifications were set for de-amidation of asparagine (N) and glutamine (Q). 
In a second search, also phosphorylation of serine (S),threonine (T), and/or tyrosine (Y), 
methylation of lysine (K) or arginine (R), and ubiquitination (GlyGly) of K were included 
as variable modifications up to a maximum of 3 modifications per peptide. 
A homo sapiens database downloaded from Uniprot (http://www.uniprot.org, 
117448 entries, at November 30th 2011) was used together with a contaminants database 
that contains sequences of common contaminants as for instance: BSA (P02769, bovin 
serum albumin precursor), Trypsin (P00760, bovin), Trypsin (P00761, porcin), Keratin 
K22E (P35908, human), Keratin K1C9 (P35527, human), Keratin K2C1 (P04264, human), 
and Keratin K1CI (P35527, human). The “label-free quantification” as well as the “match 
between runs” (set to 2 minutes) options were enabled. 
The MS proteomics data have been deposited to the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org) via the PRIDE partner repository [32] 
with the dataset identifier PXD000615 (PRIDE: PXD000615).
Filtering and further bioinformatic analysis of the MaxQuant/Andromeda 
workflow output and the analysis of the abundances of the identified protein groups 
were performed with the Perseus 1.3.0.4 module (available at the MaxQuant suite). 
Accepted were peptides and proteins with a false discovery rate (FDR) of less than 0.1 
and proteins with at least 2 identified and quantified peptides of which at least 1 should 
be unique and at least 1 should be unmodified. Reversed hits were deleted from the 

























MS1 intensitiy (LFQ) value of 0 for both sample and control. The normal logarithm was 
taken from normalised LFQ as obtained from MaxQuant. Zero Log LFQ values (NaN) 
were replaced by 4.5. All samples were measured one time by nanoLC-LTQ-OrbitrapXL-
MS as described by Lu et.al. [29]. The 3 biological replicates for each test condition were 
grouped. Only proteins with 3 valid values in at least 1 group of triplicate samples were 
included to make sure the protein was clearly measured in all 3 samples. A two sample 
t-test was performed using the “LFQ intensity” columns obtained with FDR threshold 0.1 
and S0=1. 4OHT treated samples were tested against untreated samples with the same 
tetracycline concentrations. 
Results
The effect of 4OHT on T47D-ERβ cell proliferation 
The T47D-ERβ cell line, consisting of T47D human ductal breast epithelial cancer cells 
with tetracycline-dependent ERβ expression and a constant ERα expression, was 
used as the model to investigate ER-mediated cellular effects of 4OHT on E2-induced 
cell proliferation. When only ERα is expressed in the T47D-ERβ cells, E2-induced cell 
proliferation is decreased by an increasing concentration of 4OHT (Figure 1). The 
maximum decrease of cell proliferation is observed at 300 nM 4OHT. To be able to analyse 
differences in protein expression at an effective, non-cytotoxic 4OHT concentration, a 
Figure 1: Effect of 4OHT on the E2-induced proliferation of T47D-ERβ cells exposed to 1000 ng/ml 







































































concentration of 300 nM 4OHT was then chosen as the exposure concentration for the 
T47D-ERβ cells in the proteomics experiment.
Protein groups and networks influenced by 4OHT exposure in T47D-ERβ cells with 
varying ERα/ERβ ratios 
In the total data set obtained from the 4OHT-exposed and unexposed T47D-ERβ cells 
with varying ERα/ERβ ratios 2856 proteins were detected, of which 1739 proteins 
remained after very strict filtering (protein groups identified by at least 2 peptides of 
which at least 1 peptide had to be unique in the database and at least 1 peptide had 
to be unmodified, and only proteins with 3 valid values in at least 1 group of triplicate 
samples were included). At an FDR of 0.1 protein samples of 4OHT-exposed T47D-ERβ 
cells expressing ERα and ERβ show 45 significantly different expressed protein groups 
due to the 4OHT exposure when compared to unexposed T47D-ERβ cells expressing ERα 
and ERβ (Figure 2A). In Figure 3A the top ten affected molecular and functional classes 
are shown, including protein synthesis, gene expression, RNA post-transcriptional 
processing, and post-translational modifications. Table A shows the significantly up- 
and down-regulated protein groups of 4OHT-exposed T47D-ERβ cells expressing ERα 
and ERβ when compared to unexposed T47D-ERβ cells expressing ERα and ERβ and 
their biological functions. Table B reveals 18 networks that were affected in 4OHT-
exposed T47D-ERβ cells expressing ERα and ERβ compared to unexposed T47D-ERβ cells 
expressing ERα and ERβ, including top networks involved in RNA post-transcriptional 
modification, protein synthesis, gene expression, cellular assembly and organisation, 
free radical scavenging, cell cycle, and DNA replication, recombination, and repair.
For bioinformatics network analysis, Ingenuity Pathway Analysis (Ingenuity 
Systems Inc.) was used. For significantly modified protein groups, protein ID’s were used 
















































































































































0 0,5 1 1,5 2 2,5
Figure 2: Vulcano plot of protein groups influenced by 4OHT exposure in T47D-ERβ cells when (A) 
ERα and ERβ are both expressed and (B) only ERα is expressed. Blue dots: not significantly changed 
proteins after 4OHT treatment. Red dots: significantly changed proteins after 4OHT treatment at FDR 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The biological functions corresponding with modified protein expression were 
identified using Fisher’s exact test at a cutoff P value of 0.05. The network significance 
score was calculated by Ingenuity Pathway Analysis with the right-tailed Fisher’s exact 
test. This score indicates the likelihood that the assembly of a set of proteins in a network 
could be explained by random chance.
Ingenuity Pathway Analysis predicted that in T47D-ERβ cells expressing ERα and 
ERβ, cell proliferation is increased upon 4OHT exposure when compared to unexposed 
T47D-ERβ cells expressing ERα and ERβ, with a P value of 8.95*10-3 (P value obtained 
from Ingenuity Pathway Analysis, diseases and biofunctions). Apoptosis is predicted 
to be decreased by Ingenuity Pathway Analysis in T47D-ERβ cells expressing ERα and 
ERβ upon 4OHT exposure when compared to unexposed T47D-ERβ cells expressing ERα 
and ERβ, with a P value of 2.56*10-4 (P value obtained from Ingenuity Pathway Analysis, 
diseases and biofunctions). 
Using an FDR of 0.1, protein samples of T47D-ERβ cells expressing only ERα show 
26 significantly modified protein groups due to the 4OHT exposure when compared 
to unexposed T47D-ERβ cells expressing only ERα (Figure 2B). In Figure 3B the top ten 
affected molecular and functional classes are shown, that including cell death and 
survival, DNA replication, recombination and repair, and protein synthesis. In Table C 
the significantly up- and down-regulated protein groups and their biological functions 
are shown. 
Table D reveals 11 networks that were affected in 4OHT-exposed T47D-ERβ cells 
expressing only ERα compared to unexposed T47D-ERβ cells expressing only ERα, 
including top networks involved in protein degradation and synthesis, DNA replication, 
recombination and repair, cell cycle, and RNA post-transcriptional modification.
Ingenuity Pathway Analysis predicted that in T47D-ERβ cells only expressing ERα, 
cell proliferation is decreased upon 4OHT exposure when compared to unexposed 
T47D-ERβ cells expressing only ERα, with a P value of 3.09*10-3 (P value obtained from 
Ingenuity Pathway Analysis, diseases and biofunctions). Apoptosis is predicted to be 
increased by Ingenuity Pathway Analysis in T47D-ERβ cells only expressing ERα upon 
4OHT exposure when compared to unexposed T47D-ERβ cells, with a P value of 3.58*10-6 





























Figure 3: Top ten molecular and cellular functional classes influenced by 4OHT exposure in T47D-ERβ 
cells when (A) ERα and ERβ are expressed and (B) only ERα is expressed. The functional categories 
most involved are displayed along the x-axis in decreasing order of significance. Yellow line: cutoff for 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Molecular and functional classes of interest influenced by 4OHT exposure
Because the aim of this study is to investigate in what way quantitative proteomics 
reflect 4OHT-induced ERα/ERβ ratio-dependent effects on cell proliferation and 
apoptosis, further functional analysis of the protein groups influenced by 4OHT 
exposure is conducted to investigate molecular and functional classes related to cell 
proliferation and apoptosis. The following Ingenuity Pathway classes are included as 
molecular and functional classes of interest: cancer, cell cycle, cell death and survival, 
cell signalling, cell-to-cell signalling and interaction, cellular assembly and organisation, 
cellular function and maintenance cellular growth and proliferation, DNA replication, 
recombination, and repair, free radical scavenging, gene expression, post-translational 
modification, protein synthesis, RNA post-transcriptional modification, and tissue 
development. Figure 4A shows the molecular and functional classes of interest affected 
in T47D-ERβ cells expressing ERα and ERβ, comparing 4OHT-exposed samples to 
unexposed samples. Especially protein synthesis and gene expression are modified by 
the 4OHT exposure. Protein relationships involved in cell proliferation and apoptosis 
are visualised in a network (Figure 4B). Cathenin, mitogen-activated protein kinase 3 
(MAPK3), and growth factor receptor-bound protein 2 (GRB2) are central proteins in the 
network of protein groups influenced by 4OHT exposure in T47D-ERβ cells expressing 
ERα and ERβ.
In T47D-ERβ cells only expressing ERα, the affected molecular and functional 
classes show differences compared to the T47D-ERβ cells expressing ERα and ERβ 
after 4OHT exposure (Figure 5A). The modifications in cell death and survival and 
DNA replication, recombination, and repair are more significant after 4OHT exposure 
when only ERα is present compared to when both ERα and ERβ are expressed. Protein 
relationships involved in cell proliferation and apoptosis are visualised in a network 
(Figure 5B). Cathenin and small ubiquitin-like modifier 2 (SUMO2) are central proteins in 
the network of protein groups influenced by 4OHT exposure in T47D-ERβ cells with only 
ERα expression.
Most proteins listed in functions like cell cycle, DNA replication, recombination, and 
repair, and protein synthesis, show opposite expression profiles upon 4OHT exposure 
when only ERα is expressed or when ERα and ERβ are present (Table B and D). This 
holds for example for ubiquitin-conjugating enzyme E2M (UBE2M, an ubiquitin-protein 
ligase involved in protein binding), ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1, 
protein binding and transcription regulator), and replication protein A3 (RPA3, involved 

























Figure 4: (A) Molecular and cellular functional classes of interest influenced by 4OHT exposure in 
T47D-ERβ cells when ERα and ERβ are expressed. The functional categories involved in this analysis 
are displayed along the x-axis in decreasing order of significance. The yellow line indicates the 
cutoff for significance (P value 0.05). (B) Network in subcellular view of protein group interactions 
based on cell proliferation and apoptosis that were identified in T47D-ERβ cells with ERα and ERβ 
expression influenced by the exposure to 4OHT. Red colored proteins: up-regulated. Green colored 
proteins: down-regulated. A more detailed legend to the protein interaction network can be found in 












































Figure 5: (A) Molecular and cellular functional classes of interest influenced by 4OHT exposure in 
T47D-ERβ cells when only ERα is expressed. The functional categories involved in this analysis are 
displayed along the x-axis in decreasing order of significance. The yellow line indicates the cutoff for 
significance (P value 0.05). (B) Network in subcellular view of protein group interactions based on cell 
proliferation and apoptosis that were identified in T47D-ERβ cells expressing only ERα influenced by 
the exposure to 4OHT. Red colored proteins: up-regulated. Green colored proteins: down-regulated. 
A more detailed legend to the protein interaction network can be found in Supplementary Figure S1, 




























Post-translational and epigenetic modifications
Since it is known that post-translational modifications can influence gene transcription 
[23-25] and protein degradation [26], and this might influence the ERα/ERβ ratio-
dependent effects of 4OHT, a MaxQuant analysis including acetylation, methylation, 
phosphorylation, and ubiquination modifications, allowing at most 3 modifications per 
peptide, was conducted. In this analysis 4297 proteins were identified, of which 1667 
remained after very strict filtering (only protein groups identified by at least 2 peptides 
of which at least 1 peptide had to be unique in the database and at least 1 peptide had 
to be unmodified, and only proteins with 3 valid values in at least 1 group of triplicate 
samples were included). 
Table E shows the detected post-translational and epigenetic modifications of protein 
groups which are significantly different in the samples. In T47D-ERβ cells expressing ERα 
and ERβ, 4OHT exposure resulted in seven significantly differently expressed protein 
groups with post-translational modifications. Ubiquitination and methylation of dynactin 
subunit 1 was detected at respectively lysine 277 and arginine 274. Dynactin is required 
for the cytoplasmic dynein-driven retrograde movement of vesicles and organelles along 
microtubules. Dynein-dynactin interaction is a key component of the mechanism of 
axonal transport of vesicles and organelles [33, 34]. Cytoplasmic leucine transfer RNA 
(tRNA) ligase, which catalyzes the specific attachment of an amino acid to its cognate 
tRNA and exhibits a post-transfer editing activity to hydrolyze mischarged tRNAs [35], 
showed acetylation and methylation at lysine 23 and arginine 28 respectively. Cytoplasmic 
fragile X mental retardation 1 (FMR1)-interacting protein 1 was observed to be 
phosphorylated at threonine 139 and methylated at lysine 149. FMR1-interacting protein 
1 is a component of the cytoplasmic FMR1 interacting protein 1-eukaryotic translation 
initiation factor-fragile X mental retardation 1 (CYFIP1-EIF4E-FMR1 ) complex which 
binds to the mRNA cap and mediates translational repression. FMR1-interacting protein 
1 may modulate invasion in cancers [36]. A type II cytoskeletal keratin protein, which 
may regulate the activity of kinases such as protein kinase C (PKC) and sarcoma (SRC) via 
binding to integrin beta-1 (ITB1) and the receptor of activated protein kinase C (receptor 
for activated C kinase 1/guanine nucleotide binding protein, beta polypeptide 2-like 1, 
RACK1/GNB2L1), was found to be methylated at arginine 602 [37, 38]. Phosphorylation of 
cytochrome c oxidase subunit 4 isoform 1 was detected at serine 158. This cytochrome 
c oxidase subunit 4 isoform 1 protein is one of the nuclear-coded polypeptide chains of 
cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport [39]. The 
mitochondrial deoxyuridine 5’-triphosphate nucleotido hydrolase was ubiquitinated at 

















































































































































































































































































































































































































































































































































































































































































































































































produces deoxyuridine monophosphate (dUMP), the immediate precursor of thymidine 
nucleotides and it decreases the intracellular concentration of dUTP deoxyuridine 
triphosphate so that uracil cannot be incorporated into DNA [40]. Histone H3.2 
was methylated at lysine 80. Histones are core components of the nucleosome. 
Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the 
cellular machineries which require DNA as a template. Histones thereby play a central 
role in transcription regulation, DNA repair, DNA replication, and chromosomal stability. 
DNA accessibility is regulated via a complex set of post-translational modifications of 
histones, also called histone code, and nucleosome remodeling [41, 42].
In T47D-ERβ cells expressing only ERα, 4OHT exposure resulted in only two 
post-translational modifications on the same protein, i.e. acetylation at lysine 9 and 
phosphorylation at serine 366 of the Lupus La protein. The Lupus La protein binds to 
the 3’ poly(U) termini of nascent RNA polymerase III transcripts, protecting them from 
exonuclease digestion and facilitating their folding and maturation [43, 44]. 
Discussion
So far, several studies into proteomic analysis of breast cancer cells in relation to 4OHT 
have been conducted in MCF-7 and T47D cells [45, 46]. However, these studies did not 
take different ERα/ERβ ratios into account. Both MCF-7 and T47D cells express no or 
only very little ERβ [20]. Taking different ERα/ERβ ratios into account is essential for a 
better understanding of the mechanism by which 4OHT exerts its effects, since 4OHT 
acts upon binding to ERα or ERβ and ERβ counteracts the cell proliferative effect of 
ERα [2, 5-8]. Therefore, in the present study a quantitative analysis of differences in 
protein expression to address the effects of ERα and ERβ in the T47D-ERβ breast cancer 
cells exposed to 4OHT was conducted by means of nanoLC-LTQ-OrbitrapXL-MS. These 
T47D-ERβ cells possess tetracycline-dependent ERβ expression in contrast to native 
T47D cells [6, 20].
To be able to analyse differences in protein expression at an effective, non-
cytotoxic 4OHT concentration, a BrdU cell proliferation assay was conducted. The 
effect of the ER agonist E2 on cell proliferation of T47D-ERβ cells was characterized and 
used to detect the ER antagonist activity of 4OHT and select the concentration to be 
tested in the proteomic analysis. In the T47D-ERβ cells expressing only ERα, E2 induces 
cell proliferation [20], which is dose-dependently decreased by 4OHT. The maximum 
decrease of cell proliferation is observed at 300 nM 4OHT, which was then chosen as the 









































Molecular and functional classes as well as network analysis of the proteomics 
data reveal several functions significantly influenced by 4OHT exposure that can be 
linked to cell proliferation or apoptosis, including DNA replication, recombination, and 
repair, cancer, cellular function and maintenance, and protein synthesis. Most proteins 
listed in these functions show opposite expression profiles in 4OHT-exposed T47D-ERβ 
cells when only ERα is expressed compared to 4OHT-exposed T47D-ERβ cells expressing 
both ERα and ERβ (Table B and D).
In samples expressing ERα and ERβ, cell proliferation was predicted to be increased 
and apoptosis to be decreased upon 4OHT exposure compared to unexposed cells. 
In the samples expressing only ERα, cell proliferation was predicted to be decreased 
upon 4OHT exposure when compared to unexposed cells. This is in line with BrdU cell 
proliferation results which reflected decreased proliferation of T47D-ERβ cells with only 
ERα expression upon exposure to 4OHT (Figure 1). Ingenuity Pathway Analysis predicted 
apoptosis to be increased upon 4OHT exposure of T47D-ERβ cells expressing only ERα. 
These ERα/ERβ ratio-dependent effects of 4OHT on cell proliferation and apoptosis 
are in line with 4OHT being an antagonist for both ERα and ERβ, with a preference for 
ERβ. The antagonist activity towards ERβ reduces the ERβ-dependent inhibition of ERα-
mediated cell proliferation, thereby facilitating increased cell proliferation.
It is also of interest to note that the proteins listed in Table B and D show opposite 
expression profiles upon 4OHT exposure when ERα and ERβ are expressed or when 
only ERα is expressed. The proteins showing this opposite expression pattern upon 
4OHT exposure of cells with different ERα/ERβ ratio are involved in functions like cell 
cycle, DNA replication, recombination, and repair, and protein synthesis. These results 
corroborate that the cellular effects of 4OHT are different depending on the ERα/ERβ 
ratio and are in line with the different cellular response with respect to cell poliferation. 
The observation that 4OHT-induced inhibition of cell proliferation is mainly observed 
for cells with low levels of ERβ is especially of interest when considering that in tumor 
tissues ERβ expression can be lost [2], whereas in non-tumorous tissue ERα and ERβ 
expression is detected [20]. 
Network analysis of protein groups involved in cell proliferation and apoptosis 
revealed that cathenin, a transcription factor known to be involved in cell proliferation 
and apoptosis [47], is connected to a lot of other proteins in the cell proliferation and 
apoptosis network for both 4OHT-exposed T47D-ERβ cells expressing only ERα and 
4OHT-exposed T47D-ERβ cells expressing ERα and ERβ. Other central proteins in the cell 
proliferation and apoptosis network are MAPK3 which is down-regulated upon 4OHT 

























in T47D-ERβ cells expressing ERα and ERβ. MAPK3 is involved in the regulation of 
proliferation, differentiation, and cell cycle progression [48]. GRB2 is involved in cellular 
growth and proliferation [49]. 
In T47D-ERβ cells expressing only ERα, next to cathenin also SUMO2, which upon 
4OHT exposure is up-regulated, has a central role in the protein interaction network. 
SUMO2 is involved in protein stability and apoptosis [50]. Both cathenin and SUMO2 
have a role in transcription regulation [51, 52]. This network analysis underlines the 
clear ERα/ERβ ratio-dependent differences in the response towards 4OHT exposure in 
T47D-ERβ cells. 
Several studies have proposed that epigenetic mechanisms might be involved 
in ERα- and ERβ-mediated physiological effects [53-55]. The present study was able 
to define some post-translational and epigenetic modifications induced by 4OHT 
exposure. With ERβ being expressed in the T47D-ERβ cells, 4OHT exposure resulted in 
acetylation, methylation, and phosphorylation of seven ribosomal and mitochondrial 
protein groups, of which several are involved in transcription regulation. Most observed 
post-translational modifications have not been described in literature before and their 
physiological consequences remain to be elucidated. However, one of the most well 
studied modifications is histone methylation, which was induced by 4OHT exposure in 
T47D-ERβ cells expressing ERα and ERβ. Garcia et al. linked histone H3.2 methylation at 
lysine 80 to gene activation [56].
When only ERα was expressed in the T47D-ERβ cells, 4OHT exposure resulted in 2 
modifications of the Lupus La protein. Acetylation at lysine 9 of the Lupus La protein has 
not been described before. Fan et al. described that phosphorylation of the Lupus La 
protein at serine 366 makes the protein transcriptionally inactive [57].
It is concluded that 4OHT affects molecular and cellular functional classes in 
T47D-ERβ cells including cell proliferation and apoptosis and induces post-translational 
modifications, with the ultimate effect being dependent on the ERα and ERβ levels and 
the ERα/ERβ ratio of the cells. There may be opposite effects regarding cell proliferation 
and apoptosis of 4OHT in cells with ERα but with or without ERβ expression. Given that 
the data presented indicate that in cells with ERα but without ERβ 4OHT will reduce 
cell proliferation, whereas in cells with ERβ in addition to ERα, 4OHT may stimulate cell 
proliferation, it could be of interest to monitor the ERα and ERβ levels and the ERα/ERβ 
ratio in breast tumor tissue to enable a more personalised medical use of 4OHT. Based 
on a randomized neo-adjuvant trial for the treatment of postmenopausal occuring 
breast cancer Madeira et al. [58] concluded that the ERα/ERβ ratio and ERβ levels could 
be used as predictors of endocrine therapy responsiveness. However, in contrast to 









































produced a significant reduction in post-treatment Ki67 scores, a marker for cell 
proliferation. It should be noted however that the post-treatment Ki67 scores in their 
ERβ-positive group upon tamoxifen treatment amounted to 76.3% (P < 0.014) (n=18) of 
the pretreatment scores whereas the values for the ERβ-negative group were 73.9% (not 
significant) (n=5) and thus actually similar probably being not statistically significant due 
to the lower group size. Furthermore, in both the ERβ-positive and ERβ-negative patient 
groups ERα-positive and ERα-negative cases were combined. Given the important role 
for ERα observed in the present study for 4OHT-induced effects on cell proliferation and 
apoptosis, this combining of ERα-positive and ERα-negative cases hampers comparison 
of the data of the trial with the proteomics data of the present study. Based on the 
proteomics data of the present study it is concluded that ERβ but also ERα levels and 
the ERα/ERβ ratio should be used as predictors of tamoxifen therapy responsiveness, 
with the presence of ERα and the absence of ERβ expression being optimal for inducing 
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Supplementary Figure S1: Legends to the protein interaction network from Ingenuity Pathway 


























Additional abbreviations used in tables.
2-5A, 2’-5’-oligoadenylates
A, adenine
AAK, adaptor-associated protein kinase
ABAT, 4-aminobutyrate aminotransferase
ABC, ATP-binding cassette




ACADL, acyl-CoA dehydrogenase, long chain








ACSF, acyl-CoA synthetase family
ACTN, alpha-actinin
ACTR, alpha-centractin





ADRM, adhesion regulating molecule
ADSS, adenylosuccinate synthase
AGL, amylo-alpha-1, 6-glucosidase, 4-alpha-
glucanotransferase
AGR, anterior gradient protein
AGRN, agrin
AHNAK, neuroblast differentiation-associated 
protein
AHSA, activator of heat shock 90kDa protein 
ATPase homolog
AHSG, alpha-2-HS-glycoprotein
AIFM, apoptosis-inducing factor, 
mitochondrion-associated
AK, adenylate kinase
AKR, aldo-keto reductase family





ALYREF, alymphoplasia/RNA export factor
AMPK, adenosine monophosphate-activated 
protein kinase
ANKRD, ankyrin repeat domain
ANLN, anillin
ANP, acidic leucine-rich nuclear 
phosphoprotein
Ant, adenine nucleotide translocator
ANX, annexin
AP, adaptor protein




APOA1BP, apolipoprotein A-I binding protein
APOBEC, apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide- 
 like
APP, amyloid precursor protein
APRT, adenine phosphoribosyltransferase
Arf, ADP-ribosylation factor










































ARHGEF, Rho guanine nucleotide exchange 
factor 2
ARL6IP, ADP-ribosylation-like factor 6 
interacting protein
ARHGAP, Rho GTPase activating protein
ARID, AT rich interactive domain
ARL6IP, ADP-ribosylation-like factor 6 
interacting protein
Arp, actin-related protein
aRPA, alternative replication protein A
ARPC, actin related protein 2/3 complex
ARPC5L, actin-related protein 2/3 complex 
subunit 5-like
ASAH, N-acylsphingosine amidohydrolase
ASAP, ArfGAP with SH3 domain, ankyrin 
repeat and PH domain
ASS, argininosuccinate synthase







ATP6V1, V-type proton ATPase subunit, 
ATPase, 
adenosinetriphosphatase
ATPIF, ATPase inhibitory factor




BAD, BCL-2-associated death promoter
BACE, Beta-secretase
BAG, BCL2-associated athanogene
BANF, barrier to autointegration factor
BARD1, BRCA1-associated RING domain 
protein 
BAX, Bcl-2–associated X protein
BCAP, B-cell receptor-associated protein
BCAT, branched chain amino-acid 
transaminase
BCL, B-cell lymphoma
BCR, breakpoint cluster region protein
BDH, 3-hydroxybutyrate dehydrogenase
BET1, blocked early in transport 1 homolog




BRCA, breast cancer susceptibility protein
BRK, BRICK
BTF, basic transcription factor
BTF3L, basic transcription factor 3-like
BTG, B-cell translocation gene




cAMP, cyclic adenosine monophosphate
CAND, cullin-associated NEDD8-dissociated 
protein
CANX, calnexin
Cap, cyclase associated protein
CAPN, calpain
CAPNS, calpain small subunit
CAPRIN, cell cycle associated protein
CARKD, carbohydrate kinase domain 
containing

































CCS, copper chaperone for superoxide 
dismutase
CCT, chaperonin containing T-complex 
protein
CCVs, clathrin-coated vesicles
CD, cluster of differentiation
CDC, cell division cycle
CDH, cadherin
CDKN, cyclin-dependent kinase inhibitor
CDKN2AIPNL, cyclin-dependent kinase 
inhibitor 2A interacting protein N-terminal 
like








CHMP, charged multivesicular body protein
CHP, calcium binding protein
CHRAC, chromatin accessibility complex
CHTOP, chromatin target of protein arginine 
methyltransferase
CIRBP, cold inducible RNA binding protein
CISD, CDGSH iron sulfur domain
Ck, casein kinase
CKAP, cytoskeleton associated protein
CKS, cyclin-dependent kinases regulatory 
subunit
CLDN, claudin
CLIC, chloride intracellular channel
CLINT, clathrin interactor
CLK, CDC-like kinase
CLUH, clustered mitochondria homolog
CMAS, cytidine monophosphate 
N-acetylneuraminic acid synthetase
CMC, cytochrome C oxidase assembly 
mitochondrial protein homolog
CMPK, cytidine monophosphate kinase




COA, cytochrome c oxidase assembly factor
COASY, CoA synthase
COMMD, copper metabolism domain 
containing
COP, coatomer protein
COPS, constitutive photomorphogenic 
homolog subunit
CORO, coronin, actin binding protein
COTL, coactosin-like
COX, cyclooxygenase
CpG islands, genomic regions where a 
cytosine nucleotide occurs next to a guanine 
nucleotide in the linear sequence of bases
CPNE, copine
CPSF, cleavage and polyadenylation 
specificity factor subunit
CPT, carnitine palmitoyltransferase
CRABP, cellular retinoic acid binding protein
Creb, cAMP response element-binding 
protein
CRIP, cysteine-rich protein
Crk, CT10 regulator of kinase, where CT10 
is the avian virus from which was isolated a 
protein, lacking kinase domains, but capable 




CSE1L, chromosome segregation 1-like
CSK, cellular SRC tyrosine kinase
CSNK, casein kinase










































CSTF, cleavage stimulation factor
CTNN, catenin
CTNNBIP, catenin, beta interacting protein
CTTN, cortactin
CTNN, catenin
CU-rich, cytosine uracil rich
CUL, cullin
CX3CL, chemokine (C-X3-C motif) ligand
CYB5R, cytochrome b5 reductase
CYC, cytochrome c
CYFIP, cytoplasmic fragile X mental 
retardation protein interacting protein
cytochrome bc1, coenzyme Q : cytochrome 
c – oxidoreductase
CYCS, cytochrome c somatic
CYFIP, cytoplasmic fragile X mental 





DAD, defender against cell death
dADP, deoxyadenosine diphosphate
DAG, dystrophin-associated glycoprotein
DAK, dihydroxyacetone kinase 2 homolog
DAP, death-associated protein
DAPK, death-associated protein kinase
dATP, deoxyadenosine triphosphate
DBI, diazepam binding inhibitor
dCDP, deoxycytidine diphosphate






DDX, DEAD (aspartic acid-glutamic acid-
alanine-aspartic acid) box







DHTKD, dehydrogenase E1 and transketolase 
domain containing
DFF, DNA fragmentation factor
DIABLO, direct inhibitors of apoptosis 
proteins binding protein with low isoelectric 
point
DLD, dihydrolipoamide dehydrogenase
DNAJ, DnaJ (Hsp40) homolog
DNM, dynamin
DNM1L, dynamin 1-like, receptor on the 
surface of cells that initiates apoptosis
DNPH, 2’-deoxynucleoside 5’-phosphate 
N-hydrolase
dNTPs, deoxynucleoside triphosphates
DOCK, dedicator of cytokinesis
DPCD, deleted in primary ciliary dyskinesia 
homolog



































DYNC1LI1, cytoplasmic dynein 1 light 
intermediate chain 1
DYNLRB, dynein light chain roadblock
E1, branched-chain alpha-keto acid 
decarboxylase
E2, lipoamide acyltransferase
E2f, a group of genes that codifies a family of 
transcription factors in higher eukaryotes
E3, lipoamide dehydrogenase
EB, end-binding protein
EBERs, Epstein-Barr virus-encoded RNAs
EBV, Epstein-Barr virus
EBP, emopamil binding protein
ECH, enoyl coenzyme A hydratase
ECHDC, enoyl CoA hydratase domain 
containing
ECHS, enoyl coenzyme A hydratase, short 
chain
ECM, extracellular matrix
EDF, endothelial differentiation-related factor
EEA, early endosome antigen
EEF, eukaryotic translation elongation factor
EFH, EF-hand domain
EFNA, ephrin-A
EGF, epidermal growth factor
EHHADH, enoyl-CoA, hydratase/3-
hydroxyacyl CoA dehydrogenase
EIF, eukaryotic initiation factor
EJC, exon junction complex
ELAVL, embryonic lethal, abnormal  
vision-like
ELF, ETS-related transcription factor
ELK, ETS domain-containing protein
ENO, enolase
ENSA, endosulfine alpha





ERCC6L, excision repair cross-complementing 
rodent repair deficiency, complementation 
group 6-like
ERF, ETS domain-containing transcription 
factor
ESYT, extended synaptotagmin-like protein
ETV, ets variant
ERH, enhancer of rudimentary homolog
ERK, extracellular signal-regulated kinase
Erm, family of three closely related proteins, 
ezrin, radixin and moesin
ERP, endoplasmic reticulum protein
ES, esterase




FAHD, fumarylacetoacetate hydrolase 
domain
FAM, family with sequence similarity
FARS, phenylalanyl-tRNA synthetase
FARSB, phenylalanyl-tRNA synthetase beta 
chain
FBLP, filamin-binding LIM protein
FBXO, F-box only protein
Fc, fragment, crystallizable
FCGR, Fc fragment of IgG receptor




FGF, fibroblast growth factor
FGFR, fibroblast growth factor receptors
FHL, four and a half LIM domains
FIS, fission










































FOS, feline osteosarcoma virus
FPR, formyl peptide receptor
FRS, fibroblast growth factor receptor 
substrate
FSH, follicle stimulating hormone
FUBP, far upstream element (FUSE) binding 
protein
FURIN, feline sarcoma upstream region 
protein
FUS, fused in sarcoma
FXN, frataxin
G, guanine
G1 phase, first growth period of the cell cycle
GAA, glucosidase, alpha, acid
GABA, gamma-aminobutyric acid
GABARAP, gamma-aminobutyric acid 
receptor-associated protein
GABARAPL, gamma-aminobutyric acid 
receptor-associated protein-like









GAPVD, GTPase activating protein and 
vacuolar sorting protein 9 domains
GAS, gamma activated sequence
GBF, golgi-specific brefeldin A-resistance 








GJA, Gap junction alpha
GLG, Golgi glycoprotein
GMPS, guanine monphosphate synthetase









GOLM, Golgi membrane protein
GOLPH3L, golgi phosphoprotein 3-like
GOSR, Golgi SNARE complex
GP, glycoprotein
G protein, guanosine nucleotide-binding 
protein
GPRC, G-protein coupled receptor family C
GPSM, G-protein signaling modulator
GRB, growth factor receptor-bound protein
GRPEL, GrpE-like
GSDMD, gasdermin domain-containing 
protein
Gsk, glycogen synthase kinase
GSN, gelsolin
GSPT, G1 to S phase transition
GST, glutathione S-transferase
GTPBP, GTP binding protein
GTF, general transcription factor
GTP, guanosine-5’-triphosphate
GTPase, enzyme that hydrolyses GTP
H2AF, H2A histone family


























H3K4me, histone H3 ‘Lys-4’ methylation






HBEGF, heparin-binding EGF-like growth 
factor
HBV, hepatitis B virus
HBZ, hemoglobin zeta
HCV, hepatitis C virus
Hdac, histone deacetylase
HDL, high density lipoprotein
HDLBP, high density lipoprotein-binding 
protein
HECTD, HECT domain containing E3 ubiquitin 
protein ligase
HELZ, helicase with zinc finger









HIGD, hypoxia inducible domain
HINT, histidine triad nucleotide-binding 
protein
HIP, HSC70 Interacting Protein
HIP1R, HSC70 Interacting Protein 1 related
HIST, histone
HIV, human immunodeficiency virus
HK, hexokinase
HMG, high-mobility group protein
HMGN, high mobility group nucleosomal 
binding domain
HMOX, heme oxygenase
HN, hematological and neurological expressed
HN1L, hematological and neurological 
expressed 1-like protein
HNF, hepatocyte nuclear factor
HNRNP, heterogeneous nuclear 
ribonucleoprotein particle
HORMAD, HORMA domain (named after the 
Hop1p, Rev7p and MAD2 
proteins)
HPD, 4-hydroxyphenylpyruvate dioxygenase
HRAS, Harvey rat sarcoma viral oncogene 
homolog
HRSP, heat-responsive protein
HSC, heat shock protein
HSD17B, hydroxysteroid (17-beta) 
dehydrogenase
HSDL, hydroxysteroid dehydrogenase like
HSF, heat shock factor
Hsp, heat shock protein
HTT, huntingtin
HYOU, hypoxia up-regulated protein
HYPK, huntingtin interacting protein K
IARS, isoleucyl-tRNA synthetase
IAV, influenza A virus
ICT, immature colon carcinoma transcript
IDH, isocitrate dehydrogenase
IER, immediate early response
IFIT, interferon-induced protein with 
tetratricopeptide repeats
IFITM, interferon-induced transmembrane 
protein
IFN, interferon
IFRD, interferon-related developmental 
regulator
Ig, immunoglobulin
IGF, insulin-like growth factor
IGSF, immunoglobulin superfamily









































Ikb, inhibitor of kappa B
IKK, inhibitor of kappa B kinase
IL, interleukin
INSR, insulin receptor
IMMT, inner membrane protein, 
mitochondrial
IMPACT, imprinted and ancient gene
IN, internexin neuronal intermediate filament 
protein
INFG, interferon gamma
INIP, INTS3 (integrator complex subunit 3) 
and NABP (nucleic acid binding 
protein) interacting protein
IPO, importin
IPS, interferon-beta promoter stimulator
IQC, IQ motif containing
IRF, interferon regulatory factor
IRS, insulin receptor substrate
ISG15, interferon -stimulated 15 kDa gene
ISGF, interferon-stimulated transcription 
factor
ISOC, isochorismatase domain containing
ISRE, IFN stimulated response element
ITAP, inhibitor of T cell apoptosis protein
ITG, integrin
ITP, inosine triphosphate
ITPR, inositol trisphosphate receptor
ITPRIP, inositol 1,4,5-trisphosphate receptor 
interacting protein
JAK, Janus kinase
JEV, Japanese encephalitis virus










KHSRP, KH-type splicing regulatory protein
KIT, gene encoding mast/stem cell growth 







LACV, La Crosse virus
LAM, laminin
LAMP, lysosomal-associated membrane 
protein
LAMTOR1, late endosomal/lysosomal 
adaptor, MAPK and MTOR activator 
1, guanyl-nucleotide exchange factor, protein 
binding
LAP, leucine aminopeptidase





Lfa, lymphocyte function-associated antigen
LGALS, lectin, galactoside-binding, soluble
Lh, luteinizing hormone
LHPP, phospholysine phosphohistidine 
inorganic pyrophosphate phosphatase
LIM domain, protein structural domains, 
composed of two contiguous zinc finger 
domains, separated by a two-amino acid 
residue hydrophobic 
linker, initialy discovered in the proteins 
Lin11, Isl-1 & Mec-3





























LRBA, lipopolysaccharide-responsive vesicle 
trafficking, beach and anchor containing
LRRC, leucine rich repeat containing





LYRM, LYR motif containing
m1A58, N(1)-methyladenine at position 58
M6PR, mannose-6-phosphate receptor
Mac1, macrophage-1 antigen
MACROD, MACRO domain containing
MAGE, melanoma antigen
MAGOH, protein mago nashi homolog
MANF, mesencephalic astrocyte-derived 
neurotrophic factor
MAP, mitogen-activated protein
MAPK, mitogen-activated protein kinase
MAPKAPK, MAP kinase activated protein 
kinase
MAPRE, microtubule-associated protein, RP/
EB family
MAPT, microtubule-associated protein tau
MATR, matrin
MAVS, mitochondria antiviral signaling 
protein
MBP, myelin basic protein
MCCC, methylcrotonoyl-CoA carboxylase




MDM2, mouse double minute 2 homolog
MEIS, myeloid ecotropic viral integration site
Mek, mitogen-activated protein kinase
MESDC, mesoderm development candidate
Met, methionine
MeV, measles virus
MGST, microsomal glutathione S-transferase
MHC, major histocompatibility complex
MIA, melanoma inhibitory activity
miRNA, microRNA
miRNPs, microribonucleoproteins
MKNK/MNK, MAP kinase-interacting serine/
threonine-protein kinase
Mlc, megalencephalic leukoencephalopathy 
with subcortical cysts
MMAB, methylmalonic aciduria (cobalamin 
deficiency) cblB type
MMP, matrix metallopeptidase
MNF, mitochondrial nucleoid factor
MPST, mercaptopyruvate sulfurtransferase
mRNA, messenger RNA
MRP, mitochondrial ribosomal protein
MSH, MutS homolog
MSK, mitogen- and stress- activated protein 
kinase
MTAP, methylthioadenosine phosphorylase
MTCH, mitochondrial carrier homolog
MTFR, mitochondrial fission regulator
MT-ND, mitochondrially encoded NADH 
dehydrogenase
MTOR, mammalian target of rapamycin





MVP, major vault protein
MX1/MxA, myxovirus (influenza virus) 
resistance
MYC, myelocytomatosis oncogene









































MYL6, myosin light polypeptide




NABP, nucleic acid binding protein
NADH, reduced nicotinamide adenine 
dinucleotide
NADPH, reduced form of nicotinamide 
adenine dinucleotide phosphate
NANS, N-acetylneuraminic acid synthase
NAP1L, nucleosome assembly protein 1-like
NASP, nuclear autoantigenic sperm protein
NCAM, neural cell adhesion molecule
NCDN, neurochondrin
NCK, non-catalytic region of tyrosine kinase
NDRG, N-myc downstream regulated gene
NDUF, NADH dehydrogenase ubiquinone
NDUFV, NADH dehydrogenase ubiquinone 
flavoprotein




NFAT, nuclear factor of activated T-cells
NFS, nitrogen fixation homolog
NHP, non-histone protein
NFkB, nuclear factor kappa-light-chain-
enhancer of activated B cells, 
lymphocytes derived from the bone marrow
NFS, nitrogen fixation
NHE, sodium-hydrogen antiporter
NHP2L1, non-histone chromosome protein 
2-like
NIP, 4-nitrophenylphosphatase
NLS, nuclear localization signals
NMD, nonsense-mediated mRNA decay
NNT, nicotinamide nucleotide 
transhydrogenase
NOL, nucleolar protein
NOLC, nucleolar and coiled-body 
phosphoprotein
Nos, nitric oxide synthases
NP, nucleoproteins
NPC, nuclear pore complex
NPF, nucleation-promoting factor
NPM, nucleophosmin/nucleoplasmin
NQO, NAD(P)H dehydrogenase, quinone
NSF, N-ethylmaleimide-sensitive factor
NUBP, nucleotide binding protein
NUCKS, nuclear casein kinase and cyclin-
dependent kinase substrate
NUDCD, nuclear distribution C domain 
containing




ODAM, odontogenic, ameloblast asssociated




OSBP, oxysterol binding protein
OST, oligosaccharyltransferase










PABPC, poly(A) binding protein cytoplasmic




























Pak, p21 activated kinase
PALLD, palladin
PARK, parkinson disease (autosomal 
recessive, early onset)





PCNA, proliferating cell nuclear antigen
PDAP, PdgfA associated protein
PDCD, programmed cell death protein
PDE, phosphodiesterase
Pdgf, platelet-derived growth factor
Pdgfr, platelet-derived growth factor 
receptor
PDI, protein disulfide isomerase
PDK, pyruvate dehydrogenase kinase
PDX, pancreatic and duodenal homeobox
PE, phosphatidylethanolamine
PEA, phosphoprotein enriched in astrocytes
PEBP, phosphatidylethanolamine-binding 
protein
PER, period circadian protein homolog
PES, pescadillo ribosomal biogenesis factor









PGRMC, progesterone receptor membrane 
component
PHB, prohibitin
PHF, plant homeo domain finger protein
PHB, prohibitin
PHGDH, phosphoglycerate dehydrogenase
PHLD, pleckstrin homology-like domain
PICALM, phosphatidylinositol binding clathrin 
assembly protein
pik3/PI3K, phosphatidylinositide 3-kinase
pIgR, polymeric immunoglobulin receptor




Pkg, cGMP-dependent protein kinase
PKM, pyruvate kinase muscle isozyme
PKN, protein kinase
PKR, protein kinase RNA-activated
PL, phospholipase
PLCG, phospholipase C gamma
PLEC, plectin






PML, promyelocytic leukemia protein
PMPCB, peptidase (mitochondrial processing) 
beta
PNMA, paraneoplastic Ma antigen
PNRC, proline-rich nuclear receptor 
coregulatory protein
POR, P450 (cytochrome) oxidoreductase
PP, protein phosphatase
PPA, pyrophosphatase
PPAP, phosphatidic acid phosphatase












































PPM, protein phosphatase, Mg2+/Mn2+ 
dependent
PPP1R, protein phosphatase 1, regulatory 
(inhibitor) subunit
PPP6C, protein phosphatase 6, catalytic 
subunit
PPP-RNA, single-stranded RNA bearing a 
5’-triphosphate group




trisphosphate-dependent Rac exchange 
factor
PRKAR, protein kinase, cAMP-dependent, 
regulatory
PRKCSH, human protein kinase C substrate
PRPF, pre-mRNA processing factor homolog
PRPH, peripherin
PSM, proteasome (prosome, macropain) 
subunit
PSPH, phosphoserine phosphatase
PTBP, polypyrimidine-tract binding protein
PTEN, phosphatase and tensin homolog
Ptk, protein tyrosine kinase
PTM, prothymosin
PTP, protein tyrosine phosphatase








PYGB, phosphorylase, glycogen, brain
QPRT, quinolinate phosphoribosyltransferase
R/r, receptor
RA, receptor alpha chain
RAB, Ras-related protein
RAB11FIP, RAB11 family interacting protein
Rac, Ras-related C3 botulinum toxin substrate
RAD, Ras associated with diabetes
RAE, RNA export homolog
RAF, rapidly accelerated fibrosarcoma
RAL, Ras-related protein
RAN, Ras-related nuclear protein
RANBP, RAN binding protein
Ras, rat sarcoma, small GTPase protein
RASA, RAS p21 protein activator








RELA, transcription factor p65
RHO, Ras homolog
RIG, retinoid-inducible gene
RIMKL, ribosomal modification protein 
rimK-like
RMI, RecQ-mediated genome instability
RNase, ribonuclease




Rock, Rho-associated, coiled-coil containing 
protein kinase
RP, ribosomal protein/replication protein
RPL, ribosomal protein, large


























RRP, ribosomal RNA processing homolog
RSK, ribosomal protein S kinase
RSU, Ras suppressor protein
RYR, ryanodine receptor
S, sinister (left)
S (concerning ribosome), Svedberg
S (concerning amino acid), serine
S1PR, sphingosine-1-phosphate receptor
SAMHD, sterile alpha motif and histidine-
aspartic domain
Sapk, stress-activated protein kinase
SARNP, SAP (SAF-A/B, Acinus and PIAS) 
domain containing ribonucleoprotein
SARNP, SAP domain containing 
ribonucleoprotein
SART, squamous cell carcinoma antigen 
recognized by T cells
SATB, special AT-rich sequence-binding 
protein
SCF, stem cell factor
SCGB, secretoglobin
SCP, sterol carrier protein
SDC, syndecan
SDH, succinate dehydrogenase complex
SEC, signal peptidase complex
SELENBP, selenium-binding protein
SEPT, septin
SERF, small EDRK-rich factor
SERPIN, serine protease inhibitor
SERTAD, SERTA domain containing
SF, splicing factor
SFN, stratifin
SFPQ, splicing factor, proline- and glutamine-
rich
SFV, Semliki forest virus
SGCB, sarcoglycan beta
SGT, small glutamine-rich tetratricopeptide 
repeat (TPR)-containing
SH, SRC homology
SH3GL, SH3-domain growth factor receptor-
bound protein 2-like endophilin





SMC, structural maintenance of 
chromosomes protein
SNAP, SNARE associated protein
SNARE, soluble NSF attachment protein 
receptor
SNC, synuclein
SNRNP, small nuclear ribonucleoprotein 
polypeptide
SNX, sorting nexin
SORBS, sorbin and SH3 domain-containing 
protein
Sos, Son of Sevenless
SPA, sperm autoantigenic protein
SPCS, signal peptidase complex subunit 
homolog
S-phase, synthesis phase
SPI2A, serine protease inhibitor A
SPR, sepiapterin reductase
SPRYD, sprouty homolog domain
SPTAN, spectrin, alpha
SPTBN, spectrin, beta
SPZ, spermatogenic leucine zipper protein
SRC, sarcoma
SRI, sorcin
SRP, signal recognition particle
SRPR, signal recognition particle receptor
SRRM, serine/arginine repetitive matrix












































SSR, signal sequence receptor
SST, somatostatin
ST, suppression of tumorigenicity
StAR, steroidogenic acute regulatory protein
STARD, StAR-related lipid transfer (START) 
domain containing








SUCLG, succinyl-coenzyme A ligase
SUFU, suppressor of fused homolog




SUMO, small ubiquitin-related modifier
SUPT16H, suppressor of Ty 16 homolog
SUPV3L, suppressor of var1, 3-like
SURF, surfeit
SYK, spleen tyrosine kinase
SYN, synapsin
SYNCRIP, synaptotagmin binding, cytoplasmic 
RNA interacting protein
SYNJ2BP, synaptojanin 2 binding protein
T, thymine
TAF, TATA-binding protein-associated factor, 
150 kDa
TAGLN, transgelin
Tap, transporter associated with antigen 
processing
TARDBP, transactive response DNA binding 
protein
TARS, threonyl-tRNA synthetase
Tat, trans-activator of transcription




TCF, T-cell-specific transcription factor
TCHH, trichohyalin
TCHP, trichoplein keratin filament-binding 
protein





TEFM, transcription elongation factor, 
mitochondrial
TERF, telomeric repeat binding factor
TERT, telomerase reverse transcriptase
TFAM, mitochondrial transcription factor A
TFG, tyrosine kinase-fused gene
TFRC, transferrin receptor




TIMM, translocase of inner mitochondrial 
membrane homolog
TIP, Tat interactive protein




TMA, translation machinery associated 
homolog




























TMX, thioredoxin-related transmembrane 
protein
TNF, tumor necrosis factor
TNFSF, tumor necrosis factor ligand 
superfamily member
TNPO, transportin
TOLLIP, Toll interacting protein
TOMM, translocase of outer mitochondrial 
membrane homolog
TP, tumor protein
TPD52L, tumor protein D52-like
TPP, tripeptidyl-peptidase
TPR, translocated promoter region
TPT, tumor protein translationally-controlled
TRADD, tumor necrosis factor receptor type 
1-associated DEATH domain protein
TRA, transformer homolog
TRAP, TNF receptor-associated protein
TRAPP, transport protein particle
TRHR, thyrotropin-releasing hormone 
receptor
TRIM, tripartite motif containing
TRIP, thyroid receptor-interacting protein
TRMT, tRNA methyltransferase
tRNA, transfer RNA
troponin t, tropomyosin-binding subunit of 
troponin
TRPC, transient receptor potential canonical 
channels
TRPS, trichorhinophalangeal syndrome
TSC22D, TGF-beta-stimulated clone 22 
domain family
TST, thiosulfate sulfurtransferase
TSTA, tissue-specific transplantation antigen
TUB, tubulin
TWF, twinfilin
TXNDC, thioredoxin domain containing
TYK, non-receptor tyrosine-protein kinase
TYMP, thymidine phosphorylase
U, uracil
U2AF, U2 small nuclear RNA auxiliary factor
UB, ubiquitin
UBCH, human polyubiquitin C
UBE, ubiquitin-conjugating enzyme
UBF, upstream binding factor
UBP43, same as USP18 in standard 
nomenclature
UBR, ubiquitin protein ligase E3 component 
n-recognin
UBXN, UBX domain containing protein
UCH, ubiquitin carboxyl-terminal esterase
UFD, ubiquitin fusion degradation protein
UFD1L, ubiquitin fusion degradation 1 like
UNC, uncoordinated protein
UQCR, ubiquinol-cytochrome c reductase
UQCRB, ubiquinol cytochrome c reductase 
binding protein
UQCRC, ubiquinol cytochrome c reductase 
complex
UQCRFS1, ubiquinol-cytochrome c reductase, 
Rieske iron-sulfur 
polypeptide 1






V1 complex, VAMP, vesicle-associated 
membrane protein
VAP, (vesicle-associated membrane protein)-
associated protein
VAT, vesicle amine transport protein











































VCAM, vascular cell adhesion molecule
VCL, vinculin
VCP, valosin containing protein
VDAC, voltage-dependent anion channel
Vegf, vascular endothelial growth factor
VHL, von Hippel-Lindau tumor suppressor, E3 
ubiquitin protein ligase
VPS, vacuolar protein sorting protein
v-Ras, virus encoded Ras gene
v-SNARE, vesicle soluble NSF attachment 
protein receptor
VSV, vesicular stomatitis virus
VTA, vacuolar protein sorting 20-associated 
homolog
VTI, vesicle transport through interaction 
with t-SNAREs
WAC, WW domain containing adaptor with 
coiled-coil
WDR, WD (tryptophan-aspartic acid) repeat 
containing
WIBG, within benign gonial cell neoplasm 
homolog
Wnt, wingless/integration protein family
WNV, west Nile virus
XPO, exportin
YARS, tyrosyl-tRNA synthetase
YBX, Y box binding protein
YIF1, YPT-interacting protein 1 interacting 
factor homolog
YTHDF, YTH domain family
YWHAH, tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation 
protein, eta polypeptide












The aim of the present thesis was to elucidate the role of estrogen receptor (ER)α and ERβ 
in cell proliferation and apoptosis induced by estrogenic compounds.  Special attention 
was paid to the importance of the receptor preference of the estrogenic compounds, 
the cellular ERα/ERβ ratio, the role of coregulators, and ER-mediated induction of 
protein expression. 
Estrogenic compounds: agonists and antagonists
To cover a wide range of potential estrogenic actions, in addition to the reference 
compound 17β-estradiol (E2) [1-3], an ERα agonist (ERA-45) [4], an ERβ agonist (ERB-041) 
[5], a partial ERα antagonist (4-hydroxytamoxifen, 4OHT) [6-8], and a full ER antagonist 
(fulvestrant) [9-13] were investigated. For the coregulator research (chapter 3 and 4) 
also genistein, a phytoestrogen which was already well characterized for its effects 
on cell proliferation by Sotoca et al. [14], was included. The intrinsic relative potency 
(reflected by EC
50
) and maximal efficacy of the selected ERα and ERβ agonists towards 
ERα and ERβ were determined in chapter 3 using ER-selective reporter gene assays. E2 
showed a 9-fold lower EC
50
 value in the U2OS-ERα than in the U2OS-ERβ cell line. The 
EC
50
 and EEF (Estradiol Equivalence Factor) values corroborated selective ERα agonist 
activity for ERA-45, and selective ERβ agonist activity for ERB-041 and genistein. For 
the U2OS-ERα reporter gene assay, the order for efficacy of the ligands as derived from 
the height of the dose response curve induced by the ligand in the U2OS-ERα reporter 
gene assay was genistein = E2 ≈ ERA-45, while for the U2OS-ERβ reporter gene assay the 
order for efficacy was genistein > E2 > ERA-45 > ERB-041. Intrinsic relative potency and 
maximal efficacy of the selected antagonists towards ERα and ERβ were characterized 
in chapter 4 using ER-selective U2OS reporter gene assays performed in the presence 
of E2 at its EC
50
. These studies indicated a preference of 4OHT to inhibit ERβ and found 
fulvestrant to be less ER-specific in its antagonizing activity. Efficacy of both antagonistic 
compounds towards both ERα and ERβ as derived from the lowest point of the dose 
response curve induced by the ligand in the U2OS reporter gene assays appeared similar.
Estrogen receptors
In previous studies it has been demonstrated that stimulation of ERα and ERβ may 
have opposite effects on cell proliferation [15-20]. Therefore it is of importance to use 
experimental models able to mimic physiologically relevant levels of ERα and ERβ. A 
model of interest consists of the T47D cell model with tetracycline-dependent ERβ 
expression and constant ERα expression developed by Ström et al. [19]. Chapter 2 
describes under which conditions these T47D-ERβ breast cancer cells with tetracycline-










tissues in vivo in rat as well as in human. At protein and messenger RNA (mRNA) level, 
ERα and ERβ levels and ratios were determined in T47D-ERβ cells exposed to a range of 
tetracycline concentrations and these levels were compared to levels found in breast, 
prostate, and uterus or endometrium tissue samples from both rat and human. The 
ERα/ERβ ratio found in rat mammary gland and in human breast tissue can be mimicked 
by exposing the T47D-ERβ cells to >150 ng/ml tetracycline, but the ERα/ERβ ratio of 
other estrogen-sensitive rat and human tissues can also be mimicked. Given the limited 
number of human samples available, it was not possible to also investigate factors 
underlying possible subtle differences in the ERα/ERβ levels and ratio between different 
subjects. One could expect that factors like (but not limited to) age [21], menstrual cycle 
[22], and consumption of supplements and food, especially for Asian countries where a 
lot of soy is consumed containing phytoestrogens such as genistein [23] influence ERα 
and ERβ levels and ratios. To be able to take these factors into account while analyzing 
data from different subjects, thereby enabling mimicking more personalized ERα and 
ERβ levels and ratios, tissue samples of a larger population should be studied.
In addition to the T47D-ERβ cells, ERα/ERβ ratios were also determined in MCF-7 
and native T47D breast cancer cell lines and compared to ERα/ERβ ratios in rat and human 
tissues. The ERα/ERβ ratios in MCF-7 and native T47D cells were relatively high due to 
a lack of ERβ expression and therefore did not reflect ratios in analyzed rat and human 
tissues. This may indicate that these cell lines may not represent adequate models to 
study the effects of estrogens in healthy tissues. Given that these cell lines are derived 
from breast  adenocarcinoma (MCF-7) [24] and breast ductal carcinoma (T47D) [25], and 
that tumor tissue is known to often express low levels of ERβ [26], the effects observed 
in the ERα-positive cell lines may rather represent responses of tumorous tissue.
In this context, it is of interest to note that at present no absolute quantitative 
techniques are available to determine ERα and ERβ levels and ratios. The qPCR and 
Western Blot analysis used in  chapter 2 of the present thesis for determination of ER levels 
and ratios are semi-quantitative techniques [27, 28]. By using these two complementary 
techniques measuring mRNA and protein levels and making relative comparisons 
to T47D-ERβ cells not exposed to tetracycline for which levels were quantified in the 
same manner as for the test samples, the effect of antibody or probe specificity was 
eliminated. To be able to investigate ER levels in a more absolute quantitative manner, 
one might consider proteomics techniques. In that case, known concentrations of 
synthetic, isotope labeled peptides similar to the target peptides should be added to the 
sample under investigation, which subsequently should be analyzed by LC-MS/MS. The 







and the abundance of the target peptide in the sample is compared to the abundance 
of the labeled peptide. By means of a standard curve, the initial concentration of the 
target peptide can then be determined. To be able to use this technique, isotope labeled 
peptides to determine ERα and ERβ levels would have to be developed, which is costly 
and time-consuming [29]. 
Coregulators
It is known that upon binding of an estrogenic compound to the estrogen receptor and 
dimerization of the ER, specific coregulators in the cell can play a key role in the gene 
transcription induced by ER binding. These coregulators are attracted to or rejected 
from the dimerized ligand-ER complex to enhance or oppose gene transcription by 
which the estrogenic compound exerts its effects [30]. In chapter 3 the modulation 
of the interaction of ERα and ERβ with various coregulators induced by estrogenic 
compounds was investigated. In this chapter the ligand-dependent modulation of the 
interaction of ERα and ERβ with coregulators was studied by using the Microarray 
Assay for Real-time Coregulator – Nuclear receptor Interaction (MARCoNI), with 154 
unique nuclear receptor coregulator peptides derived from 66 different coregulators. 
The responses in the MARCoNI assay reveal that the modulation of the interaction 
of ERα or ERβ with coregulators induced by the different agonists upon ERα or ERβ 
activation are similar and imply only a limited number of differences upon ERα or 
ERβ activation by a specific ligand. For example modulation of the interaction of 
ERs with coregulator motif DDX5_133_155 showed positive modulation with ERβ, 
but not with ERα, and this effect was consistently seen for all ER agonists. DDX5 is a 
transcriptional coactivator for the tumor suppressor protein p53 and is involved in the 
p53 transcriptional response to DNA damage and p53-dependent apoptosis [31]. The 
modulation of the interaction of ERβ with this DDX5 coactivator, but not ERα, is in line 
with ERβ counteracting ERα-mediated cell proliferation by means of apoptosis. Based 
on the observed differences in type and extent of the modulation of the interaction 
of the ERs with these coregulators between the different agonists, the compounds 
could be hierarchically clustered, which is not possible based on the outcomes of ER-
selective reporter gene or proliferation assays. 
Upon characterizing the modulation of the interaction of ER subtypes with 
coregulators upon binding of selected ER agonists in chapter 3, chapter 4 describes 
the modulation of the interaction of ERα and ERβ with coregulators induced by the 
ER antagonistic compounds 4OHT and fulvestrant. The MARCoNI assay shows similar 
ERα- and ERβ-mediated modulation index (MI) profiles for 4OHT and fulvestrant, which 










difference was observed between the MI profiles of 4OHT and fulvestrant. Fulvestrant 
shows negative and 4OHT positive modulation of the interaction of ERβ with coregulator 
motif DDX5_133_155. The recruitment of this DDX5 coactivator motif by ERβ as induced 
by tamoxifen could be beneficial for ERβ reducing ERα-mediated cell proliferation since 
it could stimulate p53-dependent apoptosis. It is of interest to note that previously 
tested agonistic compounds showed positive modulation of the interaction of ERβ with 
coregulator motif DDX5_133_155 as well. This could possibly be linked to the partial 
agonistic actions that tamoxifen and 4OHT have in specific tissues [32]. Hierarchical 
clustering based on the MI profiles could clearly discriminate the two ER antagonists 
from the ER agonist E2. However, the MARCoNI assay was unable to discriminate 
between the preferential ERβ antagonistic compound 4OHT and the less specific ER 
antagonist fulvestrant based on the modulation of the interaction of ERα and ERβ with 
coregulators. For both the ER agonists described in chapter 3 and the ER antagonists 
described in chapter 4 differences in the modulation of the interaction of ERα and ERβ 
with coregulators contribute to the ligand-dependent responses, but do not fully explain 
the differences in pharmacology between ER-mediated responses by the different 
ligands. Even though the functions of coregulators are known to some extent (Table 1), 
the importance of the subtle differences in modulation of the interaction of ERs with 
coregulators between the ER agonistic compounds E2, ERA-45, ERB-041, and genistein, 
and the ER antagonistic compounds 4OHT and fulvestrant for the ultimate biological 
effect remains to be established.
Such a comparative analysis of the modulation of the interaction of ERα and ERβ 
with various coregulators induced by different estrogenic compounds as shown in 
chapter 3 and 4 reveals a new research strategy. Although MI profiles by the different 
ERs for a given ligand show only relatively small differences, these differences might 
contribute to the ultimate effect on the compound’s specific pharmacology. The data as 
described in chapter 3 and 4 are quite exploratory  and the first results  are not yet fully 
conclusive. However, the approach shown here by studying the differential interaction 
of ERα and ERβ with coregulators is promising and it is a potentially important aspect 
of future research into the interaction of ERα and ERβ with various coregulators, ER 








Table 1: Overview of coregulators of the MARCoNI assay and short transcriptional function 





BL1S1_1_11 Biogenesis of lysosome-
related organelles 




May act as a coactivator during 
transcriptional activation by hormone-
activated nuclear receptors (NR). At 
least isoform 1 and isoform 2 are 
components of the NuA4 histone 
acetyltransferase (HAT) complex 
which is involved in transcriptional 
activation of select genes principally by 
acetylation of nucleosomal histones H4 
and H2A. This modification may both 
alter nucleosome - DNA interactions 
and promote interaction of the 
modified histones with other proteins 
which positively regulate transcription. 
This complex may be required for the 
activation of transcriptional programs 
associated with oncogene and proto-
oncogene-mediated growth induction, 
tumor suppressor-mediated growth 
arrest and replicative senescence, 
apoptosis, and DNA repair. NuA4 may 
also play a direct role in DNA repair 
when recruited to sites of DNA damage 
[33, 34].
CBP_2055_2077 Nuclear cap-binding 
protein
The CBP protein is known to 
acytelate histones as well as non-
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Cyclin D1 Regulatory component of the 
cyclin D1-CDK4 (DC) complex that 
phosphorylates and inhibits members 
of the retinoblastoma (RB) protein 
family and regulates the cell-cycle 
during G
1
/S transition. Phosphorylation 
of RB1 allows dissociation of the 
transcription factor E2F from the RB/
E2F complex and the subsequent 
transcription of E2F target genes which 






Centromere protein R Transcription coregulator that can 
have both coactivator and corepressor 
functions. Acts as a coactivator for 
estrogen receptor alpha. Induces 
apoptosis in breast cancer cells, but 
not in other cancer cells, via a caspase-
2-mediated pathway that does not 






Acts as a transcriptional coactivator 
for PPARA and possibly other nuclear 
receptors. Proposed to be a ATP-
dependent chromatin remodeling 
protein. Has DNA-dependent ATPase 
activity and binds to A/T-rich DNA. 
Associates with A/T-rich regulatory 
regions in promoters of genes that 
participate in the differentiation of 
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Scaffolding component of the 
CCR4-NOT complex which is one of the 
major cellular mRNA deadenylases and 
is linked to various cellular processes 
including translational repression 
during translational initiation and 
general transcription regulation. 
Represses the ligand-dependent 
transcriptional activation by nuclear 
receptors [45, 46].
DDX5_133_155 DEAD box protein 5 DDX5 is a transcriptional coactivator 
for the tumor suppressor protein 
p53 and is involved in the p53 
transcriptional response to DNA 
damage and p53-dependent apoptosis 
[31].






Functions as histone acetyltransferase 
and regulates transcription via 
chromatin remodeling. Acetylates all 
four core histones in nucleosomes. 
Histone acetylation gives an epigenetic 
tag for transcriptional activation. Also 
functions as acetyltransferase for 
nonhistone targets. Is proposed to 
indirectly increase the transcriptional 
activity of TP53 through acetylation. 









Hairless Has been characterized as a 
corepressor for several members of the 
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ILK_131_153 Integrin-linked protein 
kinase
Unknown
JHD2C_2054_2076 Probable JmjC domain-
containing histone 
demethylation protein 2C
May be involved in hormone-
dependent transcriptional activation 
[52].
KIF11_832_854_C854S Kinesin-like protein KIF11 Component of a large chromatin 
remodeling complex [53].
L3R2A_12_34 Loss of heterozygosity 3 





Repressor of ligand-dependent 











Functions as a transcriptional 
repressor, inhibiting the signaling of 
retinoic acid through the retinoic acid 
receptors RARA, RARB and RARG. 
Prevents retinoic acid-induced cell 




Mediator of RNA 
polymerase II 
transcription subunit 1
Component of the Mediator complex, 
a coactivator involved in the regulated 
transcription of nearly all RNA 
polymerase II-dependent genes. 
Mediator functions as a bridge to 
convey information from gene-specific 
regulatory proteins to the basal RNA 
polymerase II transcription machinery. 
Mediator is recruited to promoters 
by direct interactions with regulatory 
proteins and serves as a scaffold for the 
assembly of a functional preinitiation 
complex with RNA polymerase II and the 







Table 1: Overview of coregulators of the MARCoNI assay and short transcriptional function 
description if known (main database www.uniprot.org and www.nursa.org). (continued)
Motif Name Function





MGMT is a human DNA repair enzyme 
which carries out suicidal repair of 
mutagenic O(6)-alkylguanine lesions 
caused by alkylating carcinogens, 
undergoing conversion to R-MGMT in 
the process. The R-MGMT form has 
been characterized as an estrogen 






MLL2 is part of a complex shown to be 
a transcriptional regulator of beta-






May be involved in the regulation 
of gene expression by covalent 
modification of histone proteins. 
Isoform Long is a corepressor of 
estrogen receptor (ER). Isoform Short 
binds to ER and sequesters it in the 
cytoplasm and enhances non-genomic 







Nuclear receptor coactivator that 
directly binds nuclear receptors and 
stimulates the transcriptional activities 
in a hormone-dependent fashion. 
Involved in the coactivation of different 
nuclear receptors, such as for steroids 
(PGR, GR and ER). Displays histone 
acetyltransferase activity toward H3 
and H4. Plays a central role in creating 
multisubunit coactivator complexes 
that act via remodeling of chromatin, 
and possibly acts by participating 
in both chromatin remodeling and 
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Transcriptional coactivator for 
steroid receptors and nuclear 
receptors. Coactivator of the steroid 
binding domain (AF-2) but not of the 











Nuclear receptor coactivator that 
directly binds nuclear receptors and 
stimulates the transcriptional activities 
in a hormone-dependent fashion. Plays 
a central role in creating a multisubunit 
coactivator complex, which probably 
acts via remodeling of chromatin. 
Involved in the coactivation of different 
nuclear receptors, such as for steroids 





Enhances the androgen receptor 
transcriptional activity in prostate 
cancer cells. Ligand-independent 
coactivator of the peroxisome 






Nuclear receptor coactivator that 
directly binds nuclear receptors 
and stimulates the transcriptional 
activities in a hormone-dependent 
fashion. Coactivates expression in an 
agonist- and AF2-dependent manner. 
Involved in the coactivation of different 
nuclear receptors, such as for steroids 
(GR and ERs). Probably functions as a 
general coactivator, rather than just 
a nuclear receptor coactivator. May 
coactivate expression via a remodeling 
of chromatin and its interaction with 
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NCOR1 mediates transcriptional 
repression. It is part of a complex 
which promotes histone deacetylation 
and the formation of repressive 
chromatin structures which may 







Transcriptional corepressor. Mediates 
the transcriptional repression 
activity of some nuclear receptors by 
promoting chromatin condensation, 
thus preventing access of the basal 
transcription. Isoform 1 and isoform 
5 have different affinities for different 






NELFB in complex negatively regulates 
transcription elongation and causes 





subfamily 0 group B 
member 1
Acts as a coregulatory protein that 
inhibits the transcriptional activity 







subfamily 0 group B 
member 2
Unknown
NRBF2_128_150 Nuclear receptor-binding 
factor 2
May modulate transcriptional 
activation by target nuclear receptors. 
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NRIP1 can both co-activate and co-







Transcriptional intermediary factor 
capable of both negatively or positively 
influencing transcription, depending on 
the cellular context [93].
PAK6_248_270 p21-activated kinase 6 PAK6 kinase plays a role in the 
regulation of gene transcription. 
It inhibits androgen receptor and 
ERα-mediated transcription and may 
protect cells from apoptosis [94, 95].
PCAF_178_200 P300/CBP-associated 
factor
Functions as a histone 
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Proline-, glutamic acid- 
and leucine-rich protein 1
Coactivator of estrogen receptor-
mediated transcription and a 
corepressor of other nuclear hormone 
receptors and sequence-specific 
transcription factors. Plays a role 
in estrogen receptor (ER) genomic 
activity when present in the nuclear 
compartment by activating the ER 
target genes in a hormonal stimulation 
dependent manner. Plays a role in 
E2-mediated cell cycle progression. 
May have important functional 
implications in ER/growth factor cross-
talk. May promote tumorigenesis via 
its interaction with and modulation 
of several oncogenes. Plays a role in 
cancer cell metastasis via its ability to 
modulate E2-mediated cytoskeleton 
changes and cell migration [96-101].
PIAS2_6_28 Protein inhibitor of 
activated STAT2
Plays a crucial role as a transcriptional 
coregulator in various cellular 
pathways, including the STAT 
pathway, the p53 pathway and the 
steroid hormone signaling pathway. 
The effects of this transcriptional 
coregulation, transactivation or 
silencing may vary depending upon 
the biological context and the PIAS2 
isoform studied. However, it seems to 
be mostly involved in gene silencing. 
Binds to sumoylated ELK1 and 
enhances its transcriptional activity by 
preventing recruitment of HDAC2 by 
ELK1, thus reversing SUMO-mediated 
repression of ELK1 transactivation 
activity [102, 103].
PNRC1_306_327 Proline-rich nuclear 
receptor coactivator 1
Nuclear receptor coactivator. May play 










Table 1: Overview of coregulators of the MARCoNI assay and short transcriptional function 
description if known (main database www.uniprot.org and www.nursa.org). (continued)
Motif Name Function
PNRC2_118_139 Proline-rich nuclear 
receptor coactivator 2





activated receptor gamma 
coactivator-related 
protein 1
PPRC1 acts as a coactivator during 
transcriptional activation of nuclear 
genes related to mitochondrial 









A-interacting complex 285 
kDa protein
Unknown
PRDM2_948_970 PR domain-containing 
protein 2





activated receptor gamma 
coactivator 1-alpha
Transcriptional coactivator for steroid 




activated receptor gamma 
coactivator 1-beta
Plays a role of stimulator of 




Progestrerone receptor The steroid hormones and their 
receptors are involved in the regulation 
of eukaryotic gene expression and 
affect cellular proliferation and 
differentiation in target tissues. 
Progesterone receptor isoform B (PRB) 
is involved activation of c-SRC/MAPK 
signaling on hormone stimulation 
[111-116].
PROX1_57_79 Prospero homeobox 
protein 1
Prox1 is a prospero-related homeobox 
transcription factor that was originally 
characterized as a coregulator through 
its ability to suppress LRH-1-mediated 








Table 1: Overview of coregulators of the MARCoNI assay and short transcriptional function 
description if known (main database www.uniprot.org and www.nursa.org). (continued)
Motif Name Function
RAD9A_348_370 Cell cycle checkpoint 
control protein RAD9A
A negative coregulator in the 
repression of androgen receptor 






Directly involved in heterochromatin 
formation by maintaining overall 
chromatin structure and, in particular, 
that of constitutive heterochromatin 
by stabilizing histone methylation. 
Recruits and targets histone 
methyltransferases, leading to 
epigenetic transcriptional repression. 
Probably acts as a transcription 
repressor by recruiting chromatin-
modifying enzymes to promoters. May 
act as a tumor suppressor [119].
TF65_437_459 Transcription factor p65 Transcription factor present in almost 
all cell types and is the endpoint of a 
series of signal transduction events 
that are initiated by a vast array of 
stimuli related to many biological 
processes such as inflammation, 
immunity, differentiation, cell 
growth, tumorigenesis and apoptosis. 
Different dimer combinations act as 









In the nucleus, functions as a 
nuclear receptor coactivator 
regulating glucocorticoid, androgen, 
mineralocorticoid and progesterone 
receptor transcriptional activity. 
May play a role in the processes of 
cell growth, proliferation, migration, 
differentiation and senescence. May 
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TIF1A is a transcriptional coactivator 
that plays a role in the regulation of cell 
proliferation and apoptosis, at least in 
part via its effect on TP53 levels [128].
TIP60_476_498 60 kDa Tat-interactive 
protein
Catalytic subunit of the NuA4 histone 
acetyltransferase complex which is 
involved in transcriptional activation of 
select genes principally by acetylation 
of nucleosomal histones H4 and H2A. 
This modification may both alter 
nucleosome-DNA interactions and 
promote interaction of the modified 
histones with other proteins which 
positively regulate transcription. This 
complex may be required for the 
activation of transcriptional programs 
associated with oncogene and proto-
oncogene-mediated growth induction, 
tumor suppressor-mediated growth 
arrest and replicative senescence, 





Activates transcription of CYP11A1. 
Interaction with CREBBP and EP300 
results in a synergistic transcriptional 
activation of CYP11A1 [133].
TRIP4_149_171_C171S Thyroid receptor-
interacting protein 4
Transcription coactivator of nuclear 
receptors which functions in conjunction 
with CBP-p300 and SRC-1 and may play 
an important role in establishing distinct 
coactivator complexes under different 
cellular conditions. Plays a pivotal role 
in the transactivation of NF-kappa-B, 
SRF and AP1. Acts as a mediator of 
transrepression between nuclear 
receptor and either AP1 or NF-kappa-B. 
Plays a role in androgen receptor 
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Coactivator TRRAP is found in protein 
complexes possessing histone 
acetyltransferase activity. It is involved 
in transcription activation of for 
example proto-oncogene MYC but 
also of tumor suppressor gene p53 
[135-137].
TRXR1_132_154 Thioredoxin reductase 
TR1
The selenoprotein thioredoxin 
reductase (TrxR1) is a modulator 
of estrogen signaling by binding to 
the estrogen receptors α and β by 
modulating the estrogen receptor-
coactivator complex assembly on non-
classical estrogen response elements 









WD repeat domain 
phosphoinositide-
interacting protein 1
Plays a distinct role in controlling the 
transcription of melanogenic enzymes 
and melanosome maturation, a process 
that is distinct from starvation-induced 
autophagy [140-142].
ZNHI3_89_111 Zinc finger HIT domain-
containing protein 3
Unknown
ZNT9_449_471 Zinc transporter 9 Plays a role in the p160 coactivator 
signaling pathway that mediates 
transcriptional activation by 
nuclear receptors. Plays a role in 











Towards gene and protein expression
As described in the introduction of the current thesis, upon binding of an estrogenic 
compound to the estrogen receptor and dimerization of the ERs, attraction or rejection 
of specific coregulators, and binding to the estrogen response element (ERE), gene 
transcription is initiated and protein expression is induced [144]. This process will 
eventually lead to biological effects in the cells and organs. Cell proliferation and apoptosis 
are major biological events in every aspect of cell cycle control, but especially of interest 
in studying cancer progression [145, 146]. These events are known to be influenced by 
estrogenic compounds, exerting their effects through binding ERα and/or ERβ [145, 
146].  ERα activation induces cell proliferation [15], while ERβ activation counteracts this 
and is suggested to induce apoptosis [16-20]. This latter aspect is of importance given 
that the ERα/ERβ ratio usually increases in tumorous tissue compared to normal tissue 
due to decreased ERβ expression [26]. One of the compounds in our test panel, 4OHT, 
is an active metabolite of the widely used breast cancer drug tamoxifen [6, 147]. To 
investigate whether 4OHT exerts ERα/ERβ ratio-dependent effects on cell proliferation 
and apoptosis, in chapter 5 a quantitative proteomics study is presented. ERα/ERβ ratio-
dependent effects of 4OHT on cell proliferation and apoptosis of the T47D-ERβ human 
breast cancer cell line with tetracycline-dependent ERβ expression were characterized. 
In the cells expressing only ERα decreased cell proliferation and increased apoptosis was 
induced by 4OHT, which was opposite to the cells expressing both ERα and ERβ, for which 
increased cell proliferation and decreased apoptosis upon 4OHT exposure was found. 
Post-translational modifications like acetylation, methylation, and phosphorylation of 
several ribosomal and mitochondrial protein groups were induced by 4OHT, mostly in 
T47D-ERβ cells with both ERα and ERβ expressed. Altogether the results suggested that 
ERα/ERβ ratio-dependent major biological functions like cell proliferation and apoptosis 
are affected by 4OHT in T47D-ERβ cells. 4OHT may have differential effects in tissue, 
being more effective in reducing cell proliferation and increasing apoptosis if ERα 
dominates and ERβ expression levels are low since 4OHT then antagonizes ERα.
Biological effects
The current thesis focused on cell proliferation and apoptosis as major biological effects 
known to be influenced by estrogenic compounds and playing an important role in 
cancer progression [145, 146]. In chapter 2 it was demonstrated how different estrogen-
responsive tissues may vary in their proliferative response by exposing T47D-ERβ cells 
exposed to defined tetracycline concentrations to mimic various tissues to E2. It is 
known that ERα and ERβ levels and ratios vary between tissues as well as between cell 







the different effects estrogenic compounds can have on different tissues (for example 
tamoxifen which has anti-proliferative action in breast tissue but stimulates proliferation 
in the endometrium) [32]. However, also the difference in metabolizing capacity of the 
different tissues has been suggested to contribute to differential effects of estrogenic 
compounds. In different tissues, different cytochrome P450 (CYP) enzymes could be 
present [149-154]. In human endometrium for instance, formation of the DNA reactive 
α-hydroxytamoxifen metabolite of tamoxifen, a different metabolite than 4OHT, was 
shown [155, 156]. If the CYP enzymes present in the endometrium are more prone 
towards the formation of the DNA reactive α-hydroxytamoxifen metabolite than to 
4OHT, this could be a (partial) explanation for the proliferative action of tamoxifen in 
the endometrium despite the relatively high ERα/ERβ ratio in this tissue. Furthermore, 
it was shown that after treatment with tamoxifen, tamoxifen-associated malignant 
endometrial tumors have more frequent ERβ expression compared to non-tamoxifen-
associated endometrial cancers [157].  As shown in chapter 5 of the current thesis, 
4OHT may be less effective in reducing cell proliferation and increasing apoptosis if ERβ 
expression levels are high since 4OHT then antagonizes ERβ. This might also be a (partial) 
explanation for the proliferative action of tamoxifen in the endometrium. 
In chapter 3 it was demonstrated that ERα agonists activate cell proliferation, 
whereas ERβ seems to suppress ERα-mediated cell proliferation in the T47D-ERβ cells. 
These results corroborate that effects on cell proliferation depend on the intrinsic 
relative potency of the agonist towards ERα and ERβ and the cellular ERα/ERβ ratio. 
These ERα/ERβ ratio-dependent effects are especially of importance for anti-estrogenic 
compounds used in the hormonal treatment of ERα-positive breast cancer since the 
ERα/ERβ ratio usually increases in tumorous tissue compared to normal tissue due 
to decreased ERβ expression [26]. To obtain more insight in the 4OHT-induced ERα/
ERβ ratio-dependent proteins that are able to affect cell proliferation and apoptosis, 
in chapter 5 a quantitative proteomics study was conducted, investigating ERα/ERβ 
ratio-dependent effects induced by 4OHT, the active metabolite of the breast cancer 
drug tamoxifen. One of the main conclusions from this proteomics study presented 
in chapter 5 is that 4OHT may have differential effects in tissues depending on the 
ERα and ERβ levels and ratios, being more effective in reducing cell proliferation and 
increasing apoptosis if ERα dominates and ERβ expression levels are low since 4OHT 
then antagonizes ERα. This conclusion suggests that it may be of value to monitor ERα 
and ERβ levels and ratios throughout breast cancer treatment with tamoxifen enabling 










Madeira et al. conducted a randomized neo-adjuvant trial for the treatment of 
postmenopausal occurring breast cancer, from which it was concluded that the ERα/ERβ 
ratio and ERβ levels could be used as predictors of endocrine therapy responsiveness 
[158]. However, in contrast to the data presented in chapter 5, these authors concluded 
that especially in ERβ-positive groups tamoxifen produced a significant reduction in post-
treatment Ki67 scores, a marker for cell proliferation. The post-treatment Ki67 scores in 
their ERβ-positive group upon tamoxifen treatment and the ERβ-negative group were 
actually similar in percentage, and most probably not statistically significant due to the small 
group size. Furthermore, in both patient groups ERα-positive and ERα-negative cases were 
combined. Given the important role for ERα for 4OHT-mediated effects on cell proliferation 
and apoptosis, this combining of ERα-positive and ERα-negative cases hampers comparison 
of the data of the trial with the proteomics data presented in chapter 5.
It is also of interest to note that tamoxifen is commonly used in breast cancer 
treatment at an oral dose of 20 mg per day for 5 years [159]. This has shown to be an 
effective dose, but it is not known exactly how much of this tamoxifen and its active 
metabolite are available to the tumor cells. Plasma levels of 4OHT have been reported 
to be around 1495 pg/ml [160]. In the proteomics study presented in chapter 5, the cells 
were exposed to 300 nM 4OHT, the dose where a maximum inhibition of cell proliferation 
induced by 30 pM E2 was observed in the T47D-ERβ cell model to ascertain that the dose 
of 4OHT would be effective. This concentration of 300 nM 4OHT would (MW=387.51 
[161]) correspond to 116 ng/ml, which is about 78 times the reported plasma levels. 
This is thus a relatively high dose compared to in vivo concentrations. However, it was 
shown in the BrdU cell proliferation assay that approximately 30 times more 4OHT is 
necessary than the amount of E2 to abolish the effect of E2 on cell proliferation (EC
50
 E2 
is 30 pM, IC
50
 4OHT is approximately 30x higher). The reported plasma levels of 4OHT of 
1495 pg/ml would thus be able to abolish the effect of 130 pM E2. Plasma levels of E2 
of postmenopausal tamoxifen treated women drop with around 12% [162]. Taking into 
account that normal E2 levels in plasma in postmenopausal woman are around 15 pg/ml 
[163], with a drop of 12% corresponding to 50 pM E2 (MW = 272.38 [164]), the amount 
of 4OHT relative to the amount of E2 in plasma is also high.  To investigate if the changes 
detected by quantitative  proteomics in the present thesis would be observed at lower 
4OHT concentrations remains a topic of interest for future research.
Another point that should be taken into account when addressing the results 
described in the current thesis is the fact that ER-positive breast cancer treatment 
sometimes consists of a combination of therapeutic agents (for example a combination 







interact with cell proliferation or estrogen levels as well [166]. Although this thesis 
describes the interaction of different kinds of (anti-)estrogenic compounds with ERα and 
ERβ and eventually their effects on cell proliferation and apoptosis, interaction between 
those compounds and other therapeutics can enhance or attenuate the effects [167]. 
How the ERα and ERβ levels and ratios influence possible  combination effects resulting 
from combined exposure remains a topic for future investigations. Each combination of 
therapeutic compounds might then be carefully investigated for its ultimate biological 
effects within a cellular background of different ERα and ERβ levels and ratios. This 
thesis described and validated possible approaches for such research into ERα and ERβ 
level- and ratio-dependent combination therapy in treatment of breast cancer.
Altogether, the present thesis describes how a selection of estrogenic compounds 
with different modes of action interact with ERα and ERβ and subsequently recruit or 
reject coregulators, and how this eventually leads to a shift in protein expression and 
affects major biological events like cell proliferation and apoptosis. The results obtained 
clearly corroborate the importance of ERα and ERβ levels and ratios, especially in 
tamoxifen treatment in breast cancer.
Future perspectives 
The research in the present thesis focuses on the role of differential expression of ERα 
and ERβ and their ratios and how this affects cell proliferation and apoptosis induced 
by estrogenic compounds and the interaction of the ERs with coregulators upon 
stimulation by ligands. Although especially the importance of the receptor preference 
of the estrogenic compounds, the cellular ERα/ERβ ratio, the interaction of the ERs with 
coregulators upon stimulation by ligands, and ER subtype-mediated induction of protein 
expression is elucidated, there are some additional topics to be considered in future 
research. These are discussed in some more detail in the next sections.
Estrogenic compounds: agonists and antagonists
The compounds used in the present thesis were characterized for their potency 
and efficacy towards ERα and ERβ. From these results it was demonstrated that the 
selective ERβ agonist ERB-041 shows low potency and efficacy. Furthermore, it was 
demonstrated that 4OHT preferentially inhibits ERβ, whereas fulvestrant appears to be 
less ER subtype-specific. ER antagonistic compounds like tamoxifen and fulvestrant are 
used as breast cancer drugs for their ability to reduce ERα-mediated cell proliferation 
[13]. The downside of these compounds are their severe side effects [168, 169]. ERβ 










fulvestrant as indicated in the current thesis, showing no induction of cell proliferation 
even when ERβ was fully suppressed and only ERα was expressed. In cell proliferation 
assays as described in chapter 3 of the current thesis, no effect on cell proliferation was 
observed upon  exposure of the T47D-ERβ cells to ERB-041, although with the T47D-ERβ 
cells expressing ERβ, a suppression of cell proliferation was expected with this ERβ 
agonist since ERβ is known to suppress cell proliferation [16-20]. Suppression of cell 
proliferation could probably not be seen in the cell proliferation assay due to the low 
potency and efficacy of the ERB-041 compound. 
Several of the reported side effects of tamoxifen and fulvestrant are related to 
the endometrium. Since ERβ agonists might have less or less severe side effects, at 
least on endometrium as shown for genistein [170], it is a challenge for pharmaceutical 
companies to develop a more potent and efficient ERβ agonist than ERB-041. Genistein 
might seem an interesting candidate given that genistein has a preference for ERβ with 
high potency and efficacy as shown in the U2OS reporter gene assays in chapter 3. 
However, in vitro and rodent data have also reported that genistein can stimulate 
tumor cell proliferation and growth [171]. The dual behaviour of genistein (and any 
newly developed ERβ agonist) as drugs or food supplements for postmenopausal 
women should therefore be carefully considered.
Estrogen receptors 
In the current thesis the importance of ERα and ERβ levels and ratio for the ultimate 
biological effect of estrogenic compounds has been demonstrated by characterizing the 
effects of varying ERα and ERβ levels and ratio on estrogenic compound-induced cell 
proliferation and apoptosis. One aspect of estrogen receptors that has not been taken 
into account in the current thesis are splice variants. Splice variants are truncated (or 
sometimes elongated) forms of the ERs [172]. For ERα over 20 different splice variants 
have been reported in tumors detected on mRNA level [173]. Two of these isoforms, 
of which also protein expression could be detected, were reported to have opposing 
genomic actions compared to the full length ERα [174, 175]. Both of these isoforms have a 
truncated A/B domain and are missing their AF-1 region, involved in ligand-independent 
transactivation [174-176]. One of the two also has a shortened E and F domain and is 
missing its AF-2 region, affecting the ligand binding domain [175, 176]. For ERβ at least 
5 different splice variants are known on mRNA level [177]. They are mostly truncated in 
the E and F domain, affecting the AF-2 region and thereby the activity of ERβ [178, 179]. 
It has been shown that different splice variants occur in breast tissue and breast cancer 







cell line or in breast tissue, it is of interest to further elucidate the implications of the 
occurrence of these splice variants on their biological action. 
Coregulators
The by the different agonists and antagonistic compounds induced interaction of 
ERα or ERβ with coregulators reveals that the modulation of the interaction of ERα 
or ERβ with coregulators upon stimulation of a specific (ant)agonist show similar MI 
profiles. It was evident that MI profiles for the antagonistic compounds were generally 
opposite to that of the agonistic compounds, and the MI profiles allowed hierarchical 
clustering and clear discrimination between agonists and antagonists and even between 
different agonists. This characteristic of the MARCoNI assay to discriminate and cluster 
estrogenic compounds is not defined by the conventional ER-selective reporter gene 
or proliferation assays. It is of importance to note that these interactions of ERα or 
ERβ with coregulators were investigated using the ligand binding domain (LBD) of ERα 
and ERβ. This LBD is known to be responsible for the interaction of the ER with ligands 
and coregulators in the cells [30]. Currently, this MARCoNI assay has not been used in 
combination with full length receptors. Given the previously described opposite effects 
that splice variants of estrogen receptors might have [174, 175], it could be of interest 
to use for example cell extract containing full length receptors in the MARCoNI assay. If 
the use of cell extract in the MARCoNI assay will prove to be possible it would also be of 
interest to use T47D-ERβ cells with tetracycline-dependent ERβ expression to be able to 
investigate differential effects occurring at varying ERα/ERβ ratios. 
Furthermore, although for many of the coregulators present on the MARCoNI assay 
the function is more or less known (Table 1), the eventual biological effect of the complete 
set of modulated interactions of the ER with coregulators is not yet specified. The same 
holds true for the differential expression of coregulators in the different cells or organs 
and how coregulators interact with each other [180]. Since more and more proteins are 
identified as coregulators [181], it will be a great challenge in the near future to further 
elucidate their biological effects. In the current thesis, modulation profiles induced 
by the different ligands were compared to the compound-specific pharmacology. The 
MARCoNI assay based on the ERβ-LBD was conducted for the first time, and therefore 
the ligands were tested at concentrations expected to show maximum efficacy in the 
MARCoNI assay and compared to the efficacy of the ligands in the U2OS reporter gene 
assay and the cell proliferation assay. From the comparison between efficacy order of 
the ligands in the MARCoNI and the U2OS reporter gene assay it turned out that the 
efficacy of the ligands could not be explained by the induced MI profiles in the MARCoNI 










are also involved in efficacy of the ligands. Next to the efficacy of the ligands, to study 
the effect of the interaction of ERα and ERβ with coregulators on potency reflected by 
EC
50
 as well, full dose response curves should be conducted to broaden the knowledge 
on ligand-dependent interactions with coregulators. 
Towards gene and protein expression 
The proteomics study described in chapter 5 indicates that in the cells expressing only 
ERα decreased cell proliferation and increased apoptosis was induced by 4OHT, which 
was opposite to the cells expressing ERα and ERβ, where increased cell proliferation and 
decreased apoptosis upon 4OHT exposure was indicated by protein expression. It was 
concluded that 4OHT may have differential effects in tissues, being more effective in 
reducing cell proliferation and increasing apoptosis if ERα dominates and ERβ expression 
levels are low since 4OHT then antagonizes ERα. This study was conducted for 4OHT, the 
active metabolite of tamoxifen, since cell proliferation and apoptosis are major biological 
events of interest in cancer progression [145, 146]. Tamoxifen is a first line breast cancer 
drug. If treatment with tamoxifen does not succeed, fulvestrant is commonly used as 
a second line breast cancer drug [182]. Given the ER subtype-dependent effects of 
4OHT on protein level, it is recommended to conduct a similar proteomics study with 
fulvestrant to investigate ER subtype-dependent effects at protein level. 
Biological effects
The importance of ERα and ERβ levels and ratios is especially illustrated in this thesis, as 
ultimate biological effects of estrogenic compounds like cell proliferation and apoptosis 
seem largely dependent on the intrinsic potency towards one of the ER subtypes and 
the cellular ERα and ERβ levels and ratios present. Especially the striking differences in 
ERα- and ERβ-mediated responses to 4OHT related to cell proliferation and apoptosis 
indicated in the proteomics study described in chapter 5 underline the importance of 
determination of both ERα and ERβ levels and their ratios in breast cancer treatment. It 
was concluded that 4OHT may have differential effects in different tissues, being more 
effective in reducing cell proliferation and increasing apoptosis if ERα dominates and 
ERβ expression levels are low since 4OHT then antagonizes ERα. It would be interesting 
to validate these results in a clinical study and monitor ER levels in patients receiving 
tamoxifen treatment. Based on the results of the present thesis it may be hypothesized 
that fulvestrant may be more effective than tamoxifen/4OHT as a breast cancer drug 
in tumors with relatively high ERβ expression levels, since in chapter 4 of the current 
thesis it was shown that fulvestrant is less potent in antagonizing ERβ than 4OHT is 







ratio fulvestrant will be less prone to suppress the ERα inhibiting activity of ERβ thereby 
increasing proliferation instead of decreasing it as observed for 4OHT.
Often after about 15 months of breast cancer treatment with tamoxifen, tamoxifen 
resistance occurs [183]. One could speculate that the tumor cells adapt to the tamoxifen 
treatment by increasing ERβ expression, the action of which is then antagonized by 
tamoxifen overruling the effect of tamoxifen-mediated ERα antagonism, and facilitating 
cell proliferation. Speirs et al. already observed, by means of RT-PCR, that median ERβ 
mRNA levels were approximately 2-fold higher than ERα levels in tamoxifen-resistant 
tumors compared to tamoxifen-sensitive tumors [184]. It would be of interest to test this 
hypothesis by monitoring ERα and ERβ levels and ratios continuously during tamoxifen 
treatment, and possibly adjust treatment to for example fulvestrant upon detection of 
changing ERα and ERβ levels and ratios in the tumor tissue. However, this might be too 
invasive for the patient, since it would require regular biopsies. 
The current thesis focuses on cell proliferation and apoptosis, major biological 
events known to be influenced by estrogenic compounds and playing an important role 
in cancer progression [145, 146]. Estrogenic compounds are involved in other biological 
effects as well, for example previously shown for immune responses [23]. It is important 
to keep this in mind when planning future research into the effects of estrogenic 
compounds. Also dose and absorption, distribution, metabolism, and excretion of the 
estrogenic compounds should be taken into account [185]. 
Concluding remarks
Results of the present thesis have elucidated the action of different estrogenic 
compounds, their interaction with the two ER subtypes, and the subsequent recruitment 
or rejection of coregulators, as well as the resulting effects on cell proliferation and 
apoptosis. The results illustrate the importance of ERα and ERβ levels and their ratios, 
especially in tamoxifen treatment in breast cancer. The action of estrogenic compounds 
and their interaction with ERs as described in the present thesis should be taken into 
account and can be used as a starting point for future research into mechanisms of 
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The aim of the current thesis is to elucidate the role of estrogen receptor (ER)α and ERβ 
in cell proliferation and apoptosis induced by estrogenic compounds.  Special attention 
is paid to the importance of the receptor preference of the estrogenic compounds, the 
cellular ERα/ERβ ratio, the role of coregulators, and ER-mediated induction of protein 
expression. In chapter 1 estrogenic compounds and their interaction with estrogen 
receptors are described and the two different estrogen receptors, ERα and ERβ, are 
introduced. It is described how estrogenic compounds eventually exert biological 
effects through coregulator recruitment upon ER binding, transcription initiation, and 
protein expression.
Chapter 2 describes under which conditions T47D-ERβ breast cancer cells with 
tetracycline-dependent ERβ expression and constant ERα expression best mimic ERα/ERβ 
ratios in breast and other estrogen-sensitive tissues in vivo in rat as well as in human. At 
protein and mRNA level, ERα and ERβ levels and ratios are determined in T47D-ERβ cells 
exposed to a range of tetracycline concentrations and in rat and human breast, prostate, 
and uterus or endometrium. The ERα/ERβ ratio in rat mammary gland and in human breast 
tissue can be mimicked by exposing the T47D-ERβ cells to >150 ng/ml tetracycline, but the 
ERα/ERβ ratio of other estrogen-sensitive rat and human tissues can also be mimicked. 
The ERα/ERβ ratios in MCF-7 and native T47D cells are high due to a lack of ERβ expression 
and therefore do not reflect ratios in rat and human tissues. It is demonstrated how these 
different tissues might vary in their proliferative response towards 17β-estradiol (E2) by 
exposing T47D-ERβ cells to E2 under defined tetracycline concentrations.
In chapter 3 the modulation of the interaction of ERα and ERβ with coregulators 
in the ligand-dependent responses induced by estrogenic compounds is investigated. 
To this end, selective ERα and ERβ agonists are characterized for intrinsic relative 
potency reflected by EC
50
 and maximal efficacy towards ERα and ERβ in ER-selective 
reporter gene assays, and subsequently tested for stimulation of cell proliferation in 
T47D-ERβ cells with variable ERα/ERβ ratio and for ligand-dependent modulation of the 
interaction of ERα and ERβ with coregulators using the Microarray Assay for Real-time 
Coregulator – Nuclear receptor Interaction (MARCoNI) with 154 unique nuclear receptor 
coregulator peptides derived from 66 different coregulators. Results obtained reveal 
an important influence of the ERα/ERβ ratio and receptor selectivity of the compounds 
on stimulation of cell proliferation. ERα agonists activate cell proliferation whereas 
ERβ seems to suppress ERα-mediated cell proliferation. The responses in the MARCoNI 
assay reveal that the modulation of the interaction of ERα or ERβ with coregulators 
by a specific agonist are very similar indicating only a limited number of differences 









interaction of the ERs with coregulators between the different agonists are more 
substantial and can be used to classify the different agonists by hierarchical clustering. 
The results obtained corroborate that the ultimate effect of the model compounds on 
proliferation of estrogen-responsive cells depends on the intrinsic relative potency of 
the agonist towards ERα and ERβ and the cellular ERα/ERβ ratio whereas differences 
in the modulation of the interaction of the different ERs with coregulators for a given 
ligand might also contribute to the compound-specific pharmacology. Based on ligand-
dependent differences in the modulation of the interaction of the ERs with coregulators, 
the MARCoNI assay is able to classify the different ERα and ERβ agonists discriminating 
between different agonists for the same receptor, a characteristic not defined by the 
ER-selective reporter gene or proliferation assays. It is concluded that differences in 
the modulation of the interaction of ERα and ERβ  with coregulators contribute to the 
ligand-dependent responses but do not fully explain the differences in pharmacology 
between ER-mediated responses by the different estrogenic compounds.
To investigate if this is also the case for ER antagonists, chapter 4 handles the 
modulation of the interaction of ERα and ERβ with coregulators in the ligand-dependent 
responses induced by the ER antagonistic compounds 4-hydroxytamoxifen (4OHT) and 
fulvestrant. Comparison of these results to ligand-dependent interaction of ERα and 
ERβ with coregulators expressed in modulation index (MI) profiles for the ER agonist E2 
elucidates whether differences in the (ant)agonist-dependent interaction of ERα and ERβ 
with coregulators contribute to the differences in (ant)agonist responses. To this end, the 
selected ER antagonistic compounds are first characterized for intrinsic relative potency 
reflected by IC
50
 and maximal efficacy towards ERα and ERβ using ER-selective U2OS 
reporter gene assays, and subsequently tested for ligand-dependent modulation of the 
interaction of ERα and ERβ with coregulators using the MARCoNI assay. Results obtained 
with the U2OS reporter gene assays indicate a preference of 4OHT to bind ERβ and find 
fulvestrant to be less ER-specific. The responses in the MARCoNI assay reveal that ERα- 
and ERβ-mediated interaction with coregulators expressed in MI profiles are similar for 
4OHT and fulvestrant and generally opposite to the MI profile of the ER agonist E2. 
Hierarchical clustering with Euclidian distance as the cluster distance metric, based on 
the MI profiles, is able to clearly discriminate the two compounds with ER antagonistic 
properties from the ER agonist E2. Taken together the data reveal that modulation of the 
interaction of ERs with coregulators discriminates ER agonists from antagonists but does 
not discriminate between the preferential ERβ antagonistic compound 4OHT and the 
less specific ER antagonist fulvestrant. It is concluded that differences in modulation of 








dependent responses induced by ER agonists and ER antagonists, but the importance of 
the subtle differences in modulation of the interaction of ERs with coregulators between 
the ER antagonistic compounds 4OHT and fulvestrant for the ultimate biological effect 
remains to be established. 
To further investigate whether 4OHT, the active metabolite of the breast cancer 
drug tamoxifen, exerts ERα/ERβ ratio-dependent effects on cell proliferation and 
apoptosis, in chapter 5 the results of a quantitative proteomics study are described. 
This is of importance given that the ERα/ERβ ratio usually increases in tumorous tissue 
compared to normal tissue due to decreased ERβ expression. ERα/ERβ ratio-dependent 
effects of 4OHT on cell proliferation and apoptosis of the T47D-ERβ human breast cancer 
cell line with tetracycline-dependent ERβ expression are detected. In the cells expressing 
only ERα decreased cell proliferation and increased apoptosis is induced by 4OHT, which 
is opposite to the effects detected in cells expressing ERα and ERβ, where increased cell 
proliferation and decreased apoptosis upon 4OHT exposure is found. Post-translational 
modifications like acetylation, methylation, and phosphorylation of several ribosomal 
and mitochondrial protein groups are induced by 4OHT, mostly in T47D-ERβ cells with 
both ERα and ERβ expressed. Altogether the results suggest that effects of 4OHT on 
major biological functions like cell proliferation and apoptosis in the T47D-ERβ cells are 
affected by the ERα/ERβ ratio. 4OHT may have differential cellular effects, being more 
effective in reducing cell proliferation and increasing apoptosis if ERα dominates and 
ERβ expression levels are low since 4OHT then antagonizes ERα.
Chapter 6 presents a discussion on the implications of the mechanisms of action 
of several estrogenic compounds discussed in this thesis. Altogether the results of the 
present thesis have elucidated the action of different estrogenic compounds, their 
interaction with the two ER subtypes, and the subsequent recruitment or rejection of 
coregulators, as well as the resulting effects on cell proliferation and apoptosis, and 
these results emphasize the importance of the ERα/ERβ ratio for the ultimate effects of 













Het doel van dit proefschrift is om te verhelderen wat de rol van oestrogeenreceptor 
(ER)α en ERβ is in door oestrogene stoffen geïnduceerde celproliferatie en apoptose. 
In het bijzonder is gekeken naar de invloed van de receptorvoorkeur van de 
oestrogene stoffen, de cellulaire ERα/ERβ-ratio, de rol van coregulatoren en ER-
gemedieerde inductie van eiwitexpressie. In hoofdstuk 1 worden oestrogene stoffen 
en hun interactie met oestrogeenreceptoren beschreven waarbij de twee verschillende 
oestrogeenreceptoren, ERα en ERβ, worden geïntroduceerd. Beschreven wordt hoe 
oestrogene stoffen uiteindelijk hun biologische effect uitoefenen door middel van 
coregulatorrekrutering die optreedt bij binding aan de ER, gevolgd door het initiëren 
van transcriptie en eiwitexpressie. 
Hoofdstuk 2 beschrijft onder welke condities T47D-ERβ-borstkankercellen met 
tetracycline-afhankelijke ERβ-expressie en constante ERα-expressie het beste de ERα/
ERβ-ratio’s in borstweefsel en andere oestrogeengevoelige weefsels in vivo van zowel 
ratten als mensen imiteren. Op eiwit- en mRNA-niveau zijn de hoeveelheden ERα en 
ERβ en ERα/ERβ-ratio’s bepaald in T47D-ERβ-cellen die blootgesteld zijn aan een serie 
tetracyclineconcentraties en in borst-, prostaat- en uterus- of endometriumweefsel 
van ratten en mensen. De ERα/ERβ-ratio die aanwezig is in borstweefsel van de 
mens en de rat kan worden geïmiteerd door de T47D-ERβ-cellen bloot te stellen aan 
>150 ng/ml tetracycline; de ERα/ERβ-ratio van andere oestrogeengevoelige weefsels 
kan ook worden geïmiteerd. De ERα/ERβ-ratio’s van MCF-7- en oorspronkelijke T47D-
cellen zijn hoog vanwege een gebrek aan ERβ-expressie en daarom reflecteren ze niet 
de ratio’s die zijn gevonden in weefsel van ratten en mensen. Door T47D-ERβ-cellen 
bloot te stellen aan E2 onder gedefinieerde tetracyclineconcentraties is aangetoond 
hoe deze cellen en mogelijk ook de verschillende weefsels kunnen variëren in hun door 
17β-oestradiol (E2) geïnduceerde proliferatieve reactie.
In hoofdstuk 3 wordt de modulatie van de interactie van ERα en ERβ met 
coregulatoren in door oestrogene stoffen geïnduceerde ligandafhankelijke reacties 
onderzocht. De intrinsieke relatieve potentie van selectieve ERα- en ERβ-agonisten is 
gekarakteriseerd door de EC
50
 en maximale effectiviteit ten opzichte van ERα en ERβ 
in ER-selectieve U2OS-reportergenassays te bepalen. Vervolgens zijn deze agonisten 
getest op de mate waarin zij celproliferatie stimuleren in de T47D-ERβ-cellen met 
een variabele ERα/ERβ-ratio. Daarnaast zijn de agonisten getest op ligandafhankelijke 
modulatie van de interactie van ERα en ERβ met coregulatoren met behulp van de 
MicroarrayTest voor Real-time Coregulator – Nucleaire receptor Interactie (Microarray 
Assay for Real-time Coregulator – Nuclear receptor Interaction, MARCoNI) met 154 
unieke nucleaire receptor coregulator peptiden verkregen vanuit 66 verschillende 












ERβ-ratio en receptorselectiviteit van de stoffen op de stimulatie van celproliferatie zien. 
ERα-agonisten activeren celproliferatie terwijl actievering van ERβ de ERα-gemedieerde 
celproliferatie lijkt te remmen. De reacties in de MARCoNI-assay onthullen dat de door 
een specifieke agonist-gemoduleerde interactie van ERα en ERβ met coregulatoren 
sterk op elkaar lijken en slechts een beperkt aantal verschillen laten zien na ERα- of ERβ-
activering door een specifiek ligand. Verschillen in de modulatie van de interactie van de 
ERs met coregulatoren tussen de verschillende agonisten is substantiëler en is gebruikt 
om de verschillende agonisten te classificeren door middel van hiërarchische clustering. 
De verkregen resultaten bevestigen dat het ultieme effect van de modelstoffen op 
de proliferatie van oestrogeen-responsieve cellen  afhankelijk is van de intrinsieke 
relatieve potentie van de agonist ten opzichte van ERα en ERβ en de cellulaire ERα/
ERβ-ratio, terwijl verschillen in de modulatie van de interactie van de verschillende ERs 
met coregulatoren voor een gegeven ligand ook kunnen bijdragen aan de stofspecifieke 
farmacologie. De MARCoNI-assay blijkt, gebaseerd op ligandafhankelijke verschillen in de 
modulatie van de interactie van de ERs met coregulatoren, de verschillende ER-agonisten 
te kunnen classificeren en te kunnen discrimineren tussen verschillende agonisten voor 
dezelfde receptor. Over deze eigenschappen beschikken de ER-selectieve reportergen- 
en de proliferatie-assays niet. Uit deze resultaten is geconcludeerd dat de verschillen 
in modulatie van de interactie van ERα en ERβ met coregulatoren bijdragen aan de 
ligandafhankelijke reacties, maar dat deze niet geheel de verschillen in farmacologie 
verklaren tussen ER-gemedieerde reacties door de verschillende oestrogene stoffen.
Om te onderzoeken of dit ook het geval zou zijn voor ER-antagonisten, wordt 
in hoofdstuk 4 de modulatie van de interactie van ERα en ERβ met coregulatoren in 
de door de ER-antagonistische stoffen 4-hydroxytamoxifen (4OHT) en fulvestrant 
geïnduceerde ligandafhankelijke reacties behandeld. Vergelijking van deze resultaten 
met de ligandafhankelijke interactie van ERα en ERβ met coregulatoren voor de ER-
agonist E2, uitgedrukt in modulatie-index (MI)-profielen, heeft verhelderd of verschillen 
in de (ant)agonistafhankelijke interactie van ERα en ERβ met coregulatoren bijdragen 
aan de verschillen in (ant)agonistische reacties. Om dit te bewerkstelligen zijn de 
geselecteerde ER-antagonistische stoffen eerst gekarakteriseerd op hun intrinsieke 
relatieve potentie gereflecteerd door IC
50 
en maximale effectiviteit ten opzichte 
van ERα en ERβ met behulp van ER selectieve U2OS reportergenassays. Vervolgens 
zijn ze getest op ligandafhankelijke modulatie van de interactie van ERα en ERβ met 
coregulatoren met behulp van de MARCoNI-assay. De resultaten verkregen met de 
U2OS reportergenassays wijzen op een voorkeur van 4OHT om aan ERβ te binden en 










dat ERα- en ERβ-gemedieerde interactie met coregulatoren, uitgedrukt in MI-profielen, 
gelijk zijn voor 4OHT en fulvestrant en over het algemeen tegenovergesteld aan het 
MI-profiel van de ER-agonist E2. Hiërarchische clustering, met de Euclidische afstand 
als de clusterafstandmetriek, gebaseerd op de MI-profielen, blijkt duidelijk de twee 
ER-antagonistische stoffen te kunnen onderscheiden van de ER-agonist E2. Al met al 
onthullen de data dat de modulatie van de interactie van ERs met coregulatoren ER-
agonisten van -antagonisten kan onderscheiden, maar geen onderscheid kan maken 
tussen de antagonistische stof 4OHT met een voorkeur voor ERβ en de minder specifieke 
ER-antagonist fulvestrant. Hieruit is geconcludeerd dat de verschillen in modulatie van 
de interactie van ERα en ERβ met coregulatoren bijdragen aan de verschillen in door 
ER-agonisten en ER-antagonisten geïnduceerde ligandafhankelijke reacties, maar het 
belang van de subtiele verschillen in de modulatie van de interactie van de ERs met 
coregulatoren tussen de ER-antagonistische stoffen 4OHT en fulvestrant voor het 
uiteindelijke biologische effect moet nog worden vastgesteld.
Om verder te onderzoeken of 4OHT, de actieve metaboliet van het 
borstkankermedicijn tamoxifen, ERα/ERβ-ratio-afhankelijke effecten vertoont op 
celproliferatie en apoptose, worden in hoofdstuk 5 de resultaten van een kwantitatieve 
proteomics-studie beschreven. Dit is van belang aangezien de ERα/ERβ-ratio over 
het algemeen stijgt in tumorweefsel in vergelijking met normaal weefsel door een 
verminderde ERβ-expressie. Er zijn ERα/ERβ-ratio-afhankelijke effecten van 4OHT op 
celproliferatie en apoptose van de T47D-ERβ humane borstkankercellijn met tetracycline-
afhankelijke ERβ-expressie gedetecteerd. In de cellen met enkel ERα-expressie 
induceert 4OHT verminderde celproliferatie en meer apoptose, wat omgekeerd is 
ten opzichte van de effecten gezien in cellen met zowel ERα- als ERβ-expressie, waar 
meer celproliferatie en verminderde apoptose wordt waargenomen na blootstelling 
aan 4OHT. Door blootstelling aan 4OHT worden post-translationele modificaties zoals 
acetylatie, methylatie en fosforylatie van verschillende ribosomale en mitochondriale 
eiwitgroepen geïnduceerd, vooral in T47D-ERβ-cellen met zowel ERα- als ERβ-expressie. 
Samengevat suggereren de resultaten dat effecten van 4OHT op belangrijke biologische 
functies zoals celproliferatie en apoptose in de T47D-ERβ-cellen worden beïnvloed 
door de ERα/ERβ-ratio. 4OHT kan verschillende cellulaire effecten hebben, waarbij het 
effectiever is in het reduceren van celproliferatie en het verhogen van apoptose als ERα 
dominant is en ERβ-expressieniveaus laag zijn omdat 4OHT dan ERα tegenwerkt.
In hoofdstuk 6 worden de implicaties van de werkingsmechanismen van 
verschillende oestrogene stoffen in dit proefschrift bediscussieerd. Samengevat 












stoffen, als hun interactie met de twee ER-subtypen en de daaropvolgende rekrutering 
of afstoting van coregulatoren verhelderd, evenals de resulterende effecten op 
celproliferatie en apoptose. Hierbij ligt de nadruk op het belang van de ERα-/ERβ-ratio 
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